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Part I
General introduction

Chapter 1
Background
&
Objectives of the thesis
Despite continuing efforts to improve antenatal care, the incidence of a number of adverse 
pregnancy outcomes including low birth weight, preterm delivery, and birth defects, has not 
gone down in recent years. Birth defects affect approximately 3-4% of all live births and 
continue to be a leading cause of infant death and substantial long-term morbidity.1,2
In the Dutch health care system, the first antenatal visit usually takes place around 6-8 weeks 
after conception at a midwifery clinic or general practice. The majority of women remain 
under care in the primary health care setting. Those who have experienced previous obstetric 
complications or have already been identified to be at high risk for adverse pregnancy 
outcome due to (chronic) illness, medication use, or complicated obstetric or family histories 
are referred to a gynecologist. Although this system is reasonably adequate in signaling risks 
and problems as they develop in the course of pregnancy, yielding possibilities for secondary 
and tertiary prevention, an important potential opportunity for primary prevention is missed. 
The most critical stages of fetal development, 17 to 56 days after conception, take place 
largely before a woman may even be aware of her pregnancy. During this period of 
organogenesis, the developing fetus may have already been exposed to potentially harmful 
risks such as substance abuse, poor maternal health, chronic illness or teratogenic drugs. 
Furthermore, the most important stages of placental development occur in the first trimester.
Initiating care before conception could therefore be the most effective strategy to improve 
obstetric and fetal outcome.3-9
Setting
All but two of the studies described in this thesis were carried out between 1997 and 2001 at 
the department of Obstetrics and Gynecology of the University Medical Center Nijmegen. 
The collaborative study described in chapter 7 was carried out between the University 
Medical Center Nijmegen, the Academic Medical Center of Amsterdam, Catharina Hospital 
in Eindhoven, and Maria Hospital and Elisabeth Hospital in Tilburg in the period 1987-1990. 
The cost and effectiveness evaluation of preconception counseling (chapter 11) was carried 
out in 2002 at the departments of Public Health and Obstetrics and Gynecology of the 
Erasmus Medical Center Rotterdam.
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The objectives of the thesis can be summarized as follows:
1. To provide a review of the literature on the past and present practices and continuing 
controversies of preconception care (part I).
2. To address two preliminary issues before the implementation of preconception care can be 
considered (part II):
a. How pre-pregnancy screening for health risk factors should be carried out and 
whether this can be done effectively using a screening questionnaire,
b. Whether preconception counseling causes harm in terms of adverse psychological 
effects.
3. To study several aspects of health and lifestyle of women planning a pregnancy (part III):
a. To describe indices of maternal health and nutrition before and during early 
pregnancy and relation to pregnancy outcome,
b. To assess the impact of preconception counseling on compliance to start folic acid 
supplement use and to quit smoking using biochemical markers.
4. To evaluate an outpatient clinic for preconception care at a university hospital and to 
present a first evaluation of the costs and effectiveness of structural implementation of 
preconception care for all women planning pregnancy (Part IV).
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Chapter 2
The past and present practices and continuing 
controversies of preconception care
Sabina de Weerd, Eric A.P. Steegers
Department o f  Obstetrics and Gynecology, Erasmus Medical Center Rotterdam
Community Genet 2002;5:50-60 (extended version)
Background
The frequency of adverse pregnancy outcome including spontaneous abortion, low birth 
weight, pre-term delivery, and birth defects has not gone down despite improvements in 
antenatal care.1 This may in part be attributed to increasing maternal age at time of first 
pregnancy, smoking and alcohol use during pregnancy, environmental toxins and an 
increasing number of high-risk pregnancies among women with a chronic medical condition, 
medication use or a birth defect. Many women are unaware that their medical conditions, 
exposures, or lifestyle may have consequences in the earliest weeks of pregnancy.2 Since the 
most sensitive stages of embryonic development, organogenesis (17-56 days after conception) 
and placentation are often well underway or completed at the time of the first antenatal visit, 
many health care providers have realized that initiation of care during pregnancy may be too 
late.
The opportunity for primary prevention, to address and reduce risk factors for adverse 
pregnancy outcome before conception, has led many to believe that a shift from antenatal care 
to preconception care could be the most effective strategy to improve maternal and fetal 
outcome.3 This article is a review of the literature on the goals, components, and benefits of 
preconception care, the prior practices and current approaches, and the continuing issues and 
concerns pertaining to widespread implementation.
Methods
A Medline search of the literature was performed using the following key words: 
preconception, preconceptional, pre-pregnancy, preconceptual, and each followed by the 
words care, counseling, and screening. An additional search was done using the MESH term 
genetic screening, diabetes mellitus and pregnancy outcome, and phenylketonuria and 
pregnancy outcome, from which several articles were selected. We also reviewed reference 
lists in original and review articles, editorials, and books. Publications that pertain to some 
aspect of preconception care in the period 1973-2002 were included in this review. No other 
inclusion or exclusion criteria were used.
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Goals of preconception care
The principal goal of preconception care is to maximize the quality of fetal, newborn and 
infant life through primary prevention.3 Other goals are to promote healthy habits, to 
encourage women to attend booking clinics as soon as they are pregnant,4 and to provide 
high-risk women, particularly women of advanced age, with information about the risks of 
pregnancy, the risk of bearing a child with a birth defect or genetic disorder, and the tests 
available so informed choices can be made.5 Others have defined their goals as the 
identification of and reduction in (modifiable) risk factors before conception in order to 
improve obstetric outcome,6 the primary prevention of drug-induced anomalies, neural tube 
defects and other birth defects,2,7 and the opportunity to educate women on pregnancy 
planning and prenatal care.2 These goals pertain to the partner for the evaluation of paternal 
risk factors as well.8,9 Moos10 described 'preconceptional health promotion' as an active 
preparation for pregnancy in order to provide the healthiest possible environment to the 
earliest embryonic cells, aimed at all women of childbearing age.
Components of preconception care
Preconception care has three principal components: risk assessment, health promotion, and 
intervention. The content and definitions of each component are described below.
1. Risk assessment
Risk assessment encompasses screening for and evaluation of risk factors through assessing 
the woman’s history, which should include an evaluation of obstetric and medical history, 
infectious disease history, family history, smoking, alcohol and drug use, teratogen exposure 
at home or at work, medication use, and dietary habits.1,2,9,11-14 Table 1 provides an overview 
of risk factors to be considered for the evaluation for each of these categories.1,15 
Psychological aspects (i.e., stress factors, including domestic violence) and socio-economic 
circumstances should also be considered during a screening consultation.2 Nesbitt16 suggested 
that understanding the patient as a 'human being, wife and prospective mother' is important in 
determining prospects for successful childbearing, and that consideration of issues of marital 
status, personal attitudes, work schedule, and other activities should receive proper attention.
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Table 1. Preconceptional history: items covered in a validated screening questionnaire15
Screening items
Medical history 
Diabetes 
Thyroid disease 
Asthma 
Heart disease 
High blood pressure 
Deep venous thrombosis 
Kidney disease 
SLE
Epilepsy
Sickle cell anemia 
Cancer 
Reproductive history
Uterine or cervical abnormalities 
2 or more first trimester miscarriages 
Premature delivery (14-28 weeks GA) 
One or more intra-uterine death(s) 
Prior baby < 2750 g at birth 
Prior baby admitted to neonatal ICU 
Prior baby with birth defect 
Sickle cell disease 
Nutritional history 
Vegetarianism
Frequent consumption of snacks / pica 
History of bulimia / anorexia nervosa 
Special diet
Vitamin supplement use 
Intolerance for milk
Infectious disease history 
STD
Herpes simplex 
Chlamydia infection 
Human papillomavirus 
Gonorrhea
Viral hepatitis (or risk behavior)
HIV (or risk behavior)
Occupational exposure to blood 
Blood transfusions 
Own/ work with cats 
Immunity to rubella
Family history
Birth defects/genetic diseases
Related to partner
Race
Social history / behavior risks 
Alcohol use (no. per day)
Tobacco use (no. per day)
Marihuana, cocaine or other drug use 
Chemical use at home/ work 
Exposure to radiation at work 
Participation in sports 
Age > 34 years
Medication history
Use of prescription medication 
Use of over-the-counter medication
20
Preconception care should also include risk assessment of the partner, as there is increasing 
evidence of paternal influence on pregnancy outcome.8,9,14 Studies have illustrated that the 
prevalence of birth defects is higher among infants of men who smoke17 and that birth weight 
is lower among babies of smoking fathers,18 which may in part be attributable to passive 
smoking by the mother. Recent studies have suggested that men contribute significantly to the 
risk of preeclampsia.19,20 Paternal toxic exposures to chemicals may adversely influence 
reproduction through changes in spermatogenesis14 and have been linked to adverse 
pregnancy outcome including spontaneous abortion, stillbirth and preterm delivery.21 
Addressing preconceptional health interventions among men, such as avoidance of substance 
use and certain (occupational) exposures, may also reduce the incidence of adverse outcome. 
As men may also carry or pass on genetic risks to their offspring, it is of equal importance to 
evaluate the family history of both prospective parents.
Depending on screening results, risk assessment often includes routine or selected laboratory 
tests and/or other diagnostic examinations. Blood analyses may include hemoglobin and 
hematocrit, blood type and Rhesus factor, liver and kidney function tests, rubella titer, 
screening for (carriership of) phenylketonuria, sickle cell anemia and Tay-Sachs disease, 
CMV titer, herpes simplex titer, toxicology screen, Hepatitis, HIV and other STD
14,22-24screening. A search for inherited thrombophilias, analyses of vitamin profiles, thyroid 
function, autoimmune factors, and karyotype of both partners may also be performed. Other 
diagnostic examinations may include a Papanicolaou smear, tuberculosis skin test, urine 
screening for protein and sugar, and an ultrasound examination of the uterus, cervical 
resistance test, hysteroscopy, or hysterosalpingography if uterine disorders are suspected.23,24
2. Health promotion (preconception counseling)
After screening, couples are informed and educated on a variety of health promotion issues, 
including periconceptional folic acid supplement use,25 avoidance of alcohol, tobacco and 
other drugs, proper nutrition, and a plan for prenatal care.1,2,8-14 They may also be counseled 
on the specific risks of pregnancy based on the presence of other risk factors, which may 
include genetic issues or the recurrence risk of previous obstetric complications.5,7,23 In recent 
years, more and more women who previously were told or who assumed that they could never 
bear a child because of a (severe) congenital anomaly, chronic disease (and medication use) or 
because they have undergone an organ transplantation, are opting for pregnancy. In this 
respect, specific preconceptional counseling issues that are gaining importance are the impact
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of maternal disease on the course and outcome of pregnancy, as well as the influence of 
pregnancy on maternal well-being.23 Addressing the chances that a disease may exacerbate or 
that the severity may diminish during pregnancy allows couples at risk to make an informed 
choice whether to refrain from childbearing or opt for pregnancy.
3. Intervention
The goal of a preconceptional intervention is to modify or eliminate risk factors in order to 
minimize the risk of adverse outcome. The best known example is the initiation of folic acid 
(or multivitamin) supplement use to reduce the first occurrence26 or recurrence risk27 of neural 
tube defects. Smoking cessation, treatment of infections (i.e. urinary tract infection, 
chlamydia or other STD), vaccination against rubella and dietary modification in order to gain 
or lose weight are additional examples of common interventions that may improve outcome. 
Interventions may also encompass a change of (potentially) teratogenic drug therapy to a safer 
brand for women on chronic medication (i.e. anti coagulation, antihypertensive drugs),23 
improved control of preconceptional blood glucose levels in diabetic women,3 correction of 
vitamin deficiencies or anemia, and treatment of eating disorders.2
Target population
So far, no international consensus exists as to who should receive preconception care. The 
target population can be divided into three major groups: (1) women at high risk for adverse 
pregnancy outcome due to previous complicated pregnancies, genetic risks, chronic illness or 
medication use, (2) women currently planning a pregnancy, or (3) all women of reproductive 
age.
It is widely recognized and accepted that high-risk women should always receive 
preconception care, as those contribute most to adverse outcome.3,28 In 1974, Aubry and 
Pennington28 advocated that ‘ideally, an effort should be made to identify prior to pregnancy 
those who carry the greatest risk of perinatal wastage’, and that women at high risk for poor 
outcome should be cared for differently than low-risk women. Today, women with evident 
risk factors are often already under the care of a gynecologist (or other specialist, such as an 
internist or cardiologist), despite the general lack of structured clinics for preconception care.
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Some advocate that preconception care should be limited to high-risk women only, with focus 
on the early identification of possible risk factors for birth defects and genetic disorders.29 
Most controversies revolve around the expansion of preconception care to low-risk 
populations. At the end of the last decade, the Public Health Service Expert Panel in the US 
published a report on the content of prenatal care stating that a preconceptional consultation 
can be the single most important health care visit in terms of effect on pregnancy outcome.30 
The report emphasized the benefits of preconception care for all women. Extrapolation of 
preconception care to the population at large, i.e. all women planning pregnancy or all women 
of reproductive age, will also include apparently low-risk women who have never been 
pregnant, but may have modifiable risk factors for adverse outcome that have not been 
previously identified or addressed.
In a retrospective survey among 12,452 new mothers in the states of Maine, Michigan, West 
Virginia, and Oklahoma, Adams et al.31 estimated what percentage of women could have 
benefited from preconception counseling. Considering the risk factors smoking, alcohol 
consumption, inadequate weight and delayed initiation of prenatal care, 38% of mothers who 
planned their pregnancies could have benefited from preconception care. Levitt32 advocated 
preconception care for all women of childbearing age, with emphasis on modifiable and 
nonmodifiable risk factors, encompassing lifestyle, medical, genetic and psychosocial risks. 
Preconception health promotion may be an especially important strategy to improve outcome 
among economically disadvantaged groups because of the generally poorer health status and 
higher infant morbidity and mortality rates in these populations.16,32 Cheng24 went further by 
advocating that even if a woman who received preconception counseling were never to 
conceive, she would still benefit from the basic concepts of preconception care.
Preconception clinics & programs
Data on preconception care programs and experiences from existing clinics are limited. A few 
structured preconception clinics have been described in the literature: in London, UK,33 in 
Glasgow, UK22 and in Budapest, Hungary.6 The clinics in Great Britain were set up 
specifically for women at high risk for adverse pregnancy outcome, whereas the Hungarian 
program was aimed at all women planning a pregnancy. The structure described above is
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similar to the pre-pregnancy clinic described over 20 years ago in London.33 The clinic, 
established in 1978, was run by one consultant obstetrician only, and was set up to provide a 
referral center for family doctors and other specialists for advice on the risks and management 
of a future pregnancy. Fifty-six women visited the clinic in an 18-month period. Most women 
who attended had experienced premature labor, late abortions and fetal or neonatal death. The 
obstetrician consulted written resources or colleagues on several occasions. Opinion was 
generally based on history and medical records (if available). The clinic was mainly a center 
for authoritative advice where women’s worries were addressed.33 The clinic in Glasgow, UK 
was founded in 1982 and was attended by 1,075 couples during a 9-year period. The structure 
of the clinic was somewhat different, a research nurse, rather than a doctor, was responsible 
for initial screening and planning of tests, and a physician saw the couple 4 weeks later to 
discuss the results of the tests and establish a care plan.22 Recurrent early pregnancy loss and 
previous adverse fetal outcome were the most common indications for referral.
Another example of a program targeted at high-risk women (although not offered through 
structured preconception clinics), was the Preconceptional Intervention Program ('PIP') in 
Florida.34 The program aimed at reducing low birth weight prevalence and was targeted at 
women at high risk for delivering a low birth weight infant. The target population included 
economically disadvantaged women, women who had previously delivered a low birth weight 
infant, women who had received no prenatal care or who were less than 16 years old at the 
time of a previous delivery. The model, described in 1989, was based on the assumptions that 
'at-risk' clients can be identified, can be taught risk reduction techniques, and are capable of 
and willing to reduce risk factors. The project used a multidisciplinary team of health care 
workers (health education specialist, nurse midwife, nutritionist and social worker) and 
resources including structured risk assessment instruments and protocols.34
The center for periconceptional care in Budapest, Hungary, was aimed at prospective parents 
and encompassed three steps: (1) risk assessment by nurses (screening and clinical 
investigations); (2) optimization of health, lifestyle and nutrition three months before 
conception, and (3) ‘better protection during the first most sensitive weeks of embryonic 
development’.6 However, the term ‘better protection’ was not defined. A total of 8,837 
women and 7,600 men attended the clinic between 1984 and 1994.
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In 1993, Nasso9 developed a specific preconceptional educational program in Rochester, New 
York called ‘Planning for pregnancy’. The 2- to 3-hour class was presented to at most 16 
people at a time, and covered a broad range of topics, including prepregnancy weight, 
nutrition, genetics, infectious diseases, medical history, high-risk behavior and environmental 
toxins. Most attendees were young and healthy women, and were required to pay a fee of 
USD 10 in order to participate. The program was advertised in a local newsletter reaching 
approximately 10,000 women, however, no data are given on uptake.
In North Carolina, a preconceptional counseling program was aimed at all women of 
reproductive age. The program was incorporated into 31 health departments, serving 
predominantly low-income women,10 and was structured around the 'Preconceptional Health 
Appraisal'. The appraisal, a self-administered screening questionnaire on risk factors for 
adverse pregnancy outcome, was to be marked where applicable and was then reviewed with 
the woman by a health care professional. The sheets were given to the woman to serve as a 
reminder of actions to take in order to improve chances for a healthy pregnancy outcome. 
This approach was also introduced in other parts of the US.35
Benefits of preconception care
A 10-year evaluation of the Hungarian program showed a reduction in congenital defects after 
preconceptional counseling (20.6/1000 as compared with 35/1000 in the Hungarian 
population at large), and a lower ectopic pregnancy rate (0.2% vs. 0.8% in the general 
population).6 Screening for maternal risk factors, such as diabetes mellitus or cardiovascular 
disease, led to the referral of 3% of women to special clinics. Furthermore, genitourinary 
infections were detected and treated, and couples with fertility problems were identified 
sooner through semen screening and basal body temperature measurement. A higher birth 
weight was reported, which was attributed to lower maternal smoking rates and alcohol 
consumption after counselling.6 Evaluation of the Preconceptional Health Appraisal10 showed 
that preconceptional health promotion targeted at women not planning pregnancy in the 
immediate future, led to a higher planned-pregnancy rate in subsequent pregnancies.35
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Preconception care has been shown to improve pregnancy outcome in women with diabetes
36,37 38 2mellitus, ’ phenylketonuria, and women taking potentially teratogenic drugs. A recent 
meta-analysis by Ray et al.37 demonstrated a pooled major congenital anomaly rate (from 14 
cohort studies) of 2.1% in diabetic women who had received preconception care vs. 6.5% in 
diabetic women who had not (RR 0.36). Evaluation of the preconception care clinic in 
Glasgow also illustrated that preconception counseling improved outcome of a subsequent 
pregnancy among women with chronic disease, particularly women with diabetes and 
hypertension.22 The use of folic acid supplements during the periconceptional period has also 
been shown to reduce the risk of bearing a child with a neural tube defect.26,27
Screening for specific hereditary disorders among certain ethnic groups has also been shown 
to be effective, as this has resulted in a reduction of the live-birth prevalence of Thalassemia 
by 96% in Cyprus.39 Population-based screening programs for Cystic Fibrosis (CF) and 
Fragile X gene carriers could also reduce the number of affected newborns with these 
disorders.40,41 A preconceptional screening program (vs. prenatal screening) for these 
disorders would be a preferred strategy, considering that all reproductive options are then still 
open to the couple.40 The costs, effects and savings have been evaluated and are favorable for 
both CF and Fragile X gene carrier screening.40,41 Retrospective evaluation of psychological 
issues of CF carrier screening were also favorable, as both carriers and noncarriers uniformly 
approved of screening and were glad to have been tested.42 However, neither of the screening 
programs have been implemented because a number of other non-economical issues, 
including ethical considerations and feasibility, remain unresolved.40,41
How to deliver preconception care
1. Providers
Gynecologists can provide preconception care not only to women who have had prior birth or 
obstetric complication(s), but also to women who are under their care for other (gynecologic) 
reasons.2,22,23 Nurses,6,9,22,43 general practitioners or family physicians,14,24,44,45 midwives,46 
internists,47,48 clinical geneticists,49 paediatricians50 and workers at family planning clinics 
have all been suggested as potentially eligible health care workers to deliver preconception
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care. Hollingsworth et al. proposed that a preconception clinic should be run collaboratively 
by an internist, perinatologist, geneticist, nurse-clinician and a nutritionist.3
2. Setting
Preconception care could be provided in a primary, secondary or tertiary health care setting. It 
could be offered passively by making it a known (via commercials, posters or folders) and 
available health care facility, and thus it would be the primary responsibility of women 
themselves to ask for it. If we assume that uptake would be suboptimal if preconception care 
is merely promoted, we need to take a more direct approach. The opportunity to initiate 
prepregnancy care after a negative pregnancy test was suggested by Jack et al. and seemed 
promising.51 However, a later evaluation revealed that this did not improve preconceptional 
intervention rates.52 Other opportunities to promote availability of preconception care on a 
more personal basis could be during a regular visit to a practitioner (women who come for a 
pap smear, for oral contraceptives, or a physical examination).32 Cheng24 advocated that every 
primary care physician should seize the opportunity to evaluate preconception risks for 
women at any medical visit and provide interventions as needed. Initiating educational 
programs on good health before pregnancy at school could also contribute to improved 
awareness. Preconception health promotion activities could also take place in women’s and 
youth centers, or at high schools.32 Jones et a l29 even suggested that preconception care could 
be provided by a member of the clergy or as a premarital counseling service.
3. Tools
Several screening instruments have been developed in order to facilitate the provision of
preconception care. A self-administered screening tool named the 'Preconceptional Health
Appraisal' was developed in Chapel Hill, North Carolina. The 53-item checklist was used to
gather specific information on a woman’s potential risk factors, and the applicable items were
discussed in a subsequent consultation with a health care professional who answered
questions and initiated further referrals or interventions if needed.10 Swan and Apgar14
provided an example of a 12-item genetic screening questionnaire for preconceptual risk
assessment, with a positive reply to any question being an indication for appropriate
counseling. Perry53 gave a one-page outline for nurse practitioners on preconception care
assessment, possible interventions, and patient education to be provided. The article included
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examples of a one-page risk assessment questionnaire (‘Preconception Assessment Tool’) and 
a sample patient handout.
Bernstein et a l54 assessed whether the documentation of the delivery of preconception care 
could be improved among providers by inserting a standardized form into a patient's chart. 
The form listed the same general sections and items as shown in table 1, and was followed by 
three columns: date done, pending action, and comments/provider’s initials. Documentation 
of a complete medical history improved from 15 to 44%, and of several other categories 
(nutrition, dietary supplements, over-the-counter medication) from less than 10 to more than 
50%. Their approach differed from the one described by Cefalo:1 Bernstein et a l54 suggested 
using a standardized form during every encounter with women of reproductive age (not only 
at the initial encounter) because of the high rate of unplanned pregnancies in the US.
Obstacles of preconception care
1. How to reach the target population
Three years after the recommendations of the U.S. Public Service Expert panel for 
preconceptional care were issued, a retrospective evaluation was carried out in North Carolina 
in order to evaluate to what extend the recommendations were followed.55 Of the 147 women 
studied, only 11% had at least one preconceptional visit. Women with unplanned pregnancies, 
especially teenagers, miss this opportunity for primary prevention.2,13 Other difficult target 
groups to reach are those of low socio-economic status and certain minority groups, who are 
often without health insurance or have limited accessibility to health care, and users of alcohol 
or other drugs. It is often those women who are missed that could have benefited most from 
preconception care.31
2. Obstacles among providers
Preconception care is not routinely offered in most countries. Hence, implementing 
preconception care inevitably imply that health care providers will need to be (further) 
educated on the components of preconception care, and the provision may pose feasibility 
problems. A survey among general practitioners in the Netherlands illustrated that although
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93% considered preconception counseling part of their job, 53% lacked the specific 
knowledge needed to give adequate advice, and 30% indicated not having enough time to 
provide preconception counselling.44 A low level of provider knowledge regarding 
preconception care has also been reported by internal medicine residents.56
In the study by Peoples-Sheps et al.,55 the essential aspects of risk assessment and health 
promotion counseling were provided to only half the women who did receive preconception 
care. In 1986, Barron et al.43 concluded that opportunities to provide clients with information 
about how to have a safer pregnancy were not used as often as they could be. Bernstein et 
a l54 addressed knowledge of and attitudes towards preconception care among gynecologists 
before and after an educational intervention. Knowledge was low at baseline, with no 
significant improvement after the one-hour lecture. Provider attitudes also did not change 
significantly, and their documentation of preconception care (despite the use of a standardized 
form) was still suboptimal. The authors speculated that a single lecture might have been 
inadequate. In order to help physicians remember the essence of preconception care, Cheng24 
introduced the mnemonic ‘FIRST’ in her article on preconception care for the primary care 
practitioner: folic acid, immunize, review family genetic and ethnic history, stop smoking, 
drinking, drugs, teratogens and toxins. Clearly, these essential aspects of women’s health are 
not discussed as systematically or thoroughly as they could be by health care professionals. 
This emphasizes the need for improved educational programs for current and future providers 
of preconception care.
3. Costs o f preconception care
Data on costs and savings of preconception care programs are very limited. The only cost-
effectiveness studies reported in the literature have been specifically on preconception care
for women with diabetes mellitus, all of which illustrated cost savings in favor of 
preconception care.57-60 In Hungary, the cost of periconceptional care was estimated at USD 
150 for couples that did not require additional care (i.e., low-risk couples that were not subject 
to interventions based on the presence of risk factors). Data on costs for those who did require 
further care were not presented.6 Preconception care inevitably induces additional costs that 
encompass not only the costs of screening, additional laboratory or other tests, and occasional 
referral to other disciplines, but also the costs of campaigns and training of health care 
professionals. These additional costs may be offset by the prevention of adverse pregnancy 
outcomes, although we do not know by what magnitude. It is difficult to estimate and
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interpret the effect of a preconceptional intervention on pregnancy outcome,61 and may only 
be feasible using several well-defined end points. Moreover, the value of an informed choice 
to refrain from bearing a potentially affected child cannot be measured in terms of costs and 
effectiveness.62
4. Other
The lack of prospective trials proving the effectiveness of preconception care is a major 
obstacle to its implementation.13 Evidence-based medicine has become so deeply rooted in 
clinical practice that many physicians are critical towards preconception care. However, a 
randomized clinical trial on one aspect of preconception care is hardly feasible7 or 
justifiable,63 especially among women with modifiable risk factors. The view that randomized 
controlled trials are a ‘gold standard’ ignores the fact that they may be unnecessary, 
inappropriate, impossible or inadequate, and rarely large enough to evaluate the prevention of 
an infrequent event or outcome.64
A randomized trial on preconception care among the general population would mean that a 
huge population of women would need to be recruited, of which half would receive 
preconception counseling. The frequencies of pregnancy outcomes such as low birth weight, 
preterm delivery, congenital defects, and maternal complications would need to be compared 
between the two groups, which would be difficult considering the vast spectrum of obstetric 
outcomes and all confounders that should be adjusted for.
Possible adverse effects of counseling
The medicalization of pregnancy (interference with a naturally occurring process) is 
considered by some to be an important reason to refrain from large-scale implementation of 
preconception care for all women.63,65 For example, poor compliance to folic acid supplement 
use has been attributed to the fact that pregnancy is approached too much as a disease if a 
folic acid pill is to be taken daily.66 Increased anxiety or feelings of guilt triggered by 
screening are other possible adverse effects that make some hesitant to provide this form of 
care, especially since various studies report raised levels of anxiety amongst those with 
positive results or risks identified through various screening programs.67
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Desirability
In order for preconception care to be truly effective, desirability is vital both in the target 
population and the providers. Wallace and Hurwitz68 carried out a survey in the UK that 
revealed that a large majority of health care workers (86% of doctors and 95% of nurses) 
believed that preconception care could reduce maternal and neonatal morbidity and mortality. 
However, less that 40% of women considered preconception care to be essential and over 
10% believed it to be of no importance.68 In Hungary, the majority of couples reported to be 
satisfied with the program and reported improved self-esteem.6 The means of assessment, 
however, were not mentioned in that study.
Conclusion
Preconception care has become a health care priority for all women of childbearing potential 
in the US, which led to recommendations in order to promote and increase its provision and 
uptake.69 In most other countries, however, there is still no consensus on the implementation 
and delivery of preconception care. In light of the issues and obstacles addressed in this 
review, a series of studies on the desirability and feasibility of preconception care and the 
periconceptional period were initiated in the Netherlands. The results of these studies are 
presented in the following chapters of this thesis.
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ABSTRACT
Background: Identification of risk factors for adverse pregnancy outcome is a main 
component of preconception care, but requires adequate time and knowledge. This study 
compares self-administered questionnaires to history taking by a physician to evaluate the 
reliability of such a screening tool for prepregnancy risk detection.
Methods: One hundred ninety-three women from the outpatient clinic of Obstetrics and 
Gynecology of the University Medical Center Nijmegen, The Netherlands, were included in a 
study on preconception care. A Preconceptional Health Assessment form with risk variables 
pertaining to social, nutritional, medical, infectious disease, medication, reproductive and 
family history, and two Family History surveys (for the woman and her partner) were 
completed by 186 couples at home. A physician then orally verified the written answers. 
Agreement between the written and the oral answers was calculated using kappa statistic. 
Results: An excellent agreement level was found for all sections of the Preconceptional 
Health Assessment form (overall k=0.88) except for nutritional history (k=0.70). The Family 
History surveys also showed a high agreement level (k=0.92 for women and k=0.90 for men). 
Conclusions: The questionnaires are an accurate screening tool for preconceptional risk 
factors. We advocate their implementation in various settings to facilitate the provision of 
preconception care.
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Introduction
The importance of preconception care has long been established, and although various authors 
have emphasized its benefits for the past 15 years,1-9 implementation of this form of 
preventive medicine is still lacking. Currently, most women do not have pregnancy diagnosed 
until after the critical period of organogenesis, and may have already exposed the developing 
fetus to potentially harmful risks such as substance abuse, poor maternal health or disease, 
and teratogenic medication.
Screening and subsequent counseling before conception creates the opportunity to identify 
and reduce modifiable health risks, which could lead to improved pregnancy outcome. 
Screening couples with the intention to conceive should provide accurate information about 
their health state and cover a broad range of topics, including general lifestyle, nutrition, 
tobacco and alcohol use, obstetric and medical history, and genetic conditions in either parent 
or family. Various models for preconception risk assessment1 9-14 have been developed, but so 
far no uniform screening instrument has been repeatedly used or widely implemented. A 
standardized screening instrument may improve the delivery and documentation of 
preconception care by providers who neglect certain areas of screening due to limited time.14 
Likewise, a self-administered screening questionnaire could be an efficient tool to incorporate 
in health care settings that currently do not offer preconception care due to high workload or 
lack of knowledge.15,16 However, the accuracy of information elicited from a preconceptional 
screening questionnaire compared to history taking by a trained health professional has not 
previously been evaluated.
This study compares information elicited by two screening questionnaires, a Dutch version of 
the Preconceptional Health Assessment form developed by Cefalo and Moos3 and a Family 
History survey, to information gained orally by trained interviewers. Agreement between 
answers obtained by the two methods of screening was calculated in order to evaluate the 
accuracy and validity of these screening questionnaires for the assessment of health status, 
and obstetric, medical, and family history-related risks that could adversely affect pregnancy 
outcome.
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Methods
Study Population
Between September 1997 and April 1999, couples with a scheduled appointment at the 
fertility clinic (because of the inability to become pregnant within one year) or at the clinic for 
preconception care (due to previous obstetric complications or other maternal risk factors) of 
the University Medical Center Nijmegen were approached by letter to take part in a study on 
preconception counseling. Preconception counseling is not routinely offered to women 
presenting for infertility evaluation in the Netherlands, but was offered (as part of the study) 
to all women approached. After giving their informed consent, 193 couples were originally 
included and 186 women (96%) participated. Part of the study population was included in 
other studies on preconception counseling.17-19 The Medical Ethical Committee of the 
University Medical Center Nijmegen approved the study design.
Screening Instruments
A Dutch version of the Preconceptional Health Assessment form3 was used, which includes 
the risk categories of social, nutritional, medical, infectious disease, medication, reproductive, 
and family history. A checklist of risk factors (variables) is provided for each risk category. 
Any applicable risk factor should be marked, and a few variables, including diet, medication 
and vitamin intake, and alcohol and tobacco use, require additional written information to be 
given.
A modified version of the Family History survey, used by the Medical Genetics Department 
of the Clinical Genetics Center Groningen, The Netherlands, was also administered. One was 
to be completed by the woman and an identical one by her partner. The form contains a 
section for names, date of birth, and (where applicable) age of death of family members, and a 
list of 54 possible health risks or diseases. A checklist is provided to mark any applicable risk 
factor, and an additional section for the name, date of birth, and additional information of the 
affected family member. Although the 10 questions in the family history section of the 
Preconceptional Health Assessment form are in some way repeated in this survey, no part of 
either questionnaire was excluded so that both complete surveys could be validated.
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Procedure
After informed consent, one questionnaire pertaining to preconception health and lifestyle of 
the woman and two identical family history questionnaires (for both the woman and her 
partner) were sent home to be completed and returned during the first preconception visit at 
the clinic. A physician then orally verified all written answers during this visit by going 
through the completed survey together with the couple. A variable was considered accurate if 
identical answers were obtained, for example, if an ‘X’ was placed next to vitamin use and the 
interview confirmed vitamin intake. The variables requesting further information, such as 
brand and dosage of vitamins used, were considered accurate if no additional (or 
contradictory) information was obtained during the interview.
Data analysis
The prevalence of risk factors in the study population (identified by questionnaire and verified 
by interview) was calculated for all variables. Level of agreement between the written and 
oral form of screening was analyzed using kappa statistic (k), defined as the agreement 
beyond chance divided by the amount of agreement possible beyond chance. Kappa of 0.75 or 
above indicates an excellent level of agreement, kappa of 0.40-0.75 a fair to good agreement 
level, and kappa below 0.40, a poor level of agreement.20 Subgroup analysis was carried out 
to assess whether the clinic of recruitment (preconception care or fertility clinic) or the level 
of profession influenced the reliability of obtained answers. Level of agreement between 
written and oral answers of the different groups was considered comparable if the kappa score 
falls within the same range of accuracy (i.e., excellent, fair to good, poor). All analyses were 
carried out using SPSS 9.0.
Results
Of the 186 couples that completed the questionnaires, 65% (n=121) was recruited from the 
fertility clinic, and 35% (n=65) from the clinic for preconception care. The age of participants 
ranged from 21 to 42 years, with a mean age of 32.5 years (SD 3.9). Data on current 
profession were obtained from 145 women, and included 13 housewives, 22 unskilled 
workers (little or no vocational training), 68 trained workers, and 42 women in highly skilled 
professions (university degree).
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The agreement level was high between the two methods of screening. Kappa was > 0.75 for 
all risk categories of the Preconceptional Health Assessment form except for the nutritional 
history section (k=0.70), with an overall kappa score of 0.88. For the 54-item Family History 
survey completed by the women and men, the overall kappa score was 0.92 and 0.90, 
respectively. Subgroup analysis based on profession, including the category “profession 
unknown”, demonstrated that women with the lowest level of vocational training (unskilled 
workers) completed the surveys as accurately as women in highly skilled professions, with 
alcohol use forming the only exception (k=0.42 as compared to k=0.92). The clinic of 
recruitment (fertility clinic or preconception care clinic) did not influence the accuracy of the 
written answers as compared to interview. Only the question “Other health problems requiring 
medical or surgical care. If so, describe”, yielded a notable difference in kappa scores between 
these groups (0.82 for women seen for infertility and 0.63 for women seen for preconception 
care). The prevalence of risk factors found among study participants is shown in Tables 1-3.
Preconceptional Health Assessment Form
An excellent agreement level was found for most variables of the social history section 
(k>0.90; Table 1). Slightly lower but still good to excellent kappa scores were found for the 
risk variables “do you drink beer, wine, or hard liquor” (k=0.72) and “if so, how many drinks 
per day” (k=0.71). A high level of agreement was found for the yes/ no risk variable “tobacco 
use” (k=0.82), in contrast to “number of cigarettes smoked per day” (k=0.61). The nutritional 
history variable “eating habits”, which requests women to list all foods and drinks consumed 
the previous day (24-h recall), yielded the poorest kappa scores. Women were not accurate in 
reporting what they ate the previous day (k=0.03), nor did they give a complete list of 
products consumed (k=0.01). The variables “frequent consumption of the same foods, candy, 
or unusual things (i.e., detergent, sand)” and “vitamin supplement use” were reasonably 
accurate, as well as the “list of name(s) and dosage of vitamins” used (k=0.57). An excellent 
level of agreement was found between the written and the oral screening methods for the 
remaining nutritional history variables (k=0.83-1.00; Table 1).
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Table 1. Social, nutritional, and medical history variables: Level of agreement (Kappa)
Risk variable Prevalence 
N (%)
Kappa
Social history 0.90
Drink beer, wine, or hard liquor 138 (74.2) 0.72
Number of drinks per day 0.71
Tobacco use 71 (38.2) 0.82
Number of cigarettes per day 0.61
Marihuana, cocaine or other drug use 4 (2.2) 1.0
Chemical use at home/ work (describe) 26 (14.0) 0.95
Exposure to radiation at work 8 (4.3) 0.94
Participation in sports 111 (59.7) 0.92
Age > 34 years 64 (34.4) 0.94
Nutritional history 0.70
List of meals/ snacks consumed yesterday 185 (99.5) 0.03
Vegetarianism 5 (2.7) 0.83
Frequent consumption of snacks / pica 26 (14.0) 0.60
History of bulimia / anorexia nervosa 8 (4.3) 1.0
Special diet (describe) 8 (4.3) 1.0
Use extra vitamins 107 (57.5) 0.62
If so, list supplement(s) and dosage 0.57
Intolerance for milk 5 (2.7) 0.83
Medical history 0.96
Diabetes 6 (3.2) 0.85
Thyroid disease 7 (3.8) 1.0
Asthma 22 (11.8) 0.97
Heart disease 5 (2.7) 1.0
High blood pressure 19 (10.2) 0.97
Deep venous thrombosis 3 (1.6) 1.0
Kidney disease 6 (3.2) 1.0
SLE 2 (1.1) 1.0
Epilepsy 4 (2.2) 1.0
Sickle cell anemia 1 (0.5) 1.0
Cancer 3 (1.6) 1.0
Other health problems requiring medical 
or surgical care. If so, describe
91 (48.9) 0.76
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Table 2. Infectious disease, medication, reproductive, and family history variables:
Level of Agreement (Kappa)
Risk variable Prevalence 
N (%)
Kappa
Infectious disease history 0.95
STD 2 (1.1) 1.0
Herpes simplex 18 (9.7) 0.90
Chlamydia infection 29 (15.6) 1.0
Human papillomavirus 3 (1.6) 1.0
Gonorrhea 2 (1.1) 1.0
Viral hepatitis (or risk behavior3) 3 (1.6) 1.0
HIV (or risk behaviora) 2 (1.1) 0.80
Occupational exposure to blood 37 (19.9) 0.98
Blood transfusions 18 (9.7) 0.97
Own/ work with cats 55 (29.6) 0.97
Immunity to rubella 92 (49.5) 0.85
Medication history 0.79
Use of prescription medication 85 (45.7) 0.76
Use of over-the-counter medication 111 (59.7) 0.82
Reproductive history 0.96
Uterine or cervical abnormalities 14 (7.5) 0.88
2 or more first trimester miscarriages 25 (13.4) 0.91
Premature delivery (14-28 weeks GA) 13 (7.0) 0.96
One or more intra-uterine death(s) 10 (5.4) 1.0
Prior baby < 2750 g at birthb 24 (12.9) 1.0
Prior baby admitted to neonatal ICU 16 (8.6) 1.0
Prior baby with birth defect 9 (4.8) 1.0
Sickle cell disease 1 (0.5) 1.0
Family historyc 0.79
Birth defects 10 (5.4) 0.94
Are you and your partner related 1 (0.5) 1.0
Are you and your partner of the same race 177 (95.2) 0.23
a Risk behavior: intravenous drug use, bisexual/homosexual contacts or promiscuity. 
b Babies with a birth weight < 2750 g are admitted to the neonatal ward for observation. 
c The risk variables hemophilia, thalassemia, Tay-Sachs disease, sickle cell anemia, 
phenylketonuria, cystic fibrosis, and mental retardation were not found among participants.
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All of the medical history risk factors listed in the questionnaire were very accurate, and a 
perfect agreement level between written and oral answers was found for most variables (Table 
1). It was not possible to calculate the level of agreement for the risk factor phenylketonuria 
(PKU) as it was not present in the study population. An almost perfect level of agreement was 
found for 11 of the 12 variables in the infectious disease history section (Table 2). Syphilis as 
a risk factor did not occur among the study population. Screening through survey for 
prescription and over-the-counter medication was accurate in identifying name(s) and dosage 
of medication used (k=0.73 and k=0.76). An almost perfect agreement level was found 
between oral and written answers for Reproductive History variables, with an overall kappa of 
0.96. The majority of Family History risk variables of the Preconceptional Health Assessment 
form were not found in the study population (Table 2). The agreement level was poor for the 
question “are you and your partner of the same race?” (k=0.23), since in the interview it 
turned out that 23 couples were, but had written that they were not, and 4 couples reported 
being of the same race where this was not the case.
Family History Survey
Among the 54 risk factors, only the risk variables “muscular disease” (k=0.42), “bone 
disorders” (k=0.43), and “growth disorders, such as decreased or increased length and / or 
weight” (k=0.56) did not show a high level of agreement when compared to interview (Table 
3).
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Table 3. Family History Survey variables: Level of agreement (Kappa)
Risk variable N (%) Kappa N (%) Kappa
Women 0.92 Men 0.90
Spontaneous abortions (list No.) 100 (53.8) 0.99 73 39.2) 0.91
Prior intra-uterine deaths (list No.) 42 (22.6) 0.94 31 (16.7) 0.93
Pre-term delivery 47 (25.3) 0.93 27 (14.5) 0.84
Child death before 10 years of agea 57 (30.6) 0.91 36 19.4) 0.86
Death between 10 and 30 years of agea 14 (7.5) 0.81 19 10.2) 0.94
Growth disorders, such as increased 
decreased length and / or weight
or 6 (3.2) 0.74 2 11) 0.56
Down’s syndrome 15 (8.1) 0.96 13 7.0) 0.96
Mental retardation 15 (8.1) 0.92 13 (7.0) 0.96
Children requiring special education 38 (20.4) 1.0 20 (10.8) 0.97
(Attempted) suicide 20 (10.8) .97 13 7.0) 1.0
Persons admitted to psychiatric ward 35 (18.8) .97 23 (12.4) 1.0
Persons admitted to mental institution 9 (4.8) 1.0 9 4.8) 0.94
Neural tube defect, hydrocephalus 14 (7.5) 0.87 11 5.9) 0.90
Cleft lip and/ or palate 13 (7.0) 1.0 5 2.7) 0.79
Club foot 5 (2.7) 1.0 5 2.7) 1.0
Hip dislocation 23 (12.4) 0.98 11 5.9) 0.95
Cardiac defectsb 18 (9.7) 0.91 10 5.4) 0.95
Kidney disease 26 (14.0) 0.98 20 (10.8) 0.91
Bone disorders 5 (2.7) 0.79 2 2.7) 0.43
Other birth defects or malformations 15 (8.1) 0.77 15 (8.1) 0.89
Epilepsy 29 (15.6) 0.94 20 (10.8) 0.95
Paralysis (before 40 years of age) 7 (3.8) 0.92 4 (2.2) 1.0
Disease of the central nervous system 17 (9.1) 0.81 10 5.4) 0.82
Muscular disease 5 (2.7) 0.42 3 1.6) 0.74
Metabolic disorders 10 (5.4) 0.81 8 4.3) 0.79
Deafness, hearing loss 25 (13.4) 1.0 20 (10.8) 1.0
Blindness, poor vision, eye disease 37 (19.9) 0.97 22 11.8) 0.97
Sickle cell anemia 1 (0.5) 1.0 0 c
Blood disorders 14 (7.5) 0.87 9 (4.8) 0.94
Chronic skin disorders 23 (12.4) 0.97 26 (14.0) 1.0
Asthma, bronchitis, hayfever 77 (41.4) 1.0 59 31.7) 0.95
Lung disease 17 (9.1) 1.0 10 5.4) 0.90
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Risk variable N %) Kappa N (%) Kappa
Diabetes Mellitus 65 34.9) 0.94 40 (21.5) 0.95
Congenital and/ or chronic gastro-intestinal 22 11.8) 0.90 10 (5.4) 0.86
disorders
Cancer (specify organ) 128 (68.8) 0.95 95 (51.1) 0.90
Other chronic illnessb 4 (2.2) 0.85 4 (2.2) 0.88
Other disorders or handicaps 44 (23.7) 0.82 33 (17.7) 0.74
Involuntarily childless 42 22.6) 0.97 32 (17.2) 0.90
Voluntarily childless 20 (10.8) 1.0 13 (7.0) 1.0
Childless, reason unclear 19 (10.2) 1.0 18 (9.7) 0.97
Poor sperm quality 5 2.7) 1.0 16 (8.6) 0.96
Undescended testes 5 2.7) 1.0 6 (3.2) 1.0
Baldnessb 22 11.8) 0.95 26 (14.0) 0.98
Genital abnormalities 6 3.2) 1.0 0 -
Irregular menstrual cycle 35 18.8) 0.93 3 (1.6) 0.85
Premature menopause 11 5.9) 0.72 4 (2.2) 0.72
Endometriosis 5 2.7) 1.0 4 (2.2) 1.0
Uterine fibroids 43 (23.1) 0.95 21 (11.3) 1.0
Acne 31 (16.7) 1.0 17 (9.1) 1.0
Hirsutism 12 (6.5) 0.88 3 (1.6) 1.0
Obesity (women > 80 kg; men > 90 kg) 55 29.6) 0.99 23 (12.4) 0.97
a Excluding accidents.
b Before 35 years of age. 
c Risk factor was not present among men.
Discussion
This is the first reliability study of questionnaires used for preconception counseling. The use 
of this tool for the assessment of preconception risk factors is a reliable screening method, and 
reflects accurate information compared to detailed history taking by a physician. 
Implementation of such questionnaires as a first step in preconception care has clear potential 
benefits. By completing the forms, couples are forced to reflect on their health and lifestyle 
before the consultation. Second, a great deal of time spent on history taking could be saved if 
potential risks are already identified prior to a first consultation.
49
The questionnaires could function as an aid to various health care workers, who could 
distribute the surveys, review the identified risks (if any) and, if  appropriate, refer women at 
risk for adverse pregnancy outcome to a gynecologist, geneticist or other expert. By filtering 
out only relevant topics to be covered during the consultation, this method of screening also 
creates more time to educate women on aspects of health promotion such as periconceptional 
folic acid supplementation for the prevention of neural tube defects,21 proper nutrition, and the 
risks from substance use in pregnancy.
Shortcomings o f the screening tool
A few variables in the survey did not provide reliable data. The low kappa value for the risk 
variables “muscular disease”, “bone disorders”, and “growth disorders, such as decreased or 
increased length and/or weight”, can probably be attributed to the fact that these variables are 
not very specific. Perhaps a list of well-defined, clinically relevant risk factors, such as 
“muscular dystrophy”, “osteogenesis imperfecta”, or “dwarfism”, would yield higher kappa 
scores. A more comprehensive alternative for future applications of the questionnaire would 
be to include the phrase “ if  so, describe” to these variables. The risk variable “eating habits” 
was not well defined, but listed as: "On the back of this form, please list all meals and snacks 
that you ate and drank yesterday, including portion size". It was included in the analysis of the 
nutritional history risk section as a single variable, and yielded a notoriously poor kappa score 
(0.03). Clearly, the written 24-h recall method compared to interview was a poor way to 
assess eating habits of the women in our study. An alternative method for assessment of diet 
would be the use of an additional tool such as a validated food frequency questionnaire, 
although this would undoubtedly become too time-consuming to fill out. Moreover, the 24-h 
recall method for assessment of habitual diet has been shown to compare quite well to data 
obtained from food frequency questionnaires as well as to the results obtained from weighed 
food records.22 It therefore appears that interview (based on written 24-h recall data) is the 
most reliable and practical way to assess diet in our setting.
It should be noted that the reliability of the clearly defined nutritional risk variables, such as a 
history of bulimia or anorexia, vegetarianism or other diets, was high. In this respect, more 
specific items about certain products, i.e. foods rich in folic acid, may be more reproducible 
than a general food diary. The kappa score for the questions on vitamin supplement use, 
however, was lower, mainly because many women answered that they were not using 
vitamins, but during the interview it turned out that they were taking folic acid. The addition
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of variables on folic acid supplement intake and dosage used should be considered in order to 
improve clarity. Moreover, the apparent lack of awareness among women who regard folic 
acid as a drug and not as a vitamin supplement, reflects a need to continue to educate the 
population at large. A preconception counseling visit has recently been shown to be an 
effective opportunity to educate couples on the importance of periconceptional folic acid 
intake and stimulate those women not yet taking supplements to start.17
The survey was quite accurate in screening for alcohol and tobacco use as well as for the 
quantity of alcoholic beverages consumed daily. A larger discrepancy was found between 
smoking habits reported in the questionnaire compared to interview. It has been demonstrated 
by cotinine assay as a biochemical marker that a significant number of women tend to 
underreport or deny their smoking habits.19,23 Health care providers should keep in mind that 
self-reported smoking habits are often unreliable, whether obtained through questionnaire or 
interview. Nevertheless, a preconception screening visit still offers an important opportunity 
to address the possible obstetric complications of smoking, such as intrauterine growth 
retardation, spontaneous abortion and abruptio placentae, and stimulate smoking 
cessation.19,24 If necessary, the initiation of treatment may also be discussed at this time. 
Screening and subsequently addressing risk behavior and possible related consequences 
confronts women to think about their own health and lifestyle, while improving awareness 
and stimulating personal responsibility for preconceptional well-being.
Limitations o f the Study
Data on profession were not available for 41 women due to incomplete forms. This variable, 
used as an indicator of educational background, was missed by a relatively large group of 
women as well as the physician who verified the written answers. Subgroup analysis was 
performed to ascertain whether the survey is reliable across educational backgrounds. 
Considering that the less educated women as well as women with unknown professions 
completed the surveys as accurately as women with a higher educational background, we can 
infer that this is indeed the case. Second, this demographic characteristic was intended to 
assess whether our study sample of women was representative of the Dutch population. Based 
on data of women with known professions (excluding housewives; n=132), the percentage of 
women in highly skilled professions (32%) is reasonably in accordance with the number of 
highly trained professionals in the Netherlands (29%).25 The percentage of women with 
professions requiring little or no vocational training (17%) was quite a bit lower than in the
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general Dutch population (31%), with many more women in our study sample in skilled 
professions (52 vs. 39% in the Netherlands). However, since we do not know the profession 
of 22% of our study population, these limited data should be interpreted with care.
Our population of women is quite old compared to other study populations receiving 
preconception care. However, mean maternal age of Dutch women when they bear their first 
child, being 29.2 years in 2000 (and still increasing), is the highest in the world.26 Moreover, 
women who attend fertility clinics because of inability to become pregnant within one year 
(as was the case for two-thirds of our study population) tend to be even older when they bear 
their first child. Although it seems plausible that these women and partners with a strong 
desire to become pregnant may be more motivated, they did not complete the questionnaires 
more accurately than those attending the preconception care clinic.
Current practices
To our knowledge, this is the first study to demonstrate the applicability of a self­
administered risk assessment questionnaire prior to a first preconceptional visit. 
Administration of preconception screening questionnaires by trained professionals during a 
consultation has been reported previously.10,13,14 Bernstein et al. demonstrate that insertion of 
a standardized screening form into a patient's chart leads to improved documentation of 
preconception care.14 They note that the use of a standardized tool highlights important issues 
and prevents omission due to limited time, and could also facilitate research into the 
effectiveness of preconception care. However, because the form they used has several 
drawbacks such as lack of clarity and too much material to be covered in one visit, they argue 
for additional research for the development of a more effective form.14 Jack et al. showed that 
administration of a risk assessment survey by trained health professionals during a structured 
interview (at the time of a negative pregnancy test) led to the detection of a significant 
number of obstetric risk factors.13 A subsequent study, however, showed that risk detection 
did not improve preconceptional intervention rates,10 which was also in part attributed to a 
lack of time among clinicians.
Most health care professionals acknowledge the importance of preconception care and are
12,15,16,27very willing to take an active role. , , , A survey among general practitioners in The 
Netherlands illustrated that although 93% considered preconception counseling part of their 
job, 53% lacked specific knowledge needed to give adequate advice, and 30% indicated not
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having enough time to provide preconception counseling.15 A low level of provider 
knowledge regarding preconception care has also been reported in other settings.14,16 These 
issues further underscore the need for a clear, reliable and timesaving tool that can aid health 
care workers in the provision of preconception care.
Conclusions
The screening questionnaires used in this study are a reliable tool for use in prepregnancy risk 
detection and we therefore advocate their use in the future. Implementation of this screening 
tool in primary health care as well as clinical settings could improve accessibility of 
preconception care by facilitating its provision, and thereby reduce maternal and fetal 
morbidity through timely detection of modifiable risks. Further evaluation of these 
questionnaires and subsequent pregnancy outcome should provide conclusive evidence of the 
benefits of preconception counseling.
53
REFERENCES
1. Allaire AD, Cefalo RC. Preconceptional health care model. Eur J Obstet Gynecol Reprod Biol 
1998; 78:163-8.
2. American College of Obstetricians and Gynecologists. Preconceptional care. ACOG technical 
bulletin no. 205. Int J Gynaecol Obstet 1995;50:201-7.
3. Cefalo RC, Moos MK. Preconceptional health care: a practical guide. 2nd ed. St. Louis, Missouri: 
Mosby-Year Book, Inc, 1995.
4. Czeizel AE. Ten years of experience in periconceptional care. Eur J Obstet Gynecol Reprod Biol 
1999;84:43-9.
5. Hollingsworth DR, Jones OW, Resnik R. Expanded care in obstetrics for the 1980s: preconception 
and early postconception counseling. Am J Obstet Gynecol 1984;149:811-4.
6. Jack BW, Culpepper L. Preconception care. J Fam Prac 1991;32:306-15.
7. Jones TB, Johnson MP, Drugan A, Evans MI. Preconceptional planning. Obstet Gynecol Clin 
North Am 1990;17:801-15.
8. Olsen ME. Preconception evaluation and intervention. South Med J 1994;87:639-4.
9. Moos MK. Preconceptional health promotion: a health education opportunity for all women. 
Women Health 1989;15:55-68.
10. Jack BW, Culpepper L, Babcock J, Kogan MD, Weismiller D. Addressing preconception risks 
identified at the time of a negative pregnancy test: a randomized trial. J Fam Practice 1998;47:33- 
8.
11. Perry LE. Preconception care: a health promotion opportunity. Nurse Pract 1996;21:24-6, 32,34 
passim.
12. Barron ML, Ganong LH, Brown M. An examination of preconception health teaching by nurse 
practitioners. J Adv Nurs 1987;12:605-10.
13. Jack BW, Campanile C, McQuade W, Kogan MD. The negative pregnancy test. An opportunity 
for preconception care. Arch Fam Med 1995; 4: 340-5.
14. Bernstein PS, Sanghvi T, Merkatz IR. Improving preconception care. J Reprod Med 2000;45:546- 
52.
15. Gaytant MA, Cikot RJ, Braspenning JC, Grol RP, Merkus JM, Steegers EAP. [Preconception 
counseling in family practice; a survey of 100 family physicians]. Ned Tijdschr Geneeskd 
1998;142:1206-10.
16. Conway T, Mason E, Hu TC. Attitudes, knowledge, and skills of internal medicine residents 
regarding pre-conception care. Acad Med 1994;69:389-91.
54
17. De Weerd S, Thomas CMG, Cikot RJLM, Steegers-Theunissen RPM, de Boo TM, Steegers EAP. 
Preconception counseling improves folate status of women planning pregnancy. Obstet Gynecol 
2002;99:45-50.
18. De Weerd S, van der Bij AK, Braspenning JCC, Cikot RJLM, Braat DDM, Steegers EAP. 
Psychological impact of preconception counseling: assessment of anxiety before and during 
pregnancy. Community Genet 2001;4:129-33.
19. De Weerd S, Thomas CMG, Cikot RJLM, Steegers EAP. Maternal smoking cessation 
intervention: targeting women and their partners before pregnancy. Am J Public Health 2001; 
91:1733-4.
20. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 
1977;33:159-74.
21. Czeizel AE. Ten years of experience in periconceptional care. Eur J Obstet Gynecol Reprod Biol 
1999;84:43-9.
22. Bingham SA, Gill C, Welch A, Day K, Cassidy A, Khaw KT, et al. Comparison of dietary 
assessment methods in nutritional epidemiology: weighed records versus 24h recalls, food 
frequency questionnaires and estimated-diet records. Br J Nutr 1994;72:619-43.
23. Ford RPK, Tappin DM, Schluter PJ, Wild CJ: Smoking during pregnancy: how reliable are 
maternal self reports in New Zealand? J Epidemiol Cummunity Health 1996;51:246-51.
24. Jones-Webb R  McKiver M, Pirie P, Miner K. Relationships between physician advice and 
tobacco and alcohol use during pregnancy. Am J Prev Med 1999;16:244 -7.
25. Central Bureau for Statistics (CBS) 1999. The Hague, The Netherlands.
26. Central Bureau for Statistics (CBS) Statistical yearbook 2000. Voorburg / Heerlen, The 
Netherlands.
27. Klerman LV, Reynolds DW. Interconception care: a new role for the pediatrician. Pediatrics 
1994;93:327-9.
55

Chapter 4
Psychological impact of preconception counseling: 
Assessment of anxiety before and during pregnancy
Sabina de Weerd1 Akke K. van der Bij2 Jozé C.C. Braspenning2 Rolf J.L.M. Cikot1 
Didi D.M. Braat1 Eric A.P. Steegers3
1Department o f Obstetrics and Gynecology, University Medical Center Nijmegen
2Center for Quality o f Care Research, University o f Nijmegen
3Department o f Obstetrics and Gynecology, Erasmus Medical Center Rotterdam
Community Genet 2001;4:129-33
ABSTRACT
Objective: Assessment of anxiety levels in women and men before and after preconception 
counseling and during the first trimester of pregnancy.
Methods: Couples were recruited from the fertility clinic of the University Medical Center 
Nijmegen, the Netherlands. Anxiety was assessed using the 40-item Spielberger State-Trait 
Anxiety Inventory (STAI).
Results: 53 women and 51 men (74%) completed the STAI both before and after counseling. 
Anxiety levels did not change significantly after counseling or during the first trimester of 
pregnancy. 83.4% would recommend preconception counseling to others.
Conclusion: Preconception counseling is valued by the majority of women and men and does 
not lead to adverse psychological effects.
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Introduction
Preconception care anticipates obstetric, genetic, and other health problems that may arise in 
couples planning a pregnancy.1 Identification of risk factors through assessment of many 
different aspects of health, lifestyle and family history before conception provides a unique 
opportunity to address potentially harmful situations that may adversely affect pregnancy 
outcome. Possible risks may be signaled, couples can be educated about actions they can take 
to promote desirable outcome, and often interventions can be initiated. However, many 
conditions exist that cannot be altered. This especially applies to cases where risks related to 
family history are identified, where interventions are often not possible and couples face 
difficult decisions. Although preconception care and subsequent counseling have clear 
benefits that may contribute to better health of mother and child,1 the possible harm caused by 
this form of prevention also needs to be considered.
A frequent concern is the psychological impact of screening. The psychological harm that 
screening programs may cause include anxiety over the results, and implications and 
consequences of being labeled as ‘at risk’.2 Various studies report raised levels of anxiety 
amongst those with positive results or risks identified through various screening programs, 
and illustrate that the receipt of a negative result is not always reassuring.3 The possible 
adverse effects of screening should be evaluated before the widespread implementation of a 
population-based preventive program such as the provision of preconception care to all 
women planning to conceive. Couples may not want to know if their health state or family 
history could harm their future offspring. Whether counseling is appreciated, and whether and 
to what extend anxiety is induced by the consultation, are important preliminary issues that 
need to be evaluated.
In this study, the effect of preconception screening and subsequent counseling on anxiety 
levels was studied in couples recruited from a fertility clinic. It could be that a possible effect 
of counseling is not seen immediately, but becomes evident during pregnancy, at which time 
couples could start to worry about issues discussed at the preconception consultation or 
experience increasing anxiety because of their particularly 'precious' pregnancy after a history 
of infertility.4 Therefore, anxiety levels were evaluated again among those who became 
pregnant.
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Methods
Between September 1997 and April 1999, 121 couples attending the fertility clinic of the 
University Medical Center Nijmegen, the Netherlands, were informed by a gynecologist or 
resident about the study on the desirability and effect of preconception counseling. Most 
Dutch women do not seek care until pregnancy has been established, which poses great 
difficulty in recruiting a low-risk population preconceptionally. Study participants were 
recruited from a fertility clinic because all were planning pregnancy, and although they form a 
selected population, were not expected to differ from women conceiving naturally in terms of 
preexistent risk factors for adverse pregnancy outcome.5 The couples received a letter that 
contained information about purpose and design of the study and invited them to participate. 
After giving their informed consent, 71 women and 70 men completed the first Spielberger 
State-Trait Anxiety Inventory (STAI) questionnaire. The Medical Ethical Committee of the 
University Medical Center Nijmegen approved the study.
A validated Dutch version of the STAI-DY 6,7 was used to detect changes in anxiety levels. 
This self-evaluation questionnaire is a reliable and sensitive instrument, and one of the most 
frequently used measures of anxiety in applied psychology research.6,7 The full version 
consists of 40 items, with 20 pertaining to stress disposition (trait-anxiety) which is 
considered to be stable over time, and 20 pertaining to current anxiety levels (state-anxiety), 
which is sensitive to change. Answers are based on a four-point scale, with total scores 
ranging from 20 to 80. Precounseling trait scores were measured for comparison with STAI- 
trait scores of the Dutch population and to exclude possible bias of the study outcome. 
Changes in STAI-state scores were considered to reflect the impact of counseling (with a 
higher postcounseling score indicating an adverse effect and a lower score a reassuring 
effect). A mean increase in STAI-state score of 11 points among women and 9 points among 
men was found in the reference population after a stressful situation.6 In order to detect such a 
difference in mean STAI-state scores, 52 participants were needed for our study (a=0.05; 
power = 90%).
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Participants were asked to complete the STAI questionnaire for the first time (STAI-1) before 
their intake visit with a physician at the Obstetrics and Gynecology Department. During this 
visit, a broad range of possible risk factors for adverse pregnancy outcome was assessed using 
a Preconceptional Health assessment form1 and a family history survey. These screening 
questionnaires were completed beforehand and verified during this consultation. Another 
appointment was made 4 to 6 weeks later, allowing time for further investigations 
consultation of other experts if  necessary, at which time any applicable risk factors and their 
implications or possible consequences were discussed.
General aspects of prepregnancy health care such as smoking cessation, proper nutrition, folic 
acid supplementation, and a plan for antenatal care were also covered during the counseling 
session. Couples received the STAI again after this counseling session to be completed at 
home and returned within 2 weeks after counseling (STAI-2). Nonresponders were 
encouraged by phone to send back the questionnaires within this period. When pregnancy 
occurred, couples were asked to complete the survey once more in the first trimester (STAI- 
3). Several questions specific to anxiety during the current pregnancy and a question on the 
appreciation of preconception counseling were included in STAI-3.
Mean STAI-state and trait scores before counseling (preintervention) were determined for the 
entire study population and for the subgroups that completed more than one STAI 
questionnaire. A paired t-test was performed to assess the effect of counseling on anxiety 
among participants that completed the STAI both before and after counseling (STAI-1 and 2) 
and before counseling and during pregnancy (STAI-1 and 3). A frequency table (%) was 
made to evaluate the additional pregnancy-specific questions of STAI-3. Statistical 
significance was defined by p<0.05.
Results
Population
Seventy-one women and 70 men completed STAI-1, 56 women and 55 men completed STAI- 
2 and 42 men and 42 women completed STAI-3. The effect of counseling on anxiety could be 
evaluated in 74% of the study population (STAI-1 vs. 2), and a possible long-term effect of
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counseling (STAI-1 vs. 3) was assessed in 57% of those who became pregnant. Mean age 
(SD) of the participants was 34.5 (3.9) years. Baseline STAI-state and trait scores are 
comparable for the three subgroups (Table 1) though stress disposition is slightly higher 
among women who completed both STAI-1 and 3. As only 27 participants completed the 
STAI at all three points in time, their data were not considered to be representative.
Table 1. STAI-scores before counseling
Population1 n STAI-state STAI-trait
Women
STAI 1 71 35.5 (10.4) 35.6 (8.8)
STAI 1 and 2 53 35.2 (9.9) 34.6 (7.3)
STAI 1 and 3 24 36.8 (11.9) 37.1 (9.7)
Van der Ploeg6 127 resp.125 38.0 (12.8) 39.0 (11.1)
Men
STAI 1 70 33.9 (8.0) 32.6 (8.4)
STAI 1 and 2 51 33.5 (6.9) 32.8 (7.4)
STAI 1 and 3 24 34.7 (7.7) 32.8 (10.2)
Van der Ploeg6 126 resp.124 35.8 (8.8) 36.5 (9.5)
Figures given are means (SD).
1Precounseling scores are shown separately for women and men that completed 
STAI-1 only, STAI-1 and 2 (before and after counseling), and those that completed 
STAI-1 and 3 (before counseling and during pregnancy).
Effect on Anxiety
Preconception counseling did not induce anxiety among the study population. No significant 
change in anxiety levels was seen in men or women after counseling (Table 2).
Table 2. Change in anxiety scores (STAI-state)
After counseling p value During pregnancy p value
(STAI-1 vs. 2) paired t-test (STAI-1 vs. 3) paired t-test
Women +0.1 0.980 -1.1 0.649
Men -0.8 0.373 -2.2 0.091
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STAI-state scores were actually lower during the first trimester of pregnancy as compared to 
precounseling scores, though this difference is not statistically significant. Although STAI 
state scores of the men were lower at all points in time, no significant differences in scores 
were found between men and women. In the pregnancy-specific items related to stress, 
included in STAI-3, half of the couples reported feeling concerned when thinking about the 
baby and the majority (82%) worried to some extend about the pregnancy (Table 3). 
However, almost all had confidence in the pregnancy outcome (98.8%). The question 'Would 
you recommend preconception counseling to friends and acquaintances trying to conceive?' 
was answered affirmatively by 83.4% of couples (56% answered yes, and 27.4% would 
probably recommend preconception counseling). 14.3% would probably not recommend 
preconception counseling, and only one couple answered no.
Table 3. Anxiety specifically related to pregnancy
Question (included with STAI-3) Not at all Somewhat Quite a bit Very much
I worry about my pregnancy 17.9 61.9 14.3 6.0
I am nervous when I think about 51.2 39.3 8.3 1.2
the baby
I am confident about the outcome 1.2 15.5 53.6 29.8
of my pregnancy
Figures given are percentages.
Discussion
This is the first study on the psychological impact of preconception counseling in terms of 
anxiety before and during pregnancy. Though it is undisputed that preconception counseling 
should be accessible to women at high risk for adverse pregnancy outcome, no consensus has 
been reached whether low risk women and their partners should be offered preconception care 
as well. We feel that the women in our study can overall be considered as being at low-risk 
for adverse pregnancy outcome, based on a Dutch matched control study on outcome of 
singleton in vitro fertilizations (IVF) and spontaneously conceived pregnancies. Although 
significantly more pregnancies ended preterm and a larger number of small for gestational age 
babies were born in the IVF group, no significant differences in pregnancy complications,
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perinatal mortality, or neonatal condition were found in the study carried out at four university 
hospitals in the Netherlands.5 In addition, our study group was not a homogeneous IVF 
population but included women who took longer to conceive without any further problems.
A question often raised is whether participating in a screening program adds to the alarm 
people already feel about their health.2 This effect could be induced through expansion of 
preconception screening and subsequent counseling to a larger target group. Ideally, this issue 
should be addressed among women who have not needed to consult a gynecologist for any 
reason, since it is likely that the women in our study are already more aware of various 
aspects of preconceptional health and well-being due to their difficulty in becoming pregnant. 
However, neither women visiting fertility clinics nor women conceiving naturally are offered 
routine preconception screening in the Netherlands. In our population, no such adverse effects 
of counseling (using change in anxiety as an indicator of alarm) were found. One could 
imagine that this reassuring effect is only short-term and that anxiety levels would rise again 
once women are actually pregnant, though this was not the case. STAI-state scores were even 
lower during pregnancy than before counseling. Whether this reflects a long-term reassuring 
effect of counseling, or is perhaps due to the relief of the (often) long-awaited pregnancy, is 
unknown. Nevertheless, as only one pregnant couple indicated not having confidence in the 
pregnancy outcome, it seems likely that most couples were reassured to some extent by the 
consultation.
No postcounseling data were available for 18 women and 19 men because they did not send 
back the STAI questionnaires within the 2-week period after counseling. Efforts to collect the 
forms were ceased after this time period in order to maintain comparable data on the short­
term effect of counseling. Because the baseline anxiety level of the entire study group did not 
differ significantly from that of the women and men that did complete the second STAI 
questionnaire (Table 1), it seems that the obtained results are representative. One could 
question whether couples recruited from a fertility clinic are representative of the general 
population in terms of current anxiety and stress disposition because of their infertility. To 
address this issue, we compared precounseling STAI-state and trait scores of our study group 
to reference values found in a general Dutch population of women and men between 16 and 
40 years of age.6 Both STAI-trait and state scores were actually lower in our study group 
(Table 1), so that we could infer that women and men in our clinical setting are not more 
disposed to anxiety than the population at large. It also seems unlikely that the possible
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anticipation of screening elevates anxiety before consultation, otherwise higher pre­
counseling STAI-state scores would be expected. Furthermore, a recent American study 
showed that pregnant IVF women are similar psychologically to women who become 
pregnant naturally in terms of anxiety (as well as depression and self-esteem) at 12 and 28 
weeks gestational age.4
A study by Rose et al.8 on the feasibility and acceptability of genetic counseling in primary 
care also evaluated anxiety levels before and after consultation and again after 12 weeks using 
the short version of the STAI. A significant reduction in anxiety was found immediately after 
consultation, and returned to initial anxiety levels after 12 weeks. They conclude that 
counseling results in a short-term reduction in anxiety, with no long-term adverse effects. This 
difference with our results in postcounseling anxiety is most probably attributable to the 
difference in study population. Psychology research has shown that screening generally 
provides some certainty for those already identified as being at increased risk, regardless of 
the result,3 which could explain the reduction in anxiety found after counseling in their 
population and not among women attending our fertility clinic. In their study, couples were 
invited by letter to attend a clinic for genetic counseling, and although one-fifth came out of 
general interest, many attended the consultation because they were aware of diseases that ran 
in the family and were (or felt) at higher risk for adverse pregnancy outcome. This is in 
contrast to the specific problem for which women attended our clinic, namely to seek help in 
becoming pregnant after an unsuccessful 1-year period.
Preconception counseling, currently only offered to women at high risk for adverse pregnancy 
outcome in the Netherlands, is a largely unknown health care service among the general 
population and usually not actively sought by couples planning pregnancy. Although we only 
have one indicator, it seems that most couples appreciated counseling considering that the 
majority would recommend it to others. Despite the opportunities for prevention and 
education offered through preconception counseling, structural implementation and 
accessibility to all couples planning pregnancy remains debated. Our results, demonstrating 
acceptability and a lack of adverse psychological effects of preconception counseling, should 
be taken into account during further considerations of expanding preconception care to a 
larger target population.
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ABSTRACT
Objective: To validate the six-item short form of the state scale of the Spielberger state-trait 
anxiety inventory (STAI) for usage in screening outcomes in a Dutch population receiving 
preconception counseling.
Methods: Men and women completed the 20-item full form of the STAI-state before (n=310) 
and after preconception counseling (n=147). Prorated scores of the six-item form were 
compared to the full form using Pearson correlation coefficients and paired t-tests.
Results: Cronbach’s alpha for the Dutch translation of the short form of the STAI-state was
0.83. The short form highly correlates with the full form (r = 0.95). The short form was able 
to discriminate between different levels of anxiety and was sensitive to change.
Conclusion: The Dutch translation of the short form of the STAI-state has good reliability 
and validity was found to be useful as a quick tool to evaluate the effectiveness of screening 
programs on anxiety levels. We believe our results will be applicable to other populations, 
although this needs to be confirmed in other studies.
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Introduction
Screening programs have many potential benefits, one of the most important being a possible 
reduction in morbidity and mortality rates. However, they may also cause physical, 
psychological, or social harm.1-4 In order to evaluate whether a screening program does more 
harm than benefit to the patient, tools to measure patient-centered outcomes, besides clinical 
outcomes, are needed. One of the possible adverse effects of screening programs, such as 
screening for cancer, genetic disorders or preconception counseling, could be increased 
anxiety.1,4 Although a transient increase in anxiety should not necessarily be regarded as a 
serious disadvantage of a screening program, it may however become a problem if it persists 
or has behavioral consequences. By asking participants to complete a short anxiety 
questionnaire before and after screening, and after explaining test results, it is possible to 
evaluate the effect of a screening program on anxiety levels.
The Spielberger State-Trait Anxiety Inventory (STAI) is one of the most widely known self­
report scales to measure anxiety and has been used extensively in the past decades as a 
research and clinical instrument.5 Validation of the STAI has proven its reliability and 
sensitivity in the measure of anxiety. It has been translated in numerous languages and is a 
standard international measure in anxiety research.6 The STAI consists of two scales, each 
containing 20 items. One scale measures how one generally feels (trait) and one measures 
how one feels at the moment (state). Both scales are useful in evaluating research results. A 
difference in trait scores between an intervention and control group may bias state scores, 
since subjecs with a higher disposition to anxiety (trait) will view certain situations as more 
threatening than those that are less prone to anxiety. For evaluating the effect of interventions 
only the state scale is used as it is specifically sensitive to changes in anxiety, but this still 
produces a questionnaire with 20 items.
Due to the number of variables that can be measured in evaluating research, a shorter and less 
time consuming version of an anxiety questionnaire would be useful to evaluate one 
parameter of patient-centered outcomes. Ten-item short forms of the STAI-state have been 
constructed in the past, but were never standardized and are not widely used in clinical or 
psychological research.7-10 However, a six-item short form of the state scale has been 
constructed and validated by Marteau and Bekker,11 and also found its application in clinical
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research.12-14 There may still be some deficiencies in the construction of the short form.11 
Item-selection was done in a population of only pregnant women, which may not be 
representative for the whole population. Some studies have shown that females score higher 
on the STAI-state or trait than men15-17 or may have a different response to stressful life 
events than men.18,19 It appears that more information concerning the validity of the short 
form of the STAI-state is necessary before wide application is recommendable. One of the 
main issues raised is whether the results found can be extrapolated to a population of both 
men and women. Furthermore, no information is available concerning the validity of the short 
form in a population at high-risk for adverse screening outcomes.
The full form of the STAI has been translated into Dutch in the past and validated for the 
Dutch setting.20 So far no results are available concerning the validation of a short form of the 
STAI-state in the Netherlands. In this study we validated the Dutch translation of the six-item 
short form of the STAI-state in a population of men and women at low- or high-risk for 
unfavorable screening outcomes.
Methods
Couples recruited from the clinic for preconception care or the fertility clinic of the University 
Medical Center Nijmegen, the Netherlands, between September 1997 and April 1999, were 
included in a study on the desirability and effect of preconception counseling.21 Those 
attending the preconception care clinic (because of previous obstetric complications or other 
risk factors) were considered to be at high risk for adverse pregnancy outcome and comprised 
97 women and 72 men. The couples recruited from the fertility clinic were considered to be at 
low risk for adverse pregnancy outcome (71 women and 70 men). The results of the full STAI 
form among these couples have been described elsewhere.21
A validated Dutch version of the Spielberger State-Trait Anxiety Inventory (STAI)20 was 
used in this study to validate the six-item short form of the state scale as constructed by 
Marteau and Bekker.11 The six-item short form included the following items: calm, tense, 
upset, relaxed, content and worried. Answers are based on a four-point scale, giving a total 
sum score ranging from 20 to 80 with a low score indicating little or no anxiety and high 
score indicating an increased level of anxiety. The Medical Ethical Committee of the
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University Medical Center Nijmegen approved the study. After giving informed consent, 
participants were asked to fill out the STAI questionnaire at the clinic before the counseling 
session and within two weeks after preconception counseling.21 In order to minimize clustered 
responses, couples were requested to fill out the questionnaires independently.
To determine reliability of the Dutch translation of the six-item short form of the STAI-state, 
Chronbach’s alpha was calculated to assess internal reliability. As state anxiety is of transitory 
nature, test-retest reliability was not accounted for.22 Concurrent validity, which is the extent 
to which scores on the short form are similar to those obtained using the full form, was 
determined by using Pearson correlation coefficients and paired t-tests. Prorated scores from 
the six-item short form were compared to both the full form and the remaining 14 items to 
avoid over-inflated correlations caused by items correlating with themselves. The 
discriminative power of the short form of the STAI-state in the ability to detect different 
anxiety levels among groups was tested using one-way ANOVA analysis.
To determine the sensitivity of the short form to detect changes in anxiety state as detected by 
the full form, STAI-state scores of the short form were tested before and after preconception 
counseling using paired t-test. Assessing reliability and validity of the six-item short form was 
done in the total population, in men and women separately and in the high and low risk 
groups. Statistical significance was defined by p<0.05.
Results
Population
One hundred and sixty-eight women and 142 men completed the STAI before preconception 
counseling. Mean age (SD) of the participants was 33.9 (4.3) years. Of the 310 subjects who 
completed the STAI before counseling, 70 men and 77 women also filled out the STAI after 
counseling (46%). Results are based on statistical analysis of the 310 participants who 
completed the STAI before preconception counseling. We used parametric statistical tests as 
both the short form and full form had a normal distribution of anxiety scores.
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Chronbach’s alpha (a) for the Dutch translation of the short form of the STAI-state for the 
total population was 0.83. The short form correlated highly with the prorated 14-item form 
and the full form. Pearson correlation coefficient (r) was 0.89 (p<0.001) when comparing 6- 
to 14-items and was 0.95 (p<0.001) when comparing 6-items to the full form. Results of the 
paired t-test comparing the 6-item short form with the 14- and full-item form showed a 
significant difference in mean STAI-state scores (p<0.001 for both tests), however, in 
absolute numbers this difference was very small (38.7 versus 37.7 and 38.0). A difference in 
anxiety level was found between high-risk women and the rest of the participants using the 
full form of the STAI-state as well as with the short version (Table 1).
Table 1. STAI-state scores before preconception counseling
Population N Full form Short form
Low-risk men 70 33.9 (8.0) 35.2 (8.8)
Low-risk women 71 35.5 (10.4) 35.9 (11.2)
High-risk men 72 35.6 (8.5) 36.2 (8.8)
High-risk women 97 44.6 (9.9)* 45.3 (10.8)*
Figures given are means (SD). *p<0.001
Results of the reliability and validity of the six-item short form in men and women separately 
and in the low- and high-risk population are presented in table 2. The six-item short form 
shows good internal reliability and correlated highly with the full form in all populations. 
Both the short- and full form show similar levels of baseline anxiety and both forms are 
sensitive to change, specifically, both forms demonstrate a decline in anxiety scores after 
counseling in the high-risk population. Table 2 also demonstrates a difference in baseline 
anxiety scores between men and women and between low- and high-risk participants.
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Table 2. Reliability and validity of the six-item short (SF) form as compared to the 
full form (FF) in different sub-populations
Men Women Low-risk High-risk
N 142 168 141 169
Cronbach’s alpha 0.74 0.86 0.82 0.83
Correlation FF vs. SF 0.91 0.96 0.94 0.95
Mean STAI-state scores FF SF FF SF FF SF FF SF
Before counseling 34.2 35.3 38.3 38.9 34.4 35.1 41.1 42.3
After counseling 32.9 33.3 36.4 36.8 34.0 34.2 36.5 37.2
p value 0.073 0.041* 0.153 0.118 0.679 0.390 0.001 * 0.003*
* Statistically significant difference between pre- and postcounseling STAI-state scores (p <0.05)
Discussion
The Dutch translation of the six-item short form of the STAI-state as constructed by Marteau 
and Bekker showed good reliability and acceptable validity in a Dutch population. Internal 
reliability is high and scores from the six-item form are highly correlated with scores 
produced with the full form. However, when comparing results of the full form with the short 
version a significant difference was detected. When looking at the absolute numbers, 
however, this difference was only 38.0 versus 38.7. One can argue whether this significant 
result is clinically relevant as the instrument serves its purpose by being able to discriminate 
between different levels of anxiety and is also sensitive to change. No postcounseling data 
were available for a large proportion of the participants. However, in all subgroups, baseline 
anxiety levels did not differ significantly between the participants that completed the second 
STAI and the non-responders. It therefore seems that the obtained results are representative.
The aim of the STAI-state is to detect changes in anxiety levels. The short version is able to 
detect changes in anxiety as well as the full form and would therefore be a valuable 
instrument to use in research to determine the effect of preventive screening programs on 
anxiety levels. The advantage of this short version is that it minimizes response bias, which is 
more likely to occur with lengthy, time-consuming questionnaires. Furthermore, a short
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questionnaire is easier to use when many patient-centered outcomes are assessed and many 
questionnaires are used. This is usually the case in research evaluating acceptability and 
effectiveness of interventions such as screening programs.
Looking at the study performed by Marteau and Bekker, applicability of their results to the 
general population can be questioned as construction of their instrument was performed on a 
population of solely women. Our study confirms previous results that women tend to score 
higher on the STAI-state than men and appear to respond differently to stressful events than 
men. However, our results show that reliability and validity of the short STAI-state in a 
population of both men and women is good. Furthermore, the short form is also a reliable and 
valid instrument to measure anxiety in a population at high-risk for unfavorable screening 
outcomes. However, one can question whether the clinical setting of our study can be applied 
to other clinical settings. For practical reasons we administered the full form only. An 
alternative way to validate the short form would be to administer both questionnaires. It is 
possible that the self-contained six-item scale would yield different results than the same 
items administered in the context of the full form.
As we tested the short form in a low- and high-risk population and among both women and 
men, we believe our results will be applicable to other populations, although this should be 
confirmed in other studies. The instrument constructed by Marteau and Bekker has already 
been used in research and has proven to be a reliable and valid instrument to measure anxiety 
in different populations. We therefore recommend further use of their short version of the 
STAI-state in future research and evaluation of preventive programs to promote 
standardization in anxiety research.
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ABSTRACT
Background: This study describes nutritional intake and lifestyle factors in women who are 
planning a pregnancy.
Methods: A semi-quantitative, one-month food frequency questionnaire and a questionnaire 
on health practices and personal views were filled out at home. Answers were verified by 
telephone interview.
Results: Of 101 women who agreed to participate, 73 returned the questionnaires and 69 were 
eligible. Forty-six women were planning pregnancy and 23 served as controls. Alcohol use 
and smoking was reported in respectively 96% and 20% of women planning pregnancy. 
Women planning pregnancy consumed significantly larger amounts of saturated fats and 
proteins and less carbohydrates than controls (p < 0.05), and significantly higher median 
intakes of vitamin A, thiamin, riboflavin, calcium, selenium, magnesium and iron. However, 
the number (percentage) of women planning pregnancy with intakes below recommended 
dietary allowances (RDA) was 34 (74%) for iron, 27 (59%) for selenium, 22 (48%) for 
vitamin A and 42 (91%) for copper. A majority (77%) of all women considered themselves to 
have healthy nutritional habits.
Conclusions: Nutritional intake of women in the preconception period appears to be 
inadequate. Efforts to increase awareness on the importance of an adequate diet and lifestyle 
before and throughout pregnancy should be continued.
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Introduction
The preconception period continues to gain recognition as an ideal opportunity to optimize the 
health of the mother-to-be. Important lifestyle factors that could be subject to intervention 
before pregnancy include prenatal alcohol use, smoking and malnutrition.1-3 Moreover, poor 
maternal nutritional intake during pregnancy has been associated with offspring suffering 
from diabetes mellitus and cardiovascular diseases in later life.4,5 Since a number of 
nutritional and lifestyle factors for poor pregnancy outcome are modifiable, obstetricians and 
other health care providers should aim to optimize women’s health before conception. Recent 
data from national health surveys indicated that in the general population nutritional intake is 
suboptimal, and that virtually the entire population suffers to some extend from deficiencies 
of essential vitamins, minerals, and trace elements.6,7 As a poor nutritional status may lead to 
serious health problems,7 it may also have in (pre)pregnant women adverse consequences for 
their offspring. Therefore, the quality of the maternal diet should receive special attention 
before a woman conceives.1,5,8
Before well-defined nutritional interventions can be considered, however, the nutritional 
intake and habits in women of reproductive age, especially among those who are currently 
planning a pregnancy, need to be further explored. We evaluated the nutritional intakes and 
lifestyle factors in women currently planning pregnancy and in a control group of women of 
comparable age. The nutritional intakes were compared to both the Dutch recommended 
dietary allowances (RDA) and to the guidelines for adequate diet. In addition, we evaluated 
whether women planning pregnancy also prepare themselves for pregnancy by adjusting their 
nutritional intake and lifestyle. By asking women to rate their diet and lifestyle, their personal 
views and knowledge of health practices were also assessed.
Materials and Methods
This explorative study was a collaborative project between the department of Obstetrics and 
Gynecology, department of Epidemiology and Biostatistics, and department of Nutrition and 
Dietetics of the University Medical Center Nijmegen in the Netherlands. Between January 
and June 2001, women of reproductive age in Nijmegen and surrounding regions were
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recruited through advertisements in local newspapers, posters at health clinics and day care 
centers, and by word of mouth. A research fellow in preconception care and two dieticians in 
training carried out the study. Women who were already pregnant, who were breastfeeding or 
who followed an ethnic diet (i.e., Turkish) were excluded. A validated semi-quantitative food 
frequency questionnaire (FFQ) was used to estimate the intake of energy, total and saturated 
fats, total protein, mono- and disaccharides, polysaccharides (complex carbohydrates) and 
vitamins, minerals and trace elements from foods consumed in the past month.9,10
Information on demographic characteristics including age, height, weight, educational 
background, current profession, prior pregnancy, and lifestyle factors including alcohol and 
tobacco use, was obtained by a separate questionnaire. In this questionnaire, data were also 
collected on perceived health (1-10), diet (vegetarian, calorie-restricted), past and current 
vitamin supplement use and satisfaction with body weight. Personal views were assessed by 
the following questions: whether women considered their dietary habits to be healthy 
(yes/no), what could be done to improve them (open-ended), and whether they completely 
agree, agree, disagree, or completely disagree with several statements such as “I should eat 
less fat” . Volunteers received the questionnaires and were asked to fill out and return them 
within two weeks. The completed and returned forms were verified by telephone interview. 
Participants were offered the opportunity to be informed about their evaluated nutritional 
intake and habits.
The data obtained by the FFQ was converted into standardized portions, weights and products 
using the Dutch nutrient database (NEVO).11 Subsequently, the report “Portion sizes, weights 
and food code numbers”12 was used to calculate average daily dietary intake. The food codes 
were entered into the software program Becel-5 (Wageningen, the Netherlands),13 which was 
used to calculate the intakes of macronutrients and retinol, ß-carotene, ascorbic acid, 
tocopherol, cholecalciferol, thiamin, riboflavin, niacin, pyridoxine, biotin, potassium, calcium, 
phosphorus, iron, magnesium, zinc, selenium and copper intake. The Becel-5 program could 
not calculate the dietary intakes of folate and cobalamin.
The median energy and nutrient intakes of women who were planning pregnancy and controls 
were calculated using SPSS 9.0 and 10.1. Demographic characteristics, total energy, macro- 
and micronutrient intakes of the two study samples were compared by the Mann-Whitney U 
and Kruskall Wallis tests. Macronutrient intakes were calculated in percentages in order to
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adjust for total daily energy intake. The number of women planning pregnancy whose diet 
contained less than the minimum requirements or higher amounts than the maximum 
recommended intake for each nutrient as defined by the Dutch recommended dietary 
allowances (RDA) was calculated and reported in the tables. The RDA is the average 
requirement ± 2 SD, defined as the level of intake that is adequate for almost the entire 
population.14,15 Statistical significance was defined by p<0.05.
Results
Among the 101 women who volunteered to participate, 72% completed and returned the 
questionnaires. Four women were excluded: one was pregnant, one post-menopausal, and two 
could not be reached by telephone to verify the answers of the questionnaires. This resulted in 
the evaluation of 69 women between 18 and 45 years of age, of which 46 were currently 
planning a pregnancy, and 23 who indicated not to be planning to conceive served as controls. 
Women who were planning pregnancy were significantly older than controls, median age 31.5 
and 28.0 years, respectively. Half of them were planning a first pregnancy. Demographics and 
use of vitamin supplements were not significantly different between the groups (Table 1).
Table 1. Demographic and lifestyle characteristics
Characteristic Women planning 
pregnancy («=46)
Control women 
(«=23)
Age (y) 31.5 (19-45) 28.0 (18-43)*
BMI 23.2 (18.3-30.1) 21.9 (17.8-30.1)
Primigravidae (%) 50 65
Educational background (%)
Low 2 -
Middle 38 30
High 60 70
Folic acid or multivitamin
supplement use (%) 48 52f
Age and BMI (body mass index) are given as median (range)
* P < 0.05, Mann-Whitney U test; women planning pregnancy vs. controls 
t Multivitamins only
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Table 2. Questionnaire items on alcohol use and smoking
Women planning Control women
Question pregnancy
Do you smoke? n* n
___yes 5 2
___no 37 18
___sometimes 4 3
Please mark which tobacco products:
___cigarettes 7 4
___cigars 2 1
___marijuana - -
How many cigarettes daily? t 5.5 (1-20) 8.5 (0-22)
Did you smoke during your last pregnancy?**
___yes 2 -
___no 3 -
How many cigarettes daily? 2-5 -
Do you drink alcohol?
___yes 12 4
___sometimes 21 8
___ rarely 11 8
___ never 2 3
How often do you drink alcohol?
___1-3 times/ month 20 11
___1-2 days/ week 12 6
___3-4 days/ week 3 -
___5-6 days/ week 4 1
___7 days a week 1 -
How many glasses of alcohol weekly?
___1-3 per week 10 4
___4-6 per week 5 1
___7-10 per week 5 1
___more than 10 per week - -
Did you drink during your last pregnancy?**
___yes 5 1
___no 15 6
If so, how many glasses daily? t 5 (1-5) -
* Not all questions were applicable to all women 
** Of the 23 women that had been pregnant previously 
t Median (range)
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Seven of all women reported to consume an alternative diet, of which 5 were vegetarian, one 
vegan, and one woman ate only biological products. Nine women planning pregnancy (20%) 
and 5 controls (22%) reported to smoke. Almost all of the women planning pregnancy 
reported some degree of alcohol use (Table 2), and 11% of them consumed an average of 7-10 
glasses of alcohol per week. Additional data on alcohol intake and smoking are shown in table
2.
The intake of nutrients in women who were planning pregnancy, controls, and the 
recommended dietary allowances (RDA) for the Dutch population of women aged 22-50 
years are shown in table 3. Median energy intake of women planning pregnancy and controls 
exceeded RDA by more than 300 kcal/day, 2387 and 2407 kcal/day, respectively. All but one 
of the women planning pregnancy consumed an excessive amount of saturated fats and only 2 
control women consumed diets containing less than 10% saturated fat daily (Table 3). Median 
daily protein intake was significantly higher among women planning pregnancy than controls 
(16 vs. 14%; p<0.05). Total daily intake of complex carbohydrates was significantly lower 
among women planning pregnancy than controls, 44 and 48%, respectively. The average daily 
consumption of fruits (1.5 pieces) and vegetables (2.5 servings) was below the recommended 
daily portions for both study groups. The low intake of complex carbohydrates was due to a 
low consumption of bread (4.5 slices), as well as of potatoes, rice and pastas (2.5 servings per
day).
Women planning pregnancy had significantly higher median dietary intakes of the 
micronutrients vitamin A (retinol + [ß-caroteen/6]), thiamin, riboflavin, calcium, selenium 
and magnesium than controls (Table 4). The number of women planning pregnancy who had 
a deficient intake, i.e., who did not meet the minimum RDA for each micronutrient, is also 
shown in table 4. Daily intake of vitamin A was below RDA in 48%. Cholecalcipherol intake 
was deficient in 26%, dietary iron intake deficient among 74% and selenium intake deficient 
among 59% of women planning pregnancy. Less than 10% met the RDA for copper. The 
overall intake of thiamin, riboflavin, niacin and pyridoxine as well as of vitamin C was 
adequate among most women planning pregnancy and controls.
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Table 3. Daily energy intake and percentage of total energy intake of macronutrients
RDA
Women planning 
pregnancy («=46) > RDA**
Control women 
(«=23) > RDA**
Macronutrient Median (range) n (%) Median (range) n (%)
Energy (kcal) 2071 2387 (1350-3305) 33(72) 2407(1475-4115) 16(70)
Fat (en%) 20-40 39 (30-54) 16 (39) 36 (28-49) 4(17)
Saturated fat (en%) < 10 15 (10-26) 45 (98) 13 (8-22)* 21 (91)
Protein (en%) 10 (< 25) 16(12-21) 0(0) 14 (10-18)* 0(0)
< RDA** < RDA**
Carbohydrates (en%) >40 44 (33-54) 11 (24) 48 (37-62)* 4(17)
Mono- / disaccharides (en%) 15-25 19(12-31) 8(17) 23 (4-47)* 3(13)
RDA: Recommended dietary allowance for Dutch non-pregnant women aged 22-50 years14 En%: percent of total energy intake 
* P<  0.05, Mann-Whitney U test; women planning pregnancy vs. controls
** Number (%) of women with an unbalanced diet, i.e. either exceeding the maximum or below the RDA, are shown
Table 4. Daily intake of vitamins and minerals from diet
RDA
Women planning 
pregnancy («=46) < RDA**
Control women 
(n=23) < RDA**
Micronutrient Median (range) n (%) Median (range) n (%)
Vitamins
Retinol + [ß-caroteen/6] (|ig) 800 836 (332-1828) 22 (48) 628 (353-1302)* 15 (65)
Cholecalcipherol (|ig) 2.5-5.0 3.9 (0.9-6.8) 12 (26) 4.0 (0.7-6.4) 5(22)
Tocopherol (mg) 9.3 13.9(5.2-29.8) 9 (20) 15.7(6.8-34.0) 4(17)
Thiamin (mg) 1.1 1.4 (0.8-2.4) 6(13) 1.1 (0.6-2.1)* 9 (39)
Riboflavin (mg) 1.1 1.8 (0.9-2.9) 4(9) 1.4 (0.8-3.0)* 6 (26)
Niacin (mg) 13.0 16.7(9.5-28.8) 10(22) 14.9 (6.7-22.1) 6(26)
Pyridoxine (mg) 1.1 1.9 (1.0-2.6) 1(2) 1.8 (1.0-2.6) 2(9)
Ascorbic acid (mg) 70 142 (49-349) 4(9) 115(50-385) 4(17)
Minerals
Iron (mg) 15.0 13.6 (8.9-30.7) 34 (74) 11.5 (6.2-25.8) 18 (78)
Calcium (g) 1.0 1.3 (0.6-2.5) 10(22) 1.0 (0.4-2.0)* 12 (52)
Selenium (|ig) 50-150 48 (25-74) 27 (59) 40 (25-55)* 18 (78)
Copper (mg) 1.5-3.5 1.2 (0.6-1.7) 42 (91) 1.2 (0.6-2.0) 20 (87)
Zinc (mg) 9.0 10.7(7.0-17.6) 7(15) 10.0(5.9-15.4) 9 (39)
Magnesium (mg) 250-300 370 (249-604) 1(2) 318 (151-679)* 1(4)
RDA: Recommended dietary allowance for Dutch non-pregnant women aged 22-50 years15 
* P 0 .0 5 , Mann-Whitney U test; women planning pregnancy vs. controls.
** Number (%) of women with a deficient micronutrient intake, i.e. below the RDA, are shown
Personal views on health and nutrition did not differ significantly between the two subsets of 
women. Among all women, 23% of women reported to be unsatisfied with their body weight, 
37% was satisfied and rest ambivalent. Over one third of all women were currently trying to 
lose weight. For health and well being, 74% of women gave themselves an excellent rating of 
8 or higher on a 10-point scale, and another 17% gave themselves a 7. The lowest rating, 
reported by 3% of women, was 4. A vast majority of women (77%) answered that they felt 
their eating habits are healthy. When asked what they would do if they were to improve their 
diet, 36% of women reported that they would eat less candy or other snacks, 24% would eat 
more vegetables, 20% would eat more fruit, and 14% would eat less fatty products such as 
fries, pizza or Chinese food. Only 32% of all women agreed with the statement ‘I should eat 
less fat’, and 57% agreed with the statement ‘I should eat less saturated fats’.
Discussion
In this explorative study we evaluated nutritional intakes and other lifestyle factors in women 
of reproductive age and the impact of pregnancy planning. To our knowledge, nutritional 
intakes of women planning pregnancy have not been evaluated previously. Our preliminary 
results reflect that an inadequate diet, rich in saturated fats and marginal in a number of 
essential micronutrients, is very common among women of reproductive age. Overall, 
pregnancy planning appears not to significantly affect nutritional intake, alcohol use and 
smoking habits. These data of an imbalance of macro- and micronutrients are supported by 
others that studied nutritional intakes retrospectively three months before pregnancy in a 
population of Latinas and white non-Latinas.16
Although virtually all of the women planning pregnancy exceeded the upper limit for 
saturated fat intake, not even one third of them acknowledged that they should eat less fats 
and only half agreed that they should eat less saturated fats. Therefore, we conclude that the 
women in our study overrated the adequacy of their diets and did not seem to have the 
knowledge about the contents of foods that they consume. In accordance with data of Dutch 
women planning pregnancy, less than half of women planning pregnancy reported to take 
folic acid or another vitamin supplement to reduce the risk of a neural tube defect.17,18 The 
suboptimal intake of several micronutrients and possible implications for the course and
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outcome of pregnancy, in particular of iron and copper, should be addressed. The deficient 
iron intake of the majority of potential mothers places these women at risk for developing iron 
deficiency anemia during pregnancy, resulting in increased risk of complications as preterm 
delivery,19,20 low birth weight and fetal death.20 As iron supplementation in early pregnancy is 
not routinely practiced, women should be advised to increase their intake of iron-rich foods, 
preferably of green leafy vegetables, before entering pregnancy. Maternal copper deficiency 
has been shown in animal studies to cause brain defects, connective tissue abnormalities, 
intra-uterine growth retardation, birth defects and fetal death.21 In human pregnancy, however, 
the relation between deficient copper intake and adverse pregnancy outcome, has not been 
clarified so far. Likewise, the impact of most maternal nutritional deficiencies on prenatal 
development remains to be further investigated.
All women should be advised to abstain from drinking in the periconceptional period and 
throughout pregnancy, since even as little as 1 drink per week has been associated with 
adverse effects.22 In our study, the number of women planning pregnancy who reported some 
degree of alcohol use (96%) was much higher than the reported 49% in the previously 
mentioned study16 and the 53.3% recently reported among U.S. women of childbearing age.23 
Although a significant number of women may limit or quit alcohol intake as soon as they are 
aware of their pregnancy, most of them will not realize that they are pregnant in the first most 
important weeks of embryonic development.
The validity of the nutritional data is always an issue of discussion. However, we used a 
validated and highly reproducible FFQ and evaluated this data on group level.9,10 A FFQ was 
used above the 24-hour recall or food diary method because it covers a longer period (one 
month) and may therefore give a better approximation of habitual diet.24 Moreover, subjects 
were motivated to participate, reflected by the fact that the majority would like to be informed 
about their evaluated diet. Nevertheless, overreporting of healthy nutritional habits and an 
underestimation of undesirable habits cannot be completely ruled out. Such reporting bias 
may be especially common among women planning pregnancy. It turned out from telephone 
interview that some women did indeed underreport snack consumption and overestimated 
their fruit intake in the questionnaires.
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In order to obtain a population of women of reproductive age preconceptionally, we had to 
rely on advertisements and active recruitment. Both groups of women were highly educated 
as compared to the general population, which limits the degree to which our data may be 
extrapolated to the general population. It cannot be ruled out that highly educated women are 
more concerned about their nutritional habits and were therefore more willing to participate.
From these preliminary results we conclude that women who are planning to conceive are not 
necessarily preparing themselves for pregnancy by taking dietary or other health promotion 
measures. Although they have a higher daily intake of several vitamins and minerals 
compared to other women of reproductive age, overall micronutrient intakes are often below 
RDA and unhealthy behaviors such as a high saturated fat intake, smoking and alcohol use are 
even more prevalent among women planning to conceive. In order to educate women about 
the nutritional requirements of pregnancy and the implications of nutritional status on 
pregnancy outcome, the adverse effects of smoking and alcohol use and the protective effect 
of folic acid supplements, we should continue efforts to provide preconception counseling. 
Future research on dietary practices among women planning pregnancy should include focus 
on women with a lower education and should relate nutrition and other health practices to 
subsequent pregnancy outcome to assess their impact.
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ABSTRACT
Objectives: To evaluate periconceptional maternal biochemical and hematological parameters 
and vitamin profiles in relation to the risk of early pregnancy loss and birth weight.
Design: Prospective longitudinal study
Setting: University Medical Center Nijmegen, Academic Medical Center, Amsterdam, Maria 
and Elisabeth Hospitals, Tilburg, and Catharina Hospital, Eindhoven, the Netherlands. 
Subjects: A cohort of 240 women recruited before pregnancy.
Interventions: Blood samples were taken preconceptional and at 6 and 10 weeks amenorrhea 
in which the concentrations of hemoglobin, hematocrit, creatinin, uric acid, total protein, 
serum iron, total iron binding capacity, ferritin, and the concentrations of retinol, tocopherol, 
thiamin, riboflavin, pyridoxal-5'-phosphate, cobalamin and folate were analyzed.
Main outcome measures: Risk of early pregnancy loss and birth weight.
Results: The risk of early pregnancy loss increased with increasing pre-pregnancy weight, 
and when the periconceptional decline in hematocrit, creatinin and uric acid was less 
profound (slope: p<0.01). Maternal smoking was negatively associated with birth weight 
(mean reduction of 183 g, p<0.05). Maternal age and pre-pregnancy weight were positively 
associated with birth weight (p<0.01). No significant associations were found between 
vitamin concentrations and risk of early pregnancy loss or birth weight.
Conclusions: Several periconceptional biochemical parameters are significantly associated 
with early pregnancy loss. The effects of maternal periconceptional health on embryonic 
development and subsequent pregnancy outcome should be further explored.
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Introduction
The developing embryo and fetus, dependent on maternal nutrient transfer throughout 
pregnancy, is particularly susceptible to unfavorable maternal conditions in the 
periconceptional period. During this critical stage of pregnancy, the fertilized ovum increases 
in mass 2.5 million times and organogenesis and placentation take place. Although the 
underlying mechanisms, including the role of maternal nutrition and other factors that 
ultimately result in normal or adverse pregnancy outcome, are not yet understood, an adequate 
periconceptional maternal nutritional status is considered of key importance.
Biochemical measurements in blood are considered to be an objective assessment of 
nutritional status. The relation between a poor maternal folate status and the risk of delivering 
a child with a neural tube defect1 and the reported association between maternal anemia and 
the risk for pre-term delivery2 support the association between sub-optimal maternal nutrition 
and poor pregnancy outcome. The impact of a low pre-pregnancy weight as proxy for poor 
maternal nutritional status on birth weight has also been documented.3,4 Whether marginal 
differences in maternal periconceptional vitamin profiles, in biochemical and in hematological 
parameters have an effect on pregnancy outcome is unclear. The aim of this longitudinal study 
was to investigate these markers of maternal metabolism and nutritional status in relation to 
early pregnancy loss, the most common adverse outcome of pregnancy,5 and birth weight, in a 
preconceptionally recruited cohort of women.
Methods
Between 1987 and 1990 women were recruited before pregnancy through announcements by 
the project coordinator. The first monitored pregnancy of two hundred fifty three women out 
of four hundred and four preconceptionally recruited non-pregnant women were included for 
this evaluation. Three women with a twin pregnancy were excluded and ten women were 
excluded because of abnormal pregnancy outcome, i.e., birth weight below the 2.3 percentile 
of the Dutch birth weight curve,6 pre-term delivery (<37 weeks gestation), post-term birth 
(>42 weeks gestation), or intra-uterine fetal death. A part of this cohort of women has been 
described in detail previously.7,8 This resulted in the evaluation of 240 women, comprising 
119 epileptics (99 of which were taking anti-epileptic drugs), 15 women who had previously
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delivered a child with a neural tube defect, and 106 controls. The study by Steegers et al.7 
excluded the 15 women who previously delivered a child with a neural tube defect and Cikot 
et al. included only 102 nulliparous control women with an uneventful, singleton pregnancy 
and normal outcome. The study was carried out in collaboration with 5 hospitals in the 
Netherlands: University Medical Center Nijmegen; Academic Medical Center, Amsterdam; 
Catharina Hospital, Eindhoven; and Maria and Elisabeth Hospital, Tilburg. The Medical 
Ethical Committee of the University Medical Center Nijmegen, the Netherlands, approved the 
protocol.
After informed consent was obtained, a research nurse visited the participants at home to 
obtain a medical history and socioeconomic data, to measure weight and length, and to collect 
blood samples. Venous blood samples were drawn for the analysis of hemoglobin, hematocrit, 
creatinin, uric acid, total protein, serum iron, total iron binding capacity, ferritin, retinol, 
tocopherol, thiamin, riboflavin, pyridoxal-5'-phosphate, cobalamin and folate concentrations. 
Subsequent blood samples were collected every six months prior to pregnancy in order to 
maintain up-to-date preconceptional data. A monoclonal antibody-based pregnancy test, 
menstrual history, and a basal body temperature charting confirmed pregnancy. One or two 
transvaginal ultrasonographic examinations before the 8th week of gestation were performed 
to eventually adjust for the duration of the pregnancy. Blood sampling took place again at 6 
and 10 weeks amenorrhea. Measurements of birth weight of the newborns were noted from 
medical records. Early pregnancy loss was defined as a spontaneous abortion ending before or 
at 16 weeks amenorrhea.
Analytical procedures
Full details of the laboratory procedures used to determine concentrations of retinol (vitamin 
A), tocopherol (vitamin E), thiamin (vitamin B1), riboflavin (vitamin B2), pyridoxal-5'- 
phosphate (vitamin B6), cobalamin (vitamin B12) and folate have been described elsewhere.7 
In brief, serum retinol concentrations were determined by high-performance liquid 
chromatography (HPLC), with fluorescence excitation and emission wavelengths of 348 nm 
and 470 nm, respectively. The minimum detectable concentration was 0.06 |imol/L. Precision 
of the assay in terms of intra- and inter-assay coefficients of variation (CV) for means of 
duplicate measurements (at a mean concentration of 0.96 |imol/L) were 1.1% and 5.3%, 
respectively. Likewise, tocopherol concentrations were determined in serum by HPLC with 
fluorescence detection. The fluorescence excitation and emission wavelengths were 295 nm
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and 390 nm, and the minimum detectable concentration was 0.40 |imol/L. The intra-assay CV 
was 2.8% (10 replicate determinations, mean concentration 22.2 |imol/L) and the inter-assay 
CV was 6.6% (13 simultaneous assay runs, mean concentration 23.7 |imol/L).
Plasma thiamin concentrations were determined by reversed-phase ion-pair HPLC on C18- 
coated silica, using an n-octanesulfonate containing mobile phase methanol-aqueous citrate 
buffer with a pH of 4.0 (45:55, v/v). Thiamin was oxidized to thiochrome by K3Fe(CN)6, and 
detected by fluorometry with excitation and emission wavelengths of 364 nm and 462 nm, 
respectively. The detection limit was 2.3 nmol/L, with an intra- and inter-assay CV (mean 
concentration 123 nmol/L) of 4.8% and 6.8%. Riboflavin was determined in heparinized 
plasma by HPLC with fluorescence detection. Fluorescence excitation and emission 
wavelengths were 470 nm and 520 nm. The minimum detectable concentration of this 
procedure was 10 nmol/L and the intra- and inter-assay CV (duplicate measurements) were 
3.9% and 8.2% at a mean concentration of 90 nmol/L. Pyridoxal-5'-phosphate was measured 
in whole blood by HPLC and fluorescence detection determined by excitation and emission 
wavelengths of 367 nm and 478 nm. The minimum detectable concentration was 2 nmol/L. 
Precision of the technique in terms of intra-assay CV was 1.6% (20 replicate measurements, 
mean concentration 52 nmol/L) and inter-assay CV was 5.5% (15 determinations on several 
days, mean concentration 53 nmol/L).
Cobalamin and folate concentrations in serum were determined simultaneously with the Dual 
Count SPB (Solid Phase Boil) Radioassay (Diagnostic Products Corporation, Los Angeles, 
CA, USA). Folate was also determined in erythrocytes (Dunn and Foster, 1973). The assay 
uses a dual label tracer solution (57Co-vitamin B12 and 125I-folic acid) and a suspension of the 
solid phase binders for vitamin B12 and folate. The intra- and inter-assay CV for means of 
duplicate determinations was < 5% and 10% for both vitamins. Hemoglobin (cyanid method), 
hematocrit (derived value), creatinin (Jaffé method without deproteination), uric acid 
(uricase/-catalase reaction), total protein (biurete), serum iron (guanidine / ferrozine), total 
iron binding capacity (ibid total iron) and ferritin (sandwich type immunoenzymetric assay; 
Tandem-E, Hybritech) were determined by standard methods.9
Statistics
Exploratory statistical analyses were performed. Using the data derived from the blood 
samples, a linear relationship between the logarithm of each biochemical parameter and time
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of blood sampling (preconceptional, and at 6 and 10 weeks amenorrhea) per woman was 
fitted, after which an individual slope and intercept was calculated for all participants. For 
preconceptional values, amenorrhea was set equal to zero. These computations were done 
using the SAS-procedure MIXED. Stepwise logistic and linear regression analysis was 
applied for the dependent outcomes early pregnancy loss and birth weight, respectively. 
Independent variables were the calculated individual intercepts and slopes of the biochemical 
determinants, as well as maternal age, pre-pregnancy weight, body mass index (BMI), weight 
gain until 32 weeks amenorrhea, parity, obstetric and gynaecologic history, epilepsy and use of 
anti-epileptic drugs, other medication, education, vitamin supplement use and smoking. The 
BMI was calculated as the weight in kilograms divided by the square of the height in meters. 
Criteria for in- and exclusion in the regression equations were set at p=0.10. Final logistic and 
linear regression equations were computed with as independent variables those found in the 
stepwise procedures. In testing, statistical significance was defined as p<0.05.
Results
Preconceptional blood samples were available for 116 women (48%), blood samples at 6 
weeks amenorrhea for 229 women (95%), and at 10 weeks amenorrhea for 187 women 
(78%). The longest interval between preconceptional blood sampling and pregnancy was 13 
weeks. The research nurse performed preconceptionally standardized measurement of the 
weights of 185 women (77%).
The study population (n=240) was between 19 and 42 years of age. Demographic 
characteristics, presented in Table 1, did not significantly differ between women with normal 
pregnancy outcome (n=194) and those with early pregnancy loss (n=46). As this study was 
carried out before large-scale campaigns on periconceptional folic acid supplement use for the 
prevention of neural tube defects were performed, most women in our cohort reported not to 
be taking any vitamin or food supplements in the study period at any moment. Less than 10% 
of the participants used folic acid or another vitamin supplement. All women but one were 
Caucasian.
98
Table 1. Demographic characteristics (percentages)
Characteristic Normal outcome 
(n=194)
Miscarriage
(n=46)
Age* 30 (3.5) 30 (4.2)
Pre-pregnancy weight (kg)* 65.0 (11.0) 66.9 (14.5)
Length (cm) * 168.4 (6.4) 168.0 (5.4)
Pre-pregnancy BMI* 22.7 (3.3) 24.0 (5.3)
Primigravidae 43 39
Folic acid supplement use 7 9
Vitamin supplement use 7 7
Smoking 24 28
Low level of education ** 46 46
High 54 54
* Data given as mean (SD)
**Educational background: Low = primary education, lower technical training
High = higher technical training, university degree
In Table 2, the hematological and biochemical parameters and vitamin profiles measured 
preconceptionally and at 6 and 10 weeks amenorrhea are presented as median concentrations 
and 25th and 75th quartiles for women with normal pregnancy outcome and women with early 
pregnancy loss. Overall, the median values of the two sub-populations are comparable for all 
parameters and fall within reference ranges.8,9
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Table 2. Preconceptional 6 weeks 
amenorrhea
10 weeks 
amenorrhea
Parameter Nonnal outcome
(n=96)
Miscarriage
(n=20)
Nonnal outcome
(/7=188)
Miscarriage
(;î=41)
Nonnal outcome 
(n = 174)
Miscarriage 
(n = 13)
Hematology
Hemoglobin ((imol/L) 8.4 (8.1-8.8) 8.1 (7.9-8.5) 8.0 (7.7-84) 8.1 (7.9-8.6) 7.8 (7.5-8.2) 7.8 (7.5-8.1)
Hematocrit (L/L) 0.41 (0.38-0.42) 0.40 (0.38-0.41) 0.38 (0.37-0.41) 0.39 (0.38-0.42) 0.37 (0.35-0.39) 0.38 (0.36-0.39)
Ferritin (|ig/L) 31 (21-47) 30 (16-42) 34 (21-49) 41 (28-60) 30 (19-45) 42 (25-64)
TIBC (junol/L) 57 (51-64) 62 (55-66) 54 (49-61) 57 (49-63) 56 (50-63) 60 (51-66)
Serum iron ((imol/L) 19 (14-23) 18 (14-22) 20 (15-25) 19 (13-24) 21 (17-24) 18 (16-21)
Biochemistry
Creatinin ((imol/L) 70 (64-77) 64 (59-75) 65 (59-71) 64 (61-71) 59 (53-64) 59 (50-68)
Uric acid (mmol/L) 0.24 (0.21-0.27) 0.24 (0.19-0.32) 0.20 (0.17-0.23) 0.23 (0.18-0.25) 0.18 (0.16-0.22) 0.22 (0.18-0.28)
Total protein (g/L) 71 (68-74) 72 (66-74) 69 (67-72) 68 (65-74) 67 (65-69) 66 (65-70)
Vitamins
Tliiamin (nmol/L) 100 (92-120) 108 (96-110) 100 (91-114) 97 (79-115) 100 (89-120) 91 (87-101)
Riboflavin (nmol/L) 290 (250-310) 290 (255-325) 270 (250-300) 290 (260-310) 280 (250-300) 280 (250-310)
Pyridoxal-5 ’ -phospliate 49 (43-59) 47 (41-54) 47 (40-56) 43 (37-51) 48 (41-57) 44 (34-56)
(mnol/L)
Cobalamin (pmol/L) 290 (220-350) 315 (270-395) 280 (230-330) 290 (220-380) 250 (180-310) 240 (150-350)
Serum folate (mnol/L) 13 (9-15) 13 (10-19) 13 (10-17) 13 (10-17) 14 (11-19) 13 (10-14)
Red cell folate 480 (410-570) 465 (410-600) 520 (420-680) 520 (440-650) 550 (440-710) 540 (355-595)
(mnol/L)
Retinol ((imol/L) 1.7 (1.5-1.9) 1.6 (1.4-1.9) 1.6 (1.4-1.9) 1.6 (1.4-1.9) 1.6 (1.4-1.7) 1.5 (1.3-2.0)
Tocopherol ((imol/L) 18 (15-20) 17 (15-20) 15 (13-17) 16 (13-19) 17 (14-19) 15 (12-18)
The intercepts of the hematological values were not significantly associated with birth weight 
or early pregnancy loss. The risk of early pregnancy loss however, significantly increased 
when the physiological decline in hematocrit concentrations in the first trimester of pregnancy 
was less profound (p-value for slope: < .01 in the logistic regression, Figures shown below).
Weeks amenorrhea
weeks amenorrhea
weeks amenorrhea
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No significant association was found between the course of periconceptional hemoglobin, 
ferritin, total iron binding capacity (TIBC) and iron concentrations and early pregnancy loss, 
or between the slope of any hematological parameter and birth weight. The probability of 
early pregnancy loss increased with a diminished first trimester physiological decline in uric 
acid concentration (p<0.01) as well as with a diminished decline in creatinin concentration 
(p<0.01). Periconceptional total protein concentrations did not affect the risk for early 
pregnancy loss or birth weight. The preconceptional levels and first trimester changes in the 
concentrations of retinol, tocopherol, thiamin, riboflavin, pyridoxal-5'-phosphate, cobalamin, 
red cell and serum folate were unrelated to early pregnancy loss and birth weight.
Other factors
Smoking was reported by approximately one fourth of all women during the study period 
(Table 1) and was negatively associated with birth weight, with a mean reduction of 183 
grams in babies born to smoking mothers (p<0.05). Maternal age was significantly positively 
related to birth weight (p<0.01; partial r2=0.26). Pre-pregnancy weight was positively related 
to the risk of early pregnancy loss (p<0.05) as well as to birth weight (p<0.01; partial 
r2=0.24). Pre-pregnancy BMI and weight gain during pregnancy, measured as the difference 
in weight at 6 weeks and 32 weeks amenorrhea, were not associated with birth weight. Parity, 
educational background, epilepsy or use of anti-epileptic drugs, other medication use or use of 
vitamin supplements were not significantly associated with the risk of early pregnancy loss or 
to birth weight.
Discussion
This is the first longitudinal study initiated before pregnancy in which a wide spectrum of 
maternal biochemical parameters and vitamin profiles in relation to early pregnancy loss and 
birth weight are evaluated. In this population we demonstrated that maternal periconceptional 
vitamin profiles were not significantly associated with the risk of early pregnancy loss or birth 
weight. Other studies in which vitamin profiles and other maternal parameters are considered 
in relation to outcome have been initiated during pregnancy and after the periconceptional 
period.3 In terms of effect on intra-uterine growth, Kramer concluded that for protein status, 
folic acid, vitamins B6 and B12, the causal effect was unlikely, but evidence was insufficient
102
to rule out. Other vitamins, including thiamin, riboflavin, niacin, and the vitamins A, C, and 
E, received the rating of an uncertain causal effect. However, due to the small effect 
magnitude and low prevalence, the importance was regarded unlikely.3
Tamura et al. evaluated various laboratory measurements collected at 18 and 30 weeks of 
gestation in relation to birth weight.10 The authors did not find a significant association 
between vitamin A, E, proteins and birth weight, but reported a positive correlation between 
maternal serum folate and birth weight of their babies. They did not however determine red 
cell folate levels, a much more reliable reflection of the long-term folate status than serum 
folate.11 Açkurt et al assessed nutritional status biochemically among Turkish women between 
13-17 weeks gestation, 28-32 weeks gestation, and 13-17 weeks post-partum.12 In their 
evaluation of maternal blood concentrations no significant correlation between vitamin A, B2, 
B6, B12, folate or any hematological or biochemical parameter, i.e. ferritin, hematocrit, 
albumin, and birth weight was found. In a recent review on maternal nutrition and fetal 
growth, Osrin and Costello13 focused on maternal malnutrition and possible interventions, 
especially in developing countries. They concluded that the effect of micronutrients on fetal 
growth is difficult to clarify, and that although correction of vitamin profiles among women 
with deficiencies could be beneficial in many ways, the effects on fetal growth are not clear.
In our study, periconceptional vitamin profiles were not found to be useful markers for 
predicting birth weight. This may be explained by our study group consisting of relatively 
well nourished, i.e., not underweight or vitamin deficient Dutch Caucasian mothers with 
normal vitamin profiles and their newborns with a normal birth weight between the 2.3 and 
97th percentile. It cannot be excluded that preconceptional evaluation of vitamin status and 
other hematological and biochemical parameters may be beneficial in specific populations at 
high risk for underweight newborns or other adverse pregnancy outcome. For example, we 
diagnosed 52 of 292 women (18%) who attended our clinic for preconception care with an 
indication for laboratory testing, such as previous obstetric complications, as vitamin 
deficient.14 Presuming that correction of these deficiencies before conception would be 
beneficial and might improve pregnancy outcome, all of those women were supplemented and 
advised to postpone conception until adequate blood vitamin levels were reached. It would be 
very informative to study outcome of pregnancy among women with abnormal 
preconceptional vitamin profiles. However, considering the suggested protective effect of
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high folate concentrations with respect to neural tube defects15 and recurrent early pregnancy 
loss,16 it would be difficult to abstain from supplementation once deficiencies are detected.
Biochemical parameters
Serum creatinin and uric acid concentrations both reflect kidney function, and showed a 
diminished decline in women with early pregnancy loss. In normal pregnancy, a physiological 
decline in these and in other parameters, including hematocrit, occurs as a result of 
hemodilution due to plasma volume expansion, which can be observed from 6 weeks of 
gestation.17 Inadequate plasma volume expansion has been associated with poor pregnancy 
outcome. This is especially evident in women with preeclampsia18,19 as well as in pregnancies 
complicated by intra-uterine growth retardation.20 The diminished decrease in creatinin, uric 
acid, and hematocrit the women in our study with early pregnancy loss may also indicate 
insufficient volume expansion and thereby maladaptation to pregnancy that ultimately results 
in early pregnancy loss.
Altered production and excretion of uric acid among women with a complicated pregnancy 
has also been related to the hypothetical function of uric acid as an anti-oxidant. De Jong et al 
found impaired uric acid clearance at 13 weeks gestation, reflected by higher serum uric acid 
concentrations, among women who developed gestational hypertension and delivered a child 
small-for-gestational age.21 They also found uric acid production to be decreased before the 
development of clinically manifest gestational hypertension and preeclampsia, in women both 
with and without a small for gestational age child.
When interpreting the diminished decline in uric acid, creatinin and hematocrit concentrations 
among women who miscarried, several issues need to be addressed. First, we do not know 
whether some of the mechanisms underlying the development of a hypertensive disorder in 
pregnancy are similar to those that lead to early pregnancy loss. Although the decline in 
creatinin and uric acid concentrations as well as in hematocrit was significantly diminished 
among these women as compared to those with normal outcome, these differences were not 
prominent that they could be used as a predictor for pregnancy outcome. We cannot be certain 
whether the reduced decline in several parameters was caused by failure of the pregnancy or 
vice-versa. Moreover, if  this were due to insufficient volume expansion, a diminished decline 
in other parameters would be expected as well.
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Finally, hyperhomocysteinemia, a sensitive marker for folate, cobalamin or pyridoxine 
deficiency22,23 and related genetic risk factors (677 C ^ T  mutation in the MTHFR-gene) 24 
may play a more prominent role in the occurrence of early pregnancy loss. The relation 
between these factors and pregnancy outcome were not considered in the present study.
Other factors
Maternal age appeared to be the strongest predictor for birth weight, even after adjustment for 
smoking, parity, educational background and pre-pregnancy weight. This is in contrast to the 
12 studies considered by Kramer who reported no significant effect of maternal age on birth 
weight.3 A very young maternal age (less than 16 years) has been shown to negatively 
influence birth weight, likely because teenage girls are still growing.25
Maternal smoking has been shown to reduce birth weight by approximately 200 g as 
compared to neonates of mothers who did not smoke.26 An effect of similar magnitude was 
demonstrated among smoking mothers in the present study, with a mean reduction in birth 
weight of 183 g. The observation that lighter women tend to have lighter babies was also
3,4,13,27found in our study population. ’ ’ ’ In addition to pre-pregnancy weight, body mass index, 
weight gain during pregnancy, and maternal mid-upper arm circumference, have also been 
positively related to birth weight.27 It is clear that pre-pregnancy weight has a significant 
influence on fetal growth as well as on other outcomes of pregnancy, and that being too light 
as well as too heavy can both have adverse consequences. In our cohort of women, a higher 
maternal weight was related to a higher birth weight, but also increased the risk of early 
pregnancy loss. To our knowledge, the relation between pre-pregnancy weight and early 
pregnancy loss has not been reported before. However, a higher maternal weight has been 
reported as a risk factor for other adverse outcomes of pregnancy. In a cohort of 167,750 
women, a higher pre-pregnancy weight was found to significantly increase the risk of late
28 29,30fetal death. Maternal obesity has also been strongly linked to the risk of preeclampsia. ’ 
The pathophysiological features suggested to be involved, being increased lipid availability, 
higher cholesterol and triglyceride levels, insulin resistance, and endothelial dysfunction, may 
also be related to an increased risk for early pregnancy loss.
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We demonstrated for the first time that the periconceptional decline in several biochemical 
and hematological parameters is diminished in healthy women whose pregnancy ends in a 
miscarriage. However, this finding should be regarded as exploratory and its clinical 
applicability remains to be ascertained. Secondly, assuming that blood vitamin concentrations 
reflect nutritional status, we infer that our study sample was overall well nourished and that 
none of the nutritional parameters tested in our study are useful predictors for outcome in an 
apparently healthy population of Dutch women. Marginal differences in vitamin profiles 
within the normal range appear to be unrelated to early pregnancy loss or birth weight. 
Nevertheless, whether the parameters used in this study as a proxy for maternal nutritional 
health status directly reflect their availability at tissue level to the developing embryo and 
fetus, is not clear. Metabolic processes in the placenta or within the mother were not 
considered. We therefore need to continue to explore the mechanisms that underlie the effects 
of maternal periconceptional health, including markers of volume expansion and oxidative 
stress, on embryonic and fetal growth and development in order to clarify their impact on 
pregnancy outcome.
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ABSTRACT
Objective: To assess whether counseling women planning pregnancy to start or continue folic 
acid supplementation improves folate status.
Methods: Women and their partners reported folic acid supplement intake in a 
preconceptional health questionnaire, and the women were categorized as initial ‘users’ or 
‘non-users’ of supplements before counseling. The use of periconceptional folic acid was 
addressed at a subsequent preconceptional consultation. Differences between reported 
supplement users and non-users before counseling as well as between women with pre­
counseling red cell and serum folate levels above and below 590 nmol/L and 20 nmol/L, 
respectively, were analyzed.
Results: A total of 111 (66%) of 168 eligible women participated. Estimated mean red cell 
folate levels of women who reported no use of folic acid supplements before counseling 
increased significantly after 4 months from 540 nmol/L to 680 nmol/L. Red cell folate levels 
of women who reported taking supplements (44%) remained stable up to one year after 
counseling. Women with low precounseling folate levels showed a highly significant mean 
increase in red cell folate from 475 nmol/L to 689 nmol/L 4 months after counseling. 
Conclusion: Addressing periconceptional folic acid use at a preconceptional consultation 
improves folate status among women planning to conceive.
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Introduction
In the past decade consistent evidence has been reported on supplemental folic acid use for 
the prevention of neural tube defects.1-4 This has led national health authorities in the 
Netherlands in 1992 and 1993 and worldwide to recommend periconceptional folic acid 
intake and to initiate various campaigns to promote its use. Media activities, women’s 
magazines, leaflets, information added to oral contraceptives and provided by health care 
workers have contributed to increased knowledge and adequate folic acid intake.5,6 However, 
the impact of such efforts is disappointing considering that 50-97% of women planning 
pregnancy are still not taking folic acid in the recommended period (4 weeks before until 8 
weeks after conception) or do not take supplements at all.7-11 Poor compliance has led to 
folate fortification of foods in different countries in order to increase folate status, though this 
policy has not been implemented in most European countries including the Netherlands. In 
addition, consumption of extra folate as natural food folates has been shown to be ineffective 
in optimizing folate status.12 This dependence on supplemental folic acid to optimize 
periconceptional folate status emphasizes the need for a stronger, or possibly an alternative 
approach to reach a larger group of women.
A pre-pregnancy consultation is an ideal opportunity to address the use of folic acid among 
the target population and may be more effective than large population-based campaigns. 
Instead of assessing reported folic acid intake to ascertain compliance, measuring blood folate 
concentrations to determine long-term folate status may be more reliable since women who do 
not follow the recommendation could feel guilty and may give biased answers. As part of a 
study on preconception counseling in the Netherlands, we evaluated whether periconceptional 
folic acid supplementation recommendation has a positive effect on folate status of women 
planning pregnancy. Therefore, we chose to question supplement use only before counseling 
and to evaluate changes in folate concentrations in blood to assess compliance after 
intervention. Furthermore, folate status of women already taking supplements was evaluated 
biochemically to assess whether they continue to use supplements, regardless of time until 
pregnancy. Red cell folate was chosen as the primary outcome measure of this study because 
it represents tissue stores and therefore more accurately reflects long-term folate status than 
does serum folate.13
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Materials and Methods
Between September 1997 and April 1999, couples with a scheduled appointment at the clinic 
for preconception care of the University Medical Center Nijmegen (due to previous obstetric 
complications, maternal disease or medication use) or at the fertility clinic (because of the 
inability to become pregnant within one year) were approached by letter to take part in a study 
on preconception counseling. After giving their informed consent, 193 couples were invited 
for participation of which 186 couples attended the first intake visit. Due to pregnancy 18 
women were excluded, which resulted in 168 women eligible for participation in this study. 
The Medical Ethical Committee of the University Medical Center Nijmegen approved the 
study.
Before the first visit to the outpatient department (the intake visit), couples were asked to 
complete a Dutch version of the Preconceptional Health Assessment form developed by 
Cefalo and Moos14 that includes a section on folic acid or other vitamin use. Based on the 
answers obtained from this questionnaire, women were categorized as initial ‘users’ or ‘non­
users’ of supplements before counseling. A physician verified the responses given in the 
questionnaire during the intake visit in order to assess pre-pregnancy risk factors. After four to 
six weeks, the counseling visit took place, at which time relevant aspects of health promotion 
were discussed, including smoking cessation, nutritional habits, antenatal care, and folic acid 
supplement intake. All women were advised to start taking a tablet of Matrilon® daily, a 
multivitamin supplement containing 400 ^g of folic acid, until 8 weeks after conception. They 
were provided with the supplements so that they could start the same day. Women who 
reported using folic acid already were encouraged to continue doing so, and also received a 
supply of Matrilon® to last until the next visit. Blood samples for the analysis of red cell and 
serum folate levels were taken at the intake and counseling visits to assess folate status before 
advice to start or continue folic acid supplementation (pre-counseling folate status), and then 
every three to four months after counseling and in the 6th, 8th, and 12th week of pregnancy. 
The longest follow-up was 18 months.
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Blood samples were drawn in EDTA vacutainer tubes and centrifuged within 2 hours for 10 
minutes at 3000 x g. Plasma was separated and stored at -35° C until analysis. Hematocrit 
was measured and whole blood was diluted 5-fold with sodium ascorbate (1 g per 100 ml) and 
stored at -35° C. Folate concentrations in red cells and serum were determined using the IMx 
Folic Acid Assay, based on the Microparticle Enzyme Immunoassay (MEIA) technology for 
the IMx immunoassay system (Abbott Laboratories, North Chicago, IL, U.S.A.). The 
hemolysates were further diluted with IMx Folate RBC Lysis Reagent (Abbott Laboratories, 
North Chicago, U.S.A). The intra-assay coefficients of variation for means of duplicate 
measurements were between 3% and 6%, and the inter-assay coefficients of variation for 
different pools of serum ranged from 6% to 10%.
Two linear mixed models for repeated measurements were used to analyze the change in 
folate status among the study population, at four months and one year after counseling. In 
both models, a fixed linear relation with time after counseling was postulated, as well as 
individual random linear coefficients. The first model was used for analysis of red cell folate 
changes among initial non-users of supplements after a time period of 4 months, 
corresponding with the duration of erythropoiesis and incorporation of folate in maturing red 
cells.
The second model included all red cell measurements up to one year after counseling, and 
was used to interpret long-term compliance of initial supplement users. Because a linear 
increase in folate concentrations is not expected after the incorporation of supplemental folic 
acid in maturing erythrocytes, this second model was not considered applicable to women that 
were not using supplements before counseling as this could result in unrealistically high 
estimated red cell levels. Additionally, changes in serum folate were analyzed using both 
models. An indicator variable to discriminate between initial reported users and non-users of 
supplements was used and another determinant based on pre-counseling folate status was 
added to the model.
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Though studies on folate status have reported a vast range in folate levels after various 
interventions,15-22 values were evaluated that would discriminate between users and nonusers. 
Due to the impossibility to give normative data on red cell and serum folate levels before 
and/or after folic acid supplementation, we used the cutoff levels assessed in the 2-month 
intervention study of 500 ^g of folic acid daily previously carried out at our department.15 
Folate concentrations of >590 nmol/L in red cells and >20 nmol/L in serum were found in all 
supplemented non-pregnant healthy women («=49) at the same laboratory in a similar 
setting.15
Folate status of men joining their partners at the counseling and following visits were also 
analyzed after 4 months as well as after one year, using the two previously described models. 
Since men were not counseled to take supplements, red cell folate data was entered into the 
four-month as well as the one-year model, thereby not accounting for the time necessary for 
incorporation of supplemental folic acid into red cells. Finally, blood samples taken at the 
intake and at the counseling visit (to determine pre-counseling folate status) were compared 
using Wilcoxon signed-rank test. All analyses were carried out using version 6.12 of the SAS 
package (SAS Institute Inc., Cary, NC, U.S.A.). P<0.05 was considered statistically 
significant.
Results
Among the 168 eligible women, 23 withdrew between the intake and the counseling visit, 33 
were lost to follow-up, and one participant was excluded because of missing pre-counseling 
data. This resulted in 111 women (66%) with multiple sample data for further analysis (34 
women from the preconception care clinic and 77 women from the fertility clinic). Of these 
women, 63 became pregnant over the course of the study period. The age of participants 
ranged from 25 to 42 years, with a mean age (SD) of 32.5 (3.5) years. Demographic 
characteristics were obtained from the Preconceptional Health Assessment Form and are 
shown in Table 1.
114
Table 1. Demographic Characteristics («=111)
Characteristic n %
Age (y)
25-29 23 20.7
30-34 55 49.5
35-39 31 27.9
> 40 2 1.8
Obstetric history
Never pregnant 66 59.5
Prior birth 36 32.4
Education by occupation*
Low 14 13.3
Middle 42 40.0
High 25 23.8
Not stated 24 22.9
Ethnicity
Caucasian 108 97.3
Other 3 2.7
* Six women had no current occupation
Folate concentrations measured in samples collected at the counseling visit were chosen to 
represent the pre-counseling folate status of the study population. Estimated red cell folate 
levels at the intake and counseling visits did not differ significantly (p=0.285), therefore it is 
very unlikely that women already started to use folic acid during the period between the two 
visits. The number of women in which the folate status after 4 months was evaluated («=97) 
is slightly lower than the number that was evaluated over the one-year period (n=111). This is 
due to an interval longer than four months between the counseling visit and the subsequent 
sampling visit(s) in 14 cases. In 138 counseling consultations the partner was present and 
follow up of 98 men was achieved. Sixty-two women (56%) indicated in the preconceptional 
health assessment form that they were not using folic acid supplements. Among women that 
were biochemically evaluated after 4 months, 52 (54%) were classified as nonusers of 
supplemental folic acid. As measured in red cells, folate status of these reported nonusers 
improved significantly 4 months after they were encouraged to start folic acid containing 
supplementation (Table 2).
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Table 2. Folate status (estimated from linear models) before and 4 months after counseling
Population n*
Precounseling 
Mean (SE)
4 months after 
counseling 
Mean (SE) P
Red cell folate (nmol/L)
Nonusers1 52 540 (30) 680 (52) < 0.01
Users1, 45 782 (33) 733 (56) NS
Serum folate (nmol/L)
Nonusersf 52 18.7 (1.3) 20.8 (1.9) NS
Users1 45 24.4 (1.4) 20.0 (2.1) < 0.05
Red cell folate (nmol/L)
< 590 nmol/L 47 475 (31) 689 (49) < 0.001
> 590 nmol/L 46 851 (31) 760 (51) NS
Serum folate (nmol/L)
< 20 nmol/L 51 14.0 (1.2) 18.0 (1.5) < 0.05
> 20 nmol/L 45 29.7 (1.2) 23.9 (1.6) < 0.01
SE = standard error; NS = not significant.
* Precounseling laboratory data were inconclusive for red cell folate in four cases and serum 
folate in one case, so that these women could only be classified as reported users or nonusers 
and not in terms of precounseling folate status. 
t According to self-report
In the analysis based on cutoff values, an even higher increase in red cell folate was seen 
among women with pre-counseling folate levels below 590 nmol/L. Estimated red cell folate 
levels of these women were comparable to that of initial reported nonusers 4 months after 
counseling, 689 nmol/L and 680 nmol/L, respectively. Red cell folate concentrations of 49 
women (44%) reporting supplement use before counseling did not change significantly over 
time (Table 3). Women with pre-counseling folate levels above 590 nmol/L also maintained 
this folate status after one year. Estimated serum folate levels between 18.0 nmol/L and 23.9 
nmol/L were found for all groups after counseling (Tables 2 and 3). No significant change 
was seen among initial reported nonusers after 4 months or after one year.
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Table 3. Folate status (estimated from linear models) before and 12 months after counseling
Population *n
Precounseling 
Mean (SE)
12 months after 
counseling 
Mean (SE) P
Red cell folate (nmol/L)
Nonusers1 62 NA NA NA
Users1 49 745 (31) 750 (80) NS
Serum folate (nmol/L)
Nonusers1 62 18.5 (1.1) 22.2 (2.0) NS
Users1 49 22.5 (1.3) 19.6 (2.3) NS
Red cell folate (nmol/L)
< 590 nmol/L 56 NA NA NA
> 590 nmol/L 51 817 (27) 812 (85) NS
Serum folate (nmol/L)
< 20 nmol/L 62 14.8 (0.9) 23.5 (2.0) < 0.001
> 20 nmol/L 48 27.2 (1.0) 20.8 (2.0) < 0.01
NA = not applicable; SE = standard error; NS = not significant.
*Precounseling laboratory data were inconclusive for red cell folate in four cases and 
serum folate in one case, so that these women could only be classified as reported users 
or nonusers and not in terms of precounseling folate status.
According to self-report.
Women with low pre-counseling serum folate levels improved significantly both after 4 
months as well as one year after counseling. However, significantly lower estimated serum 
folate levels were found at both time points among women reporting supplement use as well 
as those with high pre-counseling folate levels. Before counseling, folate status in men was 
lower than in all groups of women (Table 4). Mean estimated red cell folate levels did, 
however, improve significantly after one year.
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Table 4. Folate status (estimated from linear models) of the male population. Data shown as mean and 
standard error (SE).
n
Pre-counseling 
Mean (SE)
Follow-up 
Mean (SE) P
After 4 months
Red cell folate (nmol/L) 80* 487 (22) 534 (27) NS
Serum folate (nmol/L) 83 11.9 (1.0) 12.8 (1.3) NS
After 12 months
Red cell folate (nmol/L) 95* 485 (16) 573 (22) < 0.001
Serum folate (nmol/L) 98 11 (0.7) 13 (1.0) NS
SE = standard error; NS = not significant.
* Precounseling laboratory data were inconclusive for red cell folate in three cases.
Discussion
This study reveals that a single preconceptional consultation appears to be an appropriate way 
to emphasize the importance of periconceptional folic acid and to improve the use of a folic 
acid containing supplement among the target population. Furthermore, women encouraged to 
keep taking folic acid continue to do so. It is unlikely that supplement use changed in the 6- 
week interval between intake and counseling, because red cell folate levels did not differ 
significantly between both visits.
Although folate levels were considered to reflect compliance, we should emphasize the 
meaning of low and high folate levels. A discrepancy exists in that 12 of the 47 women 
claiming to use folic acid at intake (26%) had mean red cell folate concentrations below 590 
nmol/L, and 16 of the 60 women that indicated not using supplements (27%) showed a mean 
red cell folate concentration above 590 nmol/L. It is possible that folate levels between the 
supplement users and nonusers overlap 21 and that a subset of women have just started using 
supplements and have not yet reached this red cell folate level. Although we can only 
speculate, it is also likely that some women falsely claim to use supplements.
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The decline in serum folate levels among users of supplements and participants with high 
baseline serum levels is not in accordance with red cell folate data and cannot be explained. 
However, it is known that serum and red blood cell measurements of folate can be 
inconsistent as well as that serum levels only reflect transient folate concentrations between 
absorption and utilization or storage and are less accurate in determining true folate status 
than red cell levels.2
We did not study the influence of factors confounding folate status such as the 
methylenetetrahydrofolate reductase polymorphisms, chronic illnesses, use of antifolates, and 
nutritional intake. It was remarkable that though men were not advised to take supplements, 
their overall folate status improved over the course of the study. This may be due to an 
increased intake of dietary folate, as the importance of proper nutrition before and during 
pregnancy was also stressed during the counseling consultation. Although dietary changes 
may contribute to the improvement in folate status among women as well, the substantially 
higher folate levels of women as compared to the male population cannot be explained by diet 
alone. As enrichment of foods with folate is not allowed in the Netherlands, the only plausible 
source of folic acid that can explain this increase among the target group is by the 
supplements.
Most studies on the knowledge and use of folic acid supplements in populations of women of 
reproductive age conclude that awareness of its protective effect in the prevention of neural 
tube defects is greater than proper intake. A gap as large as 76% of women aware versus only 
16% of women taking it before pregnancy was found in an Irish population.23 Considering 
that 51% of women in that study did take supplements once pregnant, it may not be clear that 
intake should be started preconceptionally and should therefore receive greater emphasis. 
Several reasons why some women still did not take folic acid despite being aware of its 
benefits have been documented in previous studies among Dutch women and include a long 
time period between trying to conceive and actual pregnancy or forgetting to take them.4 
Perhaps Dutch women consider folic acid as a drug and therefore hesitate to take it. This is in 
contrast to a study among Irish women which illustrated that many women, had they received 
counseling on periconceptional folic acid, would be willing to take supplements and would 
prefer a pill to food fortification.8
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Whereas in some populations compliance seems to be the major problem, in other populations 
awareness has not even been achieved. In a Canadian population of women, only 1.8% had 
the specific knowledge that neural tube defects could be prevented with folic acid 
supplementation.11 A study among Israeli women demonstrated that only 5.5% of them had 
heard about folic acid and 2.8% reported to have taken it.10 Although knowledge and proper 
use of supplements is quite high in the Dutch population as compared to other parts of the 
world,4,5 we need to continue efforts to increase its intake among the target group.
Addressing periconceptional folic acid use during a pre-pregnancy visit now has been shown 
to have a positive effect on folate status. Considering the additional benefits, including the 
opportunity to discuss other aspects of good health before pregnancy, application and 
expansion of preconception care should be considered to promote the message on the primary 
prevention of neural tube defects and other aspects of health promotion.
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ABSTRACT
This study assessed the applicability of serum and urine cotinine as biochemical markers of 
self-reported smoking habits for use in a preconceptional smoking cessation program. The 
variation of serum and urine cotinine over the course of the day was investigated in a sample 
of 21 smokers and 8 passive smokers, who reported their smoking habits and exposure to 
smoke daily in a questionnaire for 10 consecutive days. Blood and urine samples were 
collected on two sampling days, one week apart. Both serum and urine cotinine assay could 
distinguish between passive and active smokers, but not between higher categories of smokers 
(10-19 and > 20 cigarettes per day) due to significant intersubject overlap. In serum, no 
significant differences were found between morning and afternoon cotinine concentrations on 
either day, in contrast to urine cotinine (with lower excretions observed in the morning). An 
overall coefficient of variation of 22% was observed for both specimens in smokers. Because 
serum cotinine is subject to lower variability over the course of the day, it is more practical 
for use in a clinical setting where appointments are scheduled throughout the day in order to 
confirm smoking status.
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Introduction
Preconceptional counseling encompasses many aspects of health promotion aimed to improve 
fetal outcome.1,2 The obstetric risks of maternal smoking, including low birth weight, preterm 
delivery, placental abruption and perinatal death are well-known.3 Altering addictive behavior 
however, ideally before conception, poses a major challenge in obstetrics.4 Preconceptional 
risk assessment, both by history taking and self-report, likely fails to identify a significant 
number of smokers and users of alcohol and other drugs, as many women and men tend to 
underreport their use.5-7 This has led to an increased interest by investigators to put emphasis 
on biochemical confirmation of smoking as a means to objectivation. For biochemical 
confirmation of smoking status, cotinine is the analyte of choice because of the specificity of 
this nicotine metabolite for tobacco smoke and its long half-life of 20 hours.8 On the other 
hand, biochemical assay results for evaluation of smoking habits do not provide a golden 
standard, nor are they a perfect quantitative measure of actual smoking behavior.9 We 
designed this prospective study to determine the overall variation of cotinine in serum and in 
urine of smokers and passive smokers over the course of the day.
Materials and Methods
Study sample
Employees and students of the University Medical Center Nijmegen, Nijmegen, the 
Netherlands, were recruited for this prospective study through advertisements. Participants 
were included if they could be defined as consistent smokers, i.e. having clearly defined 
smoking habits and smoke since at least one month, or as passive smokers, i.e. non-smokers 
whose (live-in) partner, roommate or other household member smokes regularly.
Data collection
Participants received a questionnaire on smoking habits and exposure to smoke and were 
asked to complete it daily as accurate as possible for 10 consecutive days (Table 1). Answers 
were verified in a personal interview. Using this data, participants could be categorized into 
subgroups as accurately as possible. The smokers were asked not to change their smoking 
habits.
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Table 1. Daily Questionnaire on Smoking Habits
Question Reply
1. Did you smoke today? ___  yes ___no
2. How many cigarettes? cigarettes
3. Were you exposed to smoke o f others? ___  yes ___no
4. Where were you exposed to smoke? home work
other: (explain)
5. How long were you exposed to smoke? minutes / hours (circle one)
6. How would you classify the amount o f passive minimal
smoke exposure? ___moderate
___great
___severe
On the third day of the study period they were seen at the Department of Obstetrics and 
Gynecology of the University Medical Center Nijmegen for collection of blood and urine 
samples, first between 8 and 9 a.m. and again between 3 and 4 p.m. They were instructed not 
to smoke before collection of the morning samples, and were also requested to collect a third 
urine sample that evening around 11 p.m., store it in the refrigerator, and bring it to the 
outpatient clinic the next morning before 10 a.m. The same procedure was repeated one week 
later. The Medical Ethical Committee of the University Medical Center Nijmegen, the 
Netherlands, approved the study design.
Analytical methods
Blood samples were taken by vene puncture and stored with the urine specimens in the dark 
between 0 and 4° C within one hour after collection. Blood samples were allowed to clot, 
centrifuged at 2000 x g, and serum was collected and stored with the urine samples at -30° C 
until assayed. Urine cotinine concentrations were measured in duplicate using the Double 
Antibody Nicotine Metabolite (DANM), a liquid phase radioimmunoassay (RIA) for designed 
for the quantitative analysis of cotinine concentrations in urine (Diagnostic Products 
Corporation, Los Angeles, U.S.A.).
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Creatinine was measured in urine to correct for possible dilution (Hitachi 747; Roche) by the 
Jaffé reaction, and cotinine in urine was given as the cotinine: ceatinine ratio (^g/mmol). Prior 
to this study, the RIA procedure was also made suitable for analysis of serum cotinine 
(described in detail by Wong et al).10 As a measure of accuracy, parallelism of the modified 
RIA was assessed by serial dilution of a serum specimen (with a mean cotinine concentration 
of 189 |lg/L) up to 32-fold with cotinine-free plasma, yielding a coefficient of variation of 
10.7%. The assay precision for means of duplicate measurements was determined by testing a 
plasma pool at two different dilutions (2-fold and 6-fold) in six consecutive assay runs. At a 
mean concentration of 121 ^g/L, the intra-assay coefficient of variation (CV) was 3.5% and 
inter-assay CV was 17.5%. At 343 |ig/L, the intra- and inter- assay CVs were 3.8% and 7.4%, 
respectively.10 Specificity for cotinine (as tested by the manufacturer) demonstrated moderate 
cross-reactivity of 15.2% with another major nicotine metabolite, 3-hydroxy cotinine. The 
urinary concentration of 3-hydroxy cotinine is comparable to the concentration of cotinine 
after infusion of deuterium labeled nicotine.11 For practical reasons, the cotinine metabolite 
(DANM) assay will be designated as cotinine assay. The minimum detectable concentration 
of the assay was 5 ^g/L.
Statistical analysis
Participants with a serum cotinine concentration below the detection limit of 5 p,g/L were 
assigned the value of 2.5 p,g/L for statistical analysis. Wilcoxon matched-pairs signed-ranks 
test was used to compare morning cotinine concentrations, one week apart, and afternoon 
cotinine concentrations, one week apart, for both specimens. The same analysis was 
performed for the two evening urine samples. Likewise, variation over the course of the day 
in serum and urine on both days was determined by comparing morning and afternoon 
samples using Wilcoxon matched-pairs signed-ranks test. An estimate of within-person 
variation of cotinine in serum and urine was determined by calculating the median CV using 
samples collected at the same time of day, one week apart (on day 3 and day 10 of the study). 
Pooling of the data resulted in an overall CV for each of the two specimens. Data was 
analyzed using SPSS for Windows® (SPSS 6.1, Inc) and Microsoft® Excel 7.0. Statistical tests 
were considered to be significant at a P<0.05.
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Results
The sample of volunteers originally comprised 23 smokers (17 women and 6 men), mean 
(SD) age 34.4 (14.0) years, and 8 passive smokers (7 women and one man) with a mean age 
of 28.5 (9.9) years. The smokers were classified according to the average number of cigarettes 
smoked daily, among which 3 indicated to smoke up to 9 cigarettes per day, 13 smoked 10-19 
cigarettes per day, and 5 reported to smoke 20 or more cigarettes daily. Table 2 depicts the 
median, minimum and maximum cotinine concentrations as determined in serum and urine on 
both sampling days of the whole study sample. Serum cotinine concentrations of passive 
smokers were not detectable except in one case (6 |ig/L), and ranged from < 5 -  1200 pg/L in 
active smokers. The urine cotinine: creatinine ratios of passive smokers ranged from 22 - 368 
pg/g and ranged from 71 - 13300 pg/g in active smokers.
Table 2. Cotinine in Serum and Urine of Passive Smokers (n=8) and Smokers (n=21)
Passive SMOKERS
smokers 1-9 cigarettes per 10-19 cigarettes per day >20 cigarettes per
Sample (n=8) day (n=3) (n=13) day (n=5)
SERUM *
Day 3
Morning <5 19 (17-120) 430 (170-710) 360 (210-650)
Afternoon <5 25 (18-100) 420 (140-870) 338 (240-830)
Day 10
Morning <5 27 (9-230) 320 (80-800) 370 (180-490)
Afternoon <5 (<5-6) 43 (<5-170) 330 (50-1200) 330 (280-700)
URINEt
Day 3
Morning 34 (25-117) 411(156-1000) 2790 (1020-7070) 3230 (1560-8970)
Afternoon 58 (29-368) 624 (198-650) 4710 (1090-6540) 3860 (3270-9380)
Evening 52 (24-126) 287 (208-830) 4670 (1100-11900) 7580 (2430-12500)
Day 10
Morning 41 (23-80) 381 (71-1160) 3754 (674-6630) 3030 (1980-8350)
Afternoon 55 (23-95) 713 (113-918) 3990 (598-13300) 5140 (3040-6210)
Evening 73 (22-111) 703 (82-1200) 4150 (1590-7580) 6050 (3230-8080)
* Serum cotinine: |Jg/L
t Urine cotinine (cotinine: creatinine ratio): pg/g
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Serum cotinine assay was able to clearly distinguish passive smokers from all groups of 
smokers (Table 2). The roughly ten-fold difference between median cotinine concentrations 
of smokers of 1-9 and 10-19 cigarettes daily appears to discriminate between these groups of 
smokers as well, however, some intersubject overlap of individual cotinine concentrations 
was found. Serum cotinine levels did not show a further increase among higher categories of 
smokers (i.e. 10-19 and > 20 cigarettes daily). The highest median cotinine concentrations as 
well as the greatest individual concentration of cotinine were found in the group reporting to 
smoke 10-19 cigarettes a day, and not among the heaviest smokers in the study sample (Table 
2).
No significant difference in serum cotinine was found between morning and afternoon 
samples on either day of all four smoking categories. When comparing the different sample 
days (days 3 and 10 of the study), no significant difference was found between cotinine 
concentrations in serum between the morning samples or the between the afternoon samples. 
An overall CV of 22% was found among smokers, with slightly higher median coefficients of 
variation measured in morning than in afternoon blood samples (24% vs. 19%). Serum 
cotinine concentrations of passive smokers were below the minimum detectable concentration 
of 5 pg/L in all but one case, so that the variability of serum cotinine in passive smokers could 
not be determined.
Urine cotinine assay also discriminates well between passive and active smokers. All of the 
passive smokers had cotinine levels below the cut-off provided by Diagnostic Products 
Corporation of > 500 pg/L for active smokers. However, no cutoff point with 100% 
specificity could be defined as a validation of not smoking, due to several overlapping 
individual values between the group of passive smokers and smokers of less than 10 cigarettes 
a day (Table 2). Median urine cotinine: creatinine ratios are roughly 5-15-fold higher among 
smokers of 10-19 cigarettes a day as compared to lighter smokers (1-9), but again a 
substantial amount of overlapping individual values are found between these two groups. This 
was even more apparent in the higher categories of smokers, in which not only individual 
values but also median cotinine: creatinine ratios showed a great deal of overlap.
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Morning and afternoon cotinine: creatinine ratios in urine of the whole study sample differed 
significantly on both sampling days (p=0.024 and p=0.017), with the lowest cotinine: 
creatinine ratios observed in the morning. The CV of urine cotinine in smokers was 
significantly lower when measured in morning urine (10%) as compared to 24% and 31% 
when measured in afternoon and in the evening urine samples. In contrast, the lowest CV in 
urine of passive smokers was found in the evening samples (morning, afternoon and evening 
coefficients of variation were 15%, 20%, and 13%, respectively). Pooling of data yielded an 
overall CV of 22% in urine of smokers, and of 16% in passive smokers.
Discussion
This study assessed the overall variability of cotinine in urine and plasma of smokers and 
passive smokers. Cotinine has also been measured in other body fluids including saliva, urine, 
breast milk, cervical mucus, follicular fluid and seminal plasma.10,12,13 We confined this study 
to serum and urine because of their frequent application to a range of issues including 
validation of smoking cessation, passive smoke exposure, and determination of nicotine in 
light and stronger cigarettes,12 and to limit the burden of data collection for the participants. A 
within-person CV for serum cotinine of 16.1%, measured within a period of 14 weeks, has 
been reported previously.14 Despite consistent self-reported smoking habits throughout the 
study, we found a greater overall CV for serum cotinine (22%). This may be attributed to the 
individual biological variation in our relatively small study sample.
Jarvis et al. addressed the applicability of cotinine in three specimens (plasma, urine and 
saliva) by studying the elimination of cotinine from these body fluids. Because they found a 
similar time course of elimination in each of the fluids, they conclude that plasma, urine, and 
saliva cotinine assay are equally applicable for estimating nicotine exposure.12 In our study, 
serum cotinine showed greater stability over the course of the day than urine cotinine, and 
was not confounded by time of analysis. In a clinical setting where appointments are 
scheduled throughout the day, serum cotinine assay is therefore more applicable in this 
respect.
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Serum and urine both discriminate well between smokers and passive smokers. We did not 
find serum cotinine concentrations above the minimum detectable concentration of 5 pg/L in 
passive smokers, so it seems justified to assume that self-reported 'non-smokers' are 
prevaricators if  serum cotinine concentrations above this clearly defined cutoff are found. 
Considering the large increment in values between participants smoking less than or 10 or 
more cigarettes a day, both serum as well as urine cotinine can be used to roughly assess 
whether someone smokes heavily or not, although the possibility of misclassification should 
be acknowledged. For these applications, we agree with Jarvis et al. that the choice of fluid 
sampling should depend on practical considerations rather than on pharmacokinetics.12
There are no standardized cutoff values for cotinine in the different specimens, which makes 
it difficult to compare smoking cessation rates and percentages of prevaricators ('self­
deceivers') among different study groups. For instance, in a recent Swedish study among 
pregnant women, a cutoff value of <17.5 |ig/L cotinine in serum was used to define passive 
smokers, 17.6 -  113 |ig/L for light smokers and >113 |ig/L for smokers of more that 10 
cigarettes a day (Lindqvist et al, 2002). Using these cutoffs, 6% of reported non-smokers had 
cotinine levels suggesting active smoking, though another 3% of “passive” smokers would 
have been considered to be active smokers if the cutoff we suggest (>5 pg/L) was chosen. 
That study revealed that underreporting of smoking was quite common, with 32% of reported 
light smokers likely to smoke more than 10 cigarettes a day. A New Zealand study used 
serum cotinine concentrations of <15 pg/L to define non-smokers, 15-100 pg/L for light 
smokers and >100 pg/L to define heavier smokers.6 Although their definition of smokers, 
similar to Lindqvist et al (2002) is more liberal than the one we suggest (serum cotinine > 5 
pg/L), their cutoff to discriminate between light and heavier smokers is in accordance with 
our data. For heavier smoking groups (smokers of 10-14 and 15+ cigarettes a day), similar 
serum cotinine concentrations were found. They therefore speculate that a proportion of 
smokers (reporting 10-14 cigarettes a day) underreported the amount that they actually smoke. 
However, our data show a similar lack of further increase in serum cotinine concentrations 
after an average of 19 cigarettes a day. It seems more plausible that this is due to an increased 
metabolism or steady state among heavy smokers rather than underreporting in the lighter 
group, because social pressure to stop smoking does not play a role in our study setting. Our 
participants were especially encouraged not to change their smoking habits.
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Since the daily amount of creatinine excreted in a urine specimen is approximately 10-15 
mmol/24-h, our results of cotinine:creatinine ratios (expressed in |ig/g) are approximately 
equivalent to urinary cotinine concentrations reported as |ig/L in the literature. In an 
American smoking cessation program, smoking was biochemically confirmed by urine 
cotinine assay using a cutoff level of 500 pg/L as a validation of not smoking.4 All 
participants that reported not smoking (except one) had urine cotinine concentrations below 
this level. This compares rather well with our results, considering that cotinine concentrations 
of the light smokers well exceeded this cutoff in all cases. However, a different American 
study also used a urinary cotinine cutoff level of 500 pg/L, and found an underreporting rate 
of cigarette use of 25.2%. This is the highest demonstrated deceiver rate thus far.
An Australian smoking cessation program used a urine cotinine concentration of <115 pg/L to 
validate quitters.15 This cut-off value seems quite suitable for verification of non-smokers 
when looking at our data. In our study sample, the median cotinine concentrations of all 
passive smokers were below this level, and were above 115^g/L among all the active smokers 
irrespective of time of day. Moreover, when considering the maximum cotinine 
concentrations of passive smokers, the median of 114 |ig/L still falls just below this cut-off. 
The study did not show that the smoking cessation intervention decreased smoking prevalence 
in pregnancy more so than standard care.15 The researchers speculate that a contributing factor 
is that urine cotinine is an imprecise measure of active smoking and not sensitive enough to 
detect subtle changes in smoking behavior.
Considering these discrepancies as well as the considerable within-person variability of 
cotinine, only substantial changes in smoking behavior can be detected using biochemical 
assay. However, both serum and urine cotinine analysis are applicable for confirmation of 
smokers and non-smokers at the beginning and end of a smoking cessation intervention in 
order to assess efficacy of a program. We suggest using serum assay because it varies less 
over the course of the day and is easier to interpret with a clear cutoff point of 5 pg/L as a 
validation of not smoking.
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Maternal smoking cessation intervention: targeting 
women and their partners before pregnancy
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ABSTRACT
Objective: To evaluate the impact of smoking cessation advice given to couples at a 
preconception counseling visit and to assess the reliability of self-reported smoking by serum 
cotinine assay.
Methods: Women and their partners reported smoking habits in a preconceptional health 
questionnaire. The risks of smoking during pregnancy were discussed and smoking cessation 
advice was given at a subsequent preconceptional consultation. Self-reported smoking habits 
were confirmed by serum cotinine analysis, with a concentration >5 pg/L indicating smokers. 
Results: Of the 109 participating women, 16 reported smoking though 24 confirmed as 
smokers according to serum cotinine concentrations (15% versus 22%). Among the 98 men 
that participated, 20 reported to be smokers though 36 had cotinine levels above 5 pg/L (20% 
versus 36%). Three fourths of smoking women had lower serum cotinine levels after 
counseling (a reduction of mean estimated cotinine concentrations from 214 pg/L to 99 pg/L 
after one year). No significant changes in cotinine concentrations were found among men. 
Conclusions: Preconceptional smoking cessation may help to reduce tobacco use, but does 
not motivate women to stop smoking. How to influence prevaricators and partners to give up 
smoking in order to reduce the occurrence of adverse pregnancy outcomes, will pose a 
continuing challenge for obstetricians and other health care workers.
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Pollack recently analyzed the relationship between maternal smoking and sudden infant death 
syndrome (SIDS) and the cost-effectiveness of smoking cessation programs.1 We fully agree 
that smoking cessation interventions should remain an important policy goal, but we wish to 
emphasize that such programs should especially be targeted at women before conception in 
order to protect the developing embryo from tobacco exposure during organogenesis and to 
minimize other risks.2-4 We carried out a study on preconception care in the Netherlands in 
which we evaluated the impact of smoking cessation advice given before pregnancy on 
smoking behavior of both women and their partners. Two limitations of the study by Dr. 
Pollack, being self-reported maternal smoking and lack of data on smoking by other 
household members,1 were accounted for in our study design, as we confirmed smoking by 
serum cotinine assay and also assessed paternal smoking behavior.
We confirm previous findings of maternal underreporting of smoking,5,6 as in our cohort of 
111 women followed over a one-year time period, 16 women reported smoking, whereas 24 
were identified as smokers (serum cotinine >5 pg/L, 33% underreporting). Moreover, we 
found a similar trend in men who were questioned on smoking habits, with only 20 admitting 
tobacco use as compared to 36 identified smoking men (44% underreporting). Using a linear 
model for repeated measurements to analyze data collected up to 12 months after counseling, 
the estimated mean serum cotinine concentration of smoking women decreased significantly 
after intervention (from 214 pg/L to 99 pg/L; p=0.016). Although none of the women stopped 
smoking, 75% of validated smokers and 88% of self-reported smokers reduced smoking after 
the preconception counseling intervention. The men, however, did neither reduce nor stop 
smoking.
In contrast to Dr. Pollack’s study population, our small sample of smokers did not allow 
further analyses of pregnancy outcome, but emphasizes the major underreporting of smoking 
in both genders and underscores the great difficulty in changing smoking habits. A single 
preconceptional intervention is not enough to stimulate couples planning pregnancy to stop 
smoking. We found a more prominent decrease in cotinine levels of self-reported smokers, 
which may illustrate that deceivers are more resistant to changing smoking habits. How to 
influence deceivers and partners to give up smoking in order to reduce the occurrence of SIDS 
and other adverse pregnancy outcomes, will pose a continuing challenge for obstetricians and 
other health care workers.
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ABSTRACT
Objective: To provide an overview of the outcomes from an outpatients' clinic for 
preconception counseling in the Netherlands and to assess its activities in terms of referring 
professionals, referral indications, supplementary investigations, counseling and treatment 
policy.
Design: Retrospective, descriptive.
Methods: Data were collected from the medical records of women who were seen at the 
outpatients' clinic for preconception counseling, University Medical Center St. Radboud, 
Nijmegen, the Netherlands, in the period 1 January 1996 -  6 July 2000.
Results: Of the 484 women studied, medical records were available from 459 (95%); their 
median age was 31 years (range: 19-44). Most of the women with one or more risk factors 
were referred by gynecologists (65%), followed by general practitioners (17%) and other 
specialists (14%). The main categories of referral indications were previous complicated 
obstetric history, previous fetal abnormality and chronic maternal disease. Half of the women 
were subjected to supplementary investigations indicated for one or more risk factors: 
hyperhomocysteinemia was diagnosed in 24%, other form of thrombophilia (coagulopathy) in 
21% and vitamin deficiency in 18%. The most frequent preconceptional interventions were 
the correction of hyperhomocysteinemia by means of administering folic acid or other vitamin 
supplements and change or cessation of potentially teratogenic medication.
Conclusions: The outpatients' clinic for preconception counseling helped to minimize risk 
factors for adverse pregnancy outcome among high risk women by providing extensive advice 
as well as by means of the early detection and treatment of diagnosed abnormalities.
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Introduction
The incidence of adverse pregnancy outcome, including early pregnancy loss, low birth 
weight, pre-term delivery and birth defects, has not gone down despite improvements in 
antenatal care1. Because the most sensitive developmental period of organogenesis is usually 
completed at the time of the first antenatal visit, initiating care before conception could be the 
most effective strategy to improve obstetric and fetal outcome.2 The goal of preconception 
care is to optimize maternal health before pregnancy through the identification and reduction 
of (modifiable) risk factors.1,3 A crucial component of preconception care is the provision of 
counseling and education on general aspects of pre-pregnancy health, as well as on specific 
maternal health risks, obstetric risks or the possibility of delivering an affected child. 
Although in different countries there are many who advocate preconception care for all 
women of reproductive age,1,2,4-11 no consensus has yet been reached in the Netherlands. In 
1996, an outpatient clinic for preconception care was established at the University Medical 
Center Nijmegen, the Netherlands, for women at high risk for adverse pregnancy outcome. 
This article gives an overview of the indications for referral, investigations performed, and 
interventions and counseling provided at this clinic.
Methods
Structure o f the outpatient clinic
The clinic is held weekly by a gynecologist and a resident. At the first consultation (the intake 
visit), detailed obstetric and medical histories are taken. Depending on the risk factors, a 
research nurse arranges for selected or other clinical investigations (Table 1). During the 
following weeks, other disciplines may be contacted by phone for additional information or to 
discuss a plan of care, patients may be referred to other specialists for further evaluation, and 
a search of the literature may be carried out in preparation for the subsequent counseling visit.
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The results of any investigations performed, the possible risks of (another) pregnancy, and the 
best setting for antenatal care and delivery (primary, secondary or tertiary care) are discussed 
at the counseling visit, as well as a plan of preconceptional, antenatal and postnatal care. 
Women who are already under care of another specialist due to a chronic medical condition 
and/or those who have had selected investigations performed elsewhere, are often discharged 
after a single consultation.
Table 1. Indications for preconceptional (laboratory) investigations at the University Medical Center 
Nijmegen, the Netherlands
Investigation* Indication(s)
Methionine loading test and 
Vitamin profile: t
Anticoagulant system:
Auto-immune:^
. t
Parental female and male karyotype:
Kidney function, 24-hour urine 
excretion, creatinine clearance: 
Glucose, HbA1c:
Thyroid function:
Recurrent early pregnancy loss,12-15 abruptio placen- 
tae,14-17 previous child with neural tube defect,18,19 
severe intra-uterine growth retardation16,17,20 
Early onset preeclampsia and/or HELLP-syndrome,21-23 
abruptio placentae,17,20,23 severe intra-uterine growth 
retardation,17,20,23 thrombo-embolic disorders20,22,24 
Recurrent early pregnancy loss,12 early onset 
preeclampsia and/or HELLP-syndrome,21-23 thrombo­
embolic disorders,25 symptoms of SLE 26 severe intra­
uterine growth retardation17,23 
Recurrent early pregnancy loss,12,13 congenital
anomalies24
protein Early onset preeclampsia and/or HELLP-syndrome,21 
pre-existent kidney disease 21,24 
Macrosomia, congenital defects 24 
Recurrent early pregnancy loss 12
Ultrasound of the uterus (if abnormal: Recurrent early pregnancy loss,14 pre-term delivery 25 
hysteroscopy, hysterosalpingography, laparo­
scopy, cervical resistance (Hegar) test)
Screening for infectious diseases (blood, Pre-term delivery 27 
cervix, urine):
HELLP = hemolysis, elevated liver enzymes, low platelets syndrome; SLE = systemic lupus erythematodes.
11 OO OA* All of the following investigations may be considered in case of intra-uterine death , - 
t Thrombophilia screening.
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Data collection
A research fellow, a junior home officer and a research nurse reviewed together all available 
clinical records of patients seen between 1 January 1996 - 7 July 2000. Using a checklist, 
details were collected on the indication(s) for referral and referring professionals, number of 
consultations, other disciplines consulted, laboratory and other clinical investigations 
performed and whether the results were normal or not. Interventions, recommended 
medication and/or vitamin supplements, counseling regarding risks of a pregnancy and the 
plan for future antenatal and perinatal care, were also noted from the medical records. The 
collected data were entered into a Microsoft Access ‘97® database and analyzed using 
Microsoft Excel ‘97®.
Results
During the period of evaluation, 484 women visited the outpatient clinic for preconception 
care. Medical records were available for 459 women (95%), with a median age of 31 years 
(range 19-44). Most women were referred by gynecologists (n=299; 65%), followed by 
general practitioners (n=80; 17%) and other specialists (n=64; 14%). Eleven women were 
self-ref erred (2%), and five women (1%) were referred by their midwife. A total of 1094 
consultations took place during the study period, among which 197 (18%) were by phone. 
Most women or couples were seen twice (median,2; range: 1-8 visits).
The total number of indications for referral (n=770) was higher than the number of women 
referred (n=459). All risk factors are presented, as we did not attempt to classify women 
according to most important indication for referral to the outpatient clinic. The main 
categories of referral were previous obstetric complications, particularly recurrent early 
pregnancy loss, previous fetal abnormality, and chronic maternal disease (Table 2).
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Table 2. Indication(s) for referral to the outpatients' clinic for preconception counseling, University 
Medical Center Nijmegen (1996-2000): prevalence o f risk factors* among 459 women
Indication for referral Number o f women with 
risk factor (%)
Obstetric history
Recurrent early pregnancy loss 132 (29)
Pre-term delivery 52 (11)
Preeclampsia 51 (11)
HELLP-syndrome 38 (8)
Abruptio placentae 29 (6)
Other 32 (7)
Delivery / puerperium 15 (3)
Maternal congenital anomalies
Genetic disease 12 (3)
Cardiac defect 5 (1)
Neural tube defect 5 (1)
Other 13 (3)
Chronic illnesses
Cardiovascular disease / hypertension 48 (10)
Diabetes Mellitus 25 (5)
Neurological disorder 13 (3)
Kidney / bladder disease 12 (3)
Gastro-intestinal disease 11 (2)
Thrombo-embolic disorders 22 (5)
Auto-immune disease 12 (3)
Other 17 (4)
Other maternal indications 26 (6)
Previously affected child
Intra-uterine death 56 (12)
Low birth weight 40 (9)
Perinatal / neonatal death 22 (5)
Neural tube defect 10 (2)
Cardiac defect 4 (<1)
Cleft lip / palate 3 (<1)
Other congenital defects 10 (2)
Other 14 (3)
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Paternal indications 8 (2)
Family history
Cardiovascular disease 16 (3)
Neural tube defect 6 (1)
Other congenital defects 3 (<1)
Other 8 (2)
HELLP = hemolysis, elevated liver enzymes, low platelets syndrome.
* The total number (770) is larger than 459, as a number of women had several risk factors.
Selected investigations, based on pre-pregnancy risk factors, were performed among 
approximately half of all cases. No investigations were performed if evidence from the 
literature was lacking that the investigated parameters are related to the indication for testing. 
Hyperhomocysteinemia was diagnosed in 24%, other form of thrombophilia (coagulopathy) 
was found in 21% and some kind of vitamin deficiency in 18% (Table 3). Other disciplines 
were consulted in 37% («=170) of all cases (Table 4).
Table 3. Selected investigations performed among 459 women that visited 
the outpatients' clinic for preconception counseling, 1996-2000
Investigation Number (%) Abnormal (%)
Vitamin profile 292 (64) 52 (18)
Methionine loading test 288 (63) 69 (24)
Auto-immune factors 279 (61) 18 (6)
Hematology / biochemistry 263 (57) 48 (18)
Coagulopathy 253 (55) 54 (21)
Thyroid function 222 (48) 20 (9)
Female karyotype 98 (21) 2 (2)
Male karyotype 94 (20) 2 (2)
Ultrasound examination o f the uterus 60 (13) 16 (27)
Schilling test 19 (4) 6 (32)
Hysterosalpingography 18 (4) 8 (44)
Hysteroscopy 18 (4) 6 (33)
Cervical resistance (Hegar) test 13 (3) 8 (62)
MRI 3 (<1) 3 (100)
Laparoscopy 2 (<1) 1 (50)
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Table 4. Number o f times that a gynecologist consulted another discipline* for establishment o f a 
preconceptional and antenatal plan of care, University Medical Center Nijmegen, 1996-2000
Consulted specialist number (percentage o f total 
number o f patients, «=459)
Internist 55 (12)
Another gynecologist 32 (7)
Clinical geneticist 27 (6)
Teratology Information Center1- 26 (6)
Neurologist 15 (3)
Hematologist 13 (3)
Cardiologist 10 (2)
Pediatrician 9 (2)
Urologist 8 (2)
Reumatologist 6 (1)
Surgeon 4 (<1)
Nefrologist 3 (<1)
Psychiatrist 3 (<1)
Ophthalmologist 3 (<1)
Other disciplines 13 (3)
* For several women, more than one discipline was contacted. 
t Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Bilthoven, Netherlands.
More than half of women with chronic medication use (47/80) were using drugs considered 
unsuitable during pregnancy, and were advised a change of therapy or stop the use of 
potentially teratogenic drugs before attempting to conceive (Table 5). Periconceptional folic 
acid supplement use for the prevention of neural tube defects was always addressed during the 
counseling visit. Eight women with a neural tube defect or who had previously given birth to 
a child with a neural tube defect (and were already using folic acid supplements), were 
advised to increase the daily dosage from 0.5 mg to 5 mg. Pregnancy was not primarily 
contra-indicated in the majority of cases (77%). A number of women (15%) were advised to 
postpone pregnancy in order to achieve better preconceptional control of a pre-existent 
medical condition or to adjust to (a change of) medication. Six couples (1%) were advised 
against (another) pregnancy (Table 5).
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A plan for antenatal care, including the setting (primary, secondary or tertiary care) and 
possible interventions during pregnancy were also discussed during the counseling visit. The 
most frequent recommendations pertained to the use of medication during pregnancy (such as 
aspirin or low molecular weight heparin) and the possibility of prenatal screening (by 
ultrasound, amniocentesis or villous biopsy). Seven percent of women were already pregnant 
at time of the counseling visit.
Table 5. Advice given at preconception counseling visit (459 women)
Advice Number (%)
Advice pertaining to next pregnancy*
Not contra-indicated 355 (77)
Postpone pregnancy 68 (15)
Contra-indicated 6 (1)
Preconceptional intervention**
Start folic acid supplement use1’ 187 (41)
Increase dosage (0.5 to 5 mg / day) 8 (2)
Start other vitamin supplement use 58 (13)
Start, alter or stop medication use 55 (12)
Medical procedure 7 (2)
Plan of care during (next) pregnancy**
Care in secondary setting 183 (40)
Start medication 112 (25)
Prenatal screening 90 (20)
Screening for infectious diseases 21 (5)
Cerclage 18 (4)
Induction o f labor 27 (6)
Elective cesarean section 13 (3)
Other 41 (9)
* 30 women (7%) were already pregnant.
** Excluding patients with a contra-indication for pregnancy. 
t Additional advice regarding the entire duration of pregnancy 
(periconceptional folic acid supplement use was advised to all women)
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Discussion
This article provides an overview of preconception care at the University Medical Center 
Nijmegen for high-risk women. Data on preconception care programs and experiences from 
other existing clinics are limited. A few preconception clinics have been described in the 
literature, including in Scotland and in Hungary.6,28 In Glasgow, 52% of all women were 
referred by gynecologists. Recurrent early pregnancy loss and previous adverse fetal outcome 
were the most common indications for referral, consistent with the findings from our clinic. A 
research nurse was responsible for initial screening and planning of tests, and a physician saw 
the couple 4 weeks later to discuss the results of tests and establish a plan for care.28 In 
Hungary, a preconception care program was established in 1984, in which screening and 
clinical investigations (risk assessment) were performed by nurses. The program encompassed 
preconceptional screening, optimization of health status, lifestyle and nutrition during a period 
of three months before conception, and early initiation of antenatal care.6
Efficacy
Preconception health promotion can never guarantee a successful pregnancy outcome. Certain 
preconceptional interventions are not (yet) evidence-based, due to the lack of randomized 
clinical trials. A consequence of this is that protocols for certain risk factors are inconsistent. 
For example, no consensus has been reached in the Netherlands on the screening and 
intervention strategies for recurrent early pregnancy loss.12,29 One should realize, however, 
that for many topics, especially infrequent anomalies or disorders, a randomized clinical trial 
is not feasible.30
The detection and treatment of evident risk factors for adverse pregnancy outcome is always 
of significance and does not need to be questioned. Preconception care has a positive effect on 
pregnancy outcome among women with diabetes mellitus, phenylketonuria, certain infections, 
and women who use teratogenic drugs.4 It also appears that correction of 
hyperhomocysteinemia or folate deficiency among women with recurrent early pregnancy 
loss improves subsequent pregnancy outcome.13 Recurrent early pregnancy loss was the most 
common indication of referral to our clinic, and most of selected laboratory investigations 
were based on this obstetric complication.12-14 The prevalence of abnormalities in our high 
risk population of women appears to be significantly higher as compared to vitamin profiles
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and homocysteine concentrations of women who have previously had an uneventful 
pregnancy.31 The number of high-risk women with other thrombophilia was also higher than 
prevalences reported in the literature among healthy populations.21 It is certainly always 
meaningful to counsel couples on recurrence risks of obstetric complications and congenital 
anomalies, the influence of pregnancy on the health and well-being of women with a chronic 
disease or congenital anomaly, and the possible effect of the disorder on the course and 
outcome of pregnancy.32 In this respect, a preconceptional counseling visit may in some 
instances lead a couple to choose to refrain from attempting (another) pregnancy.3
Primary prevention
Another important aspect of preconception care is to advise couples on aspects of general 
health including smoking, alcohol use and nutrition,3,4 as well as on folic acid supplement use. 
More than 6 years after the Health Council of the Netherlands issued recommendations on 
periconceptional folic acid intake for the prevention of neural tube defects,33 only half of 
Dutch women took folic acid supplements in the recommended period (4 weeks before until 8 
weeks after conception).34 In a recent study (in which folic acid concentrations were measured 
in blood before and several times after counseling among women planning pregnancy)35 we 
illustrated that more that three fourths of women who were not yet using supplements, started 
to use them after counseling. Periconceptional care was also effective in Hungary to promote 
folic acid or multivitamin supplement use and to reduce tobacco and alcohol use. In addition, 
the percentage of severe congenital anomalies was significantly lower after 10 years.6
Future
If preconception counseling were to be offered to low risk populations as well, this could be 
done in a primary health care setting, with a prominent role for the general practitioner.3,5,8 In 
a survey among midwives («=100), 78% answered that preconception care could valuably 
contribute to current obstetrics and 70% felt that it should be provided by general practitioners 
if  implemented in the Netherlands. A survey among 100 general practitioners illustrated that 
93% considered preconception care to be part of their job, however, 53% lacked specific 
knowledge needed to give adequate advice and 30% indicated a lack of time to provide 
preconception counseling.37 This could be alleviated by use of a standardized screening tool 
for risk assessment. Such a questionnaire could be filled out by women prior to their first 
visit, which may lead to referral to a gynecologist, clinical geneticist or other specialist for
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further counseling if risk factors are identified. Besides counseling, folders, CD-ROMs and 
Internet could also be used as sources of information.
Adverse effects
Medicalization of pregnancy has been suggested as a possible adverse effect of counseling.3 
This, however, does not apply to a high risk population, as those women are already under 
care in a secondary or tertiary health care setting. If preconception care were to be offered to a 
low-risk population in a primary health care setting, emphasis will be placed on education and 
improving awareness, and not so much on influencing pregnancy outcome through all kinds 
of interventions. In the questionnaire among Dutch general practitioners, the majority (74%) 
reported that preconception counseling would not lead to medicalization of pregnancy.37 In 
another recent study of ours we showed that screening and counseling does not induce anxiety 
among low risk couples, and that the majority (70/84; 83%) would recommend this form of 
care to friends and acquaintances.38
Goals to be achieved
The clinic for preconception care reduced or eliminated risk factors for adverse pregnancy 
outcome among a number of attendees. We do not know whether and to what extend obstetric 
complications and/or congenital anomalies were prevented in our population of women. 
Although we can assume a role of a metabolic variation or defect in their pathophysiology, 
clear evidence of the effectiveness of an intervention for the prevention of adverse pregnancy 
outcome is currently often unavailable. This pleads for research in these areas, for which a 
preconception care clinic offers a good framework. This evaluation is a start, but further 
research on pregnancy and subsequent outcome is needed in order to clarify the role of 
preconception care in the reduction of maternal and neonatal complications. Priorities for the 
future should include further structuring of preconception care, including the development of 
uniform protocols for selected investigations and documentation of data in a (national) 
database. Additional research on the feasibility of preconception care in the Netherlands is 
currently being performed.
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ABSTRACT
Background: Preconception counseling is widely propagated, but has not been implemented 
in most parts of the world. The study aim is to assess costs and effectiveness of preconception 
counseling for all women planning pregnancy with regard to folic acid supplementation and 
smoking cessation counseling.
Methods: Costs and effects were estimated based on 200,000 women approached yearly and 
uptake rates of 50% and 75%. Effectiveness and potential savings were based on hospital 
costs of neural tube defects, and of low birth weight, very low birth weight and perinatal death 
attributable to maternal smoking.
Results: Total costs were estimated at 4.2 and 5.9 million Euro at uptake rates of 50% and 
75%, respectively. If 50% of women would seek preconception counseling, 22 neural tube 
defects, 98 low birth weight babies, 10 very low birth weight babies and 7 perinatal deaths 
could be avoided. At 75% uptake, 33 neural tube defects, 146 low- and 15 very low birth 
weight babies and 11 perinatal deaths could be avoided.
Conclusion: Net costs of preconception counseling amount to 3.0 and 4.1 million Euro when 
considering the prevented cases and subsequent potential savings of neural tube defects and 
smoking-related morbidity only. However, in light of many other preventable adverse 
outcomes and the potential of preconception counseling to prevent significant lifetime costs of 
affected children, the net costs may ultimately result in a favorable cost-savings balance. 
Moreover, the invaluable importance of a healthy child cannot be expressed in terms of costs 
and savings alone.
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Introduction
The incidence of low birth weight, very low birth weight, and birth defects has not gone down 
in recent years. These poor neonatal outcomes are a leading cause of significant morbidity and 
often have life-long consequences for the child.1,2 Despite wide recognition that the initiation 
of obstetric care before conception may be the most effective means to reduce perinatal and 
maternal morbidity and mortality in the future,3,4 the implementation of preconception care 
has been an exception rather than rule in most parts of the world. In the Netherlands, 
preconception care is currently available to high-risk women only and debates continue on 
whether it should be offered to all women planning pregnancy.
Before the implementation of nation-wide preconception counseling can be considered, 
however, the costs and effectiveness should be evaluated. To our knowledge, no studies have 
been carried out on the cost-effectiveness of a comprehensive preconceptional screening 
program for all women planning pregnancy. Previous studies on the costs and effectiveness of 
preconception care for diabetic women5-8 and for specific programs such as Cystic Fibrosis 
and Fragile X carrier screening9,10 have all been in favor of preconception care, both from a 
medical as well as an economic viewpoint.
The purpose of this article is to provide a preliminary estimate of the costs and effectiveness 
of preconception counseling for all women planning pregnancy, regarding the modifiable, 
well-documented risk factors of maternal smoking and lack of folic acid supplement use in 
the periconceptional period. The adverse outcomes considered, low birth weight, very low 
birth weight and perinatal death attributable to maternal smoking, and neural tube defects, 
were used to estimate the effectiveness (or number of prevented adverse outcomes). The 
related health care costs were also taken into account as a measure of the potential savings 
attributable to preconception counseling.
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Methods
Cost calculation
The costs, effectiveness and potential savings of preconception counseling were estimated 
from a health care perspective under a given set of assumptions based on prior studies on 
preconception counseling, remuneration data and other relevant literature. The cost 
calculations included direct medical costs of the preconceptional consultation, treatment of 
neural tube defects and associated indirect costs such as those due to lost productivity.
Population
We considered preconception counseling to be targeted at all women planning a pregnancy, 
thereby covering both low and (potentially) high-risk women. Preconception counseling in the 
low risk population was defined as a consultation provided by general practitioner who may, 
depending on risk factors, refer a high-risk couple to secondary care. The costs per 20-minute 
session were set at 21.5 Euro according to the health care charges for 2002.11 The total 
number of births in 2000 was 206,619.12 This figure excludes another 25% of conceptions that 
end in early pregnancy loss.13 Assuming that the pregnancy planning rate in Denmark of 76% 
is comparable to the Dutch setting14 and that 10% of women who plan their pregnancies will 
remain infertile,15 the target population was estimated for ease of interpretation at 200,000 
women to be approached before conception. Mass media costs of a preconceptional screening 
program were estimated previously by Wildhagen et al. for a cost-effectiveness evaluation of 
fragile X carrier screening9 and were extrapolated to our target population. The costs were set 
at 800,000 Euro and include the individual spread of posters and leaflets. The costs and 
effectiveness of preconception counseling were calculated for an uptake rate of 50% and 75% 
respectively. Although uptake by all women planning pregnancy (100%) is desirable, we 
assumed uptake by 50% of women planning pregnancy (n=100,00) to be feasible and by 75% 
as optimally achievable (n=150,000).
Neural tube defects
Periconceptional folic acid intake has been shown by several large trials to reduce the first 
occurrence of neural tube defects, ranging from 41-100%.16' 18 To avoid selection bias of the 
most favorable study, the mean of 65% risk reduction was chosen for this evaluation. The 
birth prevalence of neural tube defects in the Netherlands, 7.6 per 10,000 live births (1995-
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1999)19 could hereby be reduced to 4.94 per 10,000 live births. In a recent study in which red 
cell folate levels were measured as a measure of compliance, we found that 56% of women do 
not take folic acid supplements before counseling and that 80% of those women start to take 
supplements after a single preconception consultation.20 The risk reduction or number of 
avoided neural tube defects is based on these women, i.e., those who start to take folic acid 
after counseling (see Figure below).
All newborns with a neural tube defect in the Southwest of the Netherlands are either born or 
admitted to the Erasmus Medical Center Rotterdam. In 1999, this encompassed 11 cases with 
an isolated spina bifida. Newborns with additional congenital anomalies were not included in 
this analysis, as they would generate additional costs not attributable to the spina bifida. From 
clinical records, data were collected on date of birth, (death), spinal level and severity of the 
defect, number of operations, days of admission, and associated morbidity (i.e., paralysis, 
incontinence). Costs were estimated using detailed patient information from hospital care 
(admissions, CT- and/or MRI scans, surgeries, including closing of the defect, placement of a 
VP-drain, vesicostoma, correction of a clubfoot in 3 cases, follow-up care) and health 
insurance for all 11 cases.
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Smoking-related morbidity
A population attributable risk (PAR) of maternal smoking to perinatal death of 6.3% as 
reported by Pollack et al. (2000),21 was used to estimate the number of avoided perinatal 
deaths if 15% of smoking women were to quit after smoking cessation counseling. This quit 
rate represents a weighted average of success rates in many settings22 and has been used 
previously by Pollack et al. (2001)23 and Marks et al. (1990)24 in cost-effectiveness 
evaluations of maternal smoking cessation. The perinatal death rate of 7.8 per 1000 births in 
2000,12 encompasses intra-uterine death (>24 weeks gestational age), still births, and neonatal 
deaths within the first 7 days of life. Although live-born neonates (who survive for several 
days) are likely to require additional care, the potential costs of this subgroup were 
disregarded due to lack of data.
Perinatal morbidity attributable to maternal smoking was defined as admittance to the 
neonatal intensive care unit (NICU) due to low birth weight (<2500 g) or very low birth 
weight (<1500 g). The total number of babies born in 2000 in the Netherlands within the birth 
weight categories 500-999 g, 1000-1499 g, 1500-1999 g, and 2000-2499 g, the number of 
admissions to neonatal intensive care units (NICU), and the number of total admissions 
(NICU and high care) per birth weight category were obtained from the National Obstetric 
Database.25 As the mean duration of stay for each category of birth weights is not reported on 
a national level, this data (for NICU admissions only) was extracted from an SPSS database 
of the Department of Pediatrics, Erasmus Medical Center Rotterdam. The mean duration of 
NICU stay within each of the birth weight categories was assumed to be comparable to that of 
other Dutch University Medical Centers (Table 1).
After discharge from the NICU, babies are kept in the high care ward for an average of 13 
days, irrespective of birth weight.26 The costs of 13 days of high care were added to NICU 
costs to estimate total hospitalization costs of NICU-admitted infants. As we did not have any 
data on duration of stay in high care per birth weight category, we also used the average of 13 
days to estimate hospitalization costs of infants admitted to high care only. The PAR of 
maternal smoking reported by Pollack et al. is 11.1% for low birth weight and 5.7% for very 
low birth weight babies,21 illustrating that maternal smoking is a greater causal factor of birth 
weights between 1500-2499 g than newborns born weighing less than 1500 g. As the PAR for 
low birth weight encompasses all births <2500 g,21 thereby including very low birth weight 
babies, we calculated the PAR of babies with a birth weight 1500-2499 alone to be 12.3%.
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The guidelines and reference costs published by Oosterbrink for NICU stay (1150) and high 
care admissions (400 Euro) were used.27 For each of the birth weight categories, the PAR of 
12.3% or 5.7% was then used to estimate costs per child (per birth weight category), total 
costs of admissions due to maternal smoking, and the avoidable costs if  15% of mothers-to-be 
were to give up smoking after counseling.
Results
Prevented adverse outcomes
When considering neural tube defects and maternal-smoking related morbidity only, 137 
adverse outcomes, specifically 22 cases of neural tube defects, 98 low birth weight babies, 10 
with a very low birth weight and 7 perinatal deaths, could be avoided if half of all women 
planning pregnancy would seek preconception counseling. If an uptake of 75% could be 
achieved, 205 adverse pregnancy outcomes could be prevented, of which 33 cases of neural 
tube defects, 146 low- and 15 very low birth weight babies, and 11 perinatal deaths 
attributable to maternal smoking.
Neural tube defects
The data of children born with a spina bifida in 1999 yielded a mean duration of 
hospitalization of 27 days (range: 5-44), and a mean of 3 surgeries in the first year of life 
(range: 0-5). The mean hospitalization costs in the first year were 26,000 Euro (range: 5,000­
51,000). One child (with the lowest costs) was abstained and died after 5 days. The total 
avoided costs due to children born less with spina bifida were estimated at 0.6 million Euro if 
half of all women would seek preconception counseling, and at 0.9 million Euro if an uptake 
of 75% women planning pregnancy was achieved.
Smoking-related morbidity
The mean duration of stay in the neonatal intensive care unit per birth weight category, 
hospitalization costs, and costs attributable to maternal smoking are given in table 1. Total 
hospitalization costs attributable to smoking, for low birth weight and very low birth weight 
babies only, amounted to 8.1 million Euro. Under the assumption that 15% of women quit 
smoking and that 50-75% of women would seek preconception counseling, 0.6 -  1.0 million 
Euro spent on hospital care of their low- and very low birth weight infants could be saved.
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Table 1. Total births in 2000 according to birth weight, neonatal hospitalization costs (million Euro), costs attributable to maternal smoking, and savings due 
to smoking cessation counseling
Outcome N*
Admission to 
NICU (ri)
NICU days 
(mean)**
Admission to 
high care (n)
Total costs Costs due to 
smoking
Savings * 
50% uptake 75% uptake
Birth weight 
500-999 g 1046 517 47 104 31.2 1.8 0.1 0.2
1000-1500 g 1383 891 18 561 26.0 1.5 0.1 0.2
1500-1999 g 2726 627 8 1408 16.4 2.0 0.2 0.2
2000-2499 g OO vo —
s-
458 5 3457 23.0 2.8 0.2 0.3
Total 96.6 8.1 0.6 1.0
* Of 206,619 births in 200012
** Excluding 13 days in high care ward (after discharge from NICU) 
t Includes 518 bom in primary care setting
J Savings based on the assumption that 15% of women quit smoking after counseling (rounded to the nearest decimal)
Total costs
The total yearly costs of nation-wide preconception counseling, assuming uptake by 100,000 
(50%) and 150,000 (75%) of women planning pregnancy, were estimated at 4.2 and 5.9 
million Euro, respectively. Total potential savings amount to 1.2 and 1.8 million Euro for the 
adverse outcomes considered in this preliminary evaluation, resulting in net costs of 3.0 and 
4.1 million Euro (Table 2). This translates into a cost-savings balance of 20,000 Euro per 
prevented adverse outcome.
Table 2. Costs of preconception counseling (Million Euro)1'
Uptake 50% 
(«=100,000)
Uptake 75% 
(«=150,000)
Costs of preconception counseling
Mass information costs 0.8 0.8
Consultation* 2.2 3.2
Folic acid supplements** 1.3 1.9
Total costs 4.2 5.9
Savings
Smoking cessation 0.6 1.0
Folic acid supplement use 0.6 0.9
Total savings 1.2 1.8
Effectiveness
Avoided neural tube defects 22 33
Avoided perinatal death 7 11
Net costs 3.0 4.1
* Based on costs of a double consultation (20 minutes) of 21.5 Euro11 
** 5.24 Euro per month; 12-month period 
1 Rounded to the nearest decimal
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Discussion
This is a first evaluation of the costs and benefits of preconception counseling, only in relation 
to the possible prevention of folic acid dependent neural tube defects and smoking-related 
pathology. This conservative evaluation thereby excluded several important factors. First, we 
did not evaluate the impact of a neural tube defect on morbidity and mortality of affected 
children after the first year of life. The life expectancy is lower for individuals with spina 
bifida, and has a dramatic impact on the quality of life. More than 50% of survivors have 
disabilities, including incontinence, impaired vision and mobility, and impaired cognitive 
function, and often require special education and developmental services.28 In the 
Netherlands, 9.3 million Euro was spent on morbidity related to neural tube defects in 1999 
alone when taking into account all age groups.29 Our estimate of savings due to affected 
children born less therefore substantially underestimates the true costs per individual. On the 
other hand, a prenatally diagnosed neural tube defect or other serious or lethal anomaly may 
lead some couples to choose to terminate the pregnancy. Furthermore, the first year cost 
analysis was limited to spina bifida, excluding lethal neural tube defects like anencephaly. 
This may have lead to some overestimation of potential savings in our study.
Several studies have suggested protective effects of folic acid (containing) supplements for 
the risk of other birth defects, including a 48% risk reduction for cleft lip and palate,30 a risk 
reduction of 24% for nonsyndromic cardiac outflow defects,31 and the recently reported risk 
reduction of 60% for nonsyndromic omphalocele by periconceptional multivitamin 
supplement use.32 As further research is warranted to confirm these studies, the additional 
benefits of periconceptional folic acid supplement use were not accounted for in the present 
study.
The well-known negative association between maternal smoking and birth weight is an 
important cause of avoidable neonatal morbidity and mortality. Although the severity of low 
birth weight is certainly not of the same magnitude as an infant born with a neural tube defect 
or perinatal death (considered together in the cost-savings estimate of 20,000 Euro per 
avoided adverse outcome), the long-term consequences of being born too light, including 
chronic illnesses and poor educational achievement33 should not be underestimated. 
Moreover, additional smoking-related morbidity and mortality, including placental
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abruption22 and sudden infant death syndrome (of which 23.6% of cases are attributable to 
maternal smoking),21 were also not accounted for in this preliminary study. We estimated that 
15% of women would stop smoking as a result of our intervention. However, if  we were to 
attain higher smoking cessation rates, the reduction in neonatal morbidity and mortality (as 
well as the potential savings of avoided costs) could be increased up to 7-fold. Increasing 
smoking cessation rates should therefore be a priority among health care workers, ideally 
before a woman conceives.
Maternal drinking is another example of the many potential risks that should be addressed 
before pregnancy. Even as little as one drink per week may have long-term consequences for 
the offspring,34 and a majority of periconceptional drinkers are unaware of their pregnancy 
during the period of highest teratogenicity.35 Other examples of modifiable risks before 
pregnancy include an inadequate vaccination status, the use of potentially teratogenic 
medications and poorly monitored maternal conditions such as maternal phenylketonuria35 
and diabetes mellitus.36 Preconception counseling has been shown to result in cost-savings 
when considering the latter group alone,5,6 primarily due to the 8-fold reduction in birth 
defects among women who receive preconception care.6
With respect to the provision of preconception counseling, our assumptions did not include 
the additional costs and efforts that may be necessary to educate general practitioners or other 
health care workers (nurses, midwives) on the components of preconception care. Although 
most topics are covered in medical school and can be taught as part of the existing programs, 
practicing physicians may desire to follow a course. Perhaps a more efficient and practical 
method would be to provide all necessary information for providers on the Internet, 
encompassing a comprehensive overview of the various preconceptional risk factors, possible 
interventions, and appropriate advice. Considering the range of topics to be covered during a 
single consultation, one could argue that 20 minutes is not enough to provide sufficient 
counseling. On the other hand, lack of time is a major obstacle to the provision of 
preconception counseling among general practitioners in the Netherlands.38 It is therefore 
unlikely that they or other health care providers would be willing to spend longer on screening 
and counseling of women planning pregnancy.
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If a preconceptional screening questionnaire were to be completed by women prior to the 
consultation, the substantial amount of time needed for history taking could be allocated to 
further assessment of the (on beforehand) identified risk factors and subsequent counseling. 
We validated a questionnaire for risk assessment to be used by health care professionals for 
this purpose and would highly recommend its use if preconception counseling for all women 
planning pregnancy were to be implemented in the future.39
In this analysis we assumed an uptake rate of 50% and 75%, respectively, although we cannot 
predict to what extend women would seek preconception counseling if it is to become widely 
offered. We recently demonstrated in a population of low-risk couples that preconception 
counseling was highly appreciated and would be recommended to others by a vast majority 
(83% )40 Despite a high rate of pregnancy planning among Dutch women, it is often those 
with unintended pregnancies pregnancy who could have benefited most from preconception 
counseling.41 Likewise, women of low socio-economic status, certain minority groups, and 
users of alcohol or other drugs may be less likely to seek preconception counseling. In order 
to reach the majority of women, the effectiveness of mass media campaigns and motivation of 
primary care physicians to inform the target population will be of key importance.
Conclusion
This preliminary evaluation demonstrates that nation-wide preconception counseling will 
require an initial investment of 4 to 6 million Euro, of which approximately 30% could be 
saved by avoidance of neural tube defects and smoking-related morbidity alone. However, in 
light of the many other preventable adverse outcomes not considered in this preliminary study 
as well as the potential of preconception care to prevent significant lifetime costs of adverse 
outcomes, the costs may ultimately result in a favorable cost-savings balance. The initiation of 
mass media campaigns to promote preconception counseling could replace the ongoing 
campaigns to promote folic acid supplement use, resulting in additional savings. Finally, the 
invaluable importance of a healthy child, and likewise, the burden to parents of a seriously 
affected child, cannot be expressed in terms of costs and savings. These issues should not be 
neglected if the implementation of preconception counseling is to be considered for all 
women planning pregnancy.
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Chapter 12
Summary
&
Conclusions
Part I
Part I of this thesis provides a general introduction to preconception care, a long-established 
concept for primary prevention of maternal and perinatal morbidity and mortality through 
detection and reduction of modifiable risks. In Chapter 1 the background and objectives of 
the thesis are presented. Chapter 2 reviews the various goals and practices described in the 
literature in different parts of the world, including issues and controversies pertaining to the 
provision and implementation of preconception care in different health care settings. 
Although preconception care has been advocated in different parts of the world for many 
years, controversies as to whom it should be offered, who should be responsible, how it 
should be provided, and how to reach the target population, are still largely unresolved.
Part II
Part II of this thesis concerns preconception screening. Chapter 3 describes the use of 
questionnaires as a screening tool for risk factors and how implementation of the 
questionnaire could facilitate preconceptional risk assessment in various settings. From this 
study we conclude that screening can be performed efficiently and reliably using a screening 
questionnaire, and that its use could save providers a great deal of time by filtering out 
relevant problems that need to be further addressed. Chapter 4 describes the effect of 
preconception screening on anxiety in a low risk population. Using the full (20-item) version 
of the Spielberger State Trait Anxiety Inventory (STAI) to measure anxiety levels before and 
after counseling, no significant change in anxiety levels among both men and women was 
found. Furthermore, the majority of couples would recommend preconception counseling to 
other couples planning to conceive. Chapter 5 describes the use of a shortened (6-item) 
version of the STAI to assess anxiety, and illustrates that the short form is valid for usage in 
screening outcomes. In this study we demonstrate that anxiety levels of high-risk women are 
lower after preconception counseling. From these studies we conclude that there are no 
adverse psychological effects attributable to preconception counseling.
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Part III
P art III  describes several aspects of periconceptional health and preparation for pregnancy. 
Preliminary data of nutritional intake and other lifestyle factors of women planning pregnancy 
are presented in C hapter 6. The dietary intake of women planning to conceive appears to be 
sub-optimal due to an excessive intake of total energy, saturated fats and protein, and a 
marginal or deficient consumption of several micronutrients including iron, vitamin A, 
vitamin D, selenium and copper. Furthermore, almost all women planning pregnancy (96%) 
indicated some degree of alcohol use and less than half of them were taking folic acid 
supplements preconceptionally. In chapter 7, we further investigated aspects of nutritional 
status of mothers-to-be. The relationships between maternal blood parameters in the 
periconceptional period and early pregnancy loss and birth weight were studied. A decreased 
decline of uric acid, creatinin, and hematocrit concentrations was associated with an increased 
risk of early pregnancy loss. The study also demonstrated a significant association between 
maternal smoking and birth weight, with a mean reduction of birth weight of 183 g among 
infants born to smoking mothers. Maternal age and pre-pregnancy weight were shown to be 
strongly positively associated with birth weight.
In the second half of p a rt III, the impact of preconception counseling was addressed by 
measuring compliance to advice given at a preconceptional visit regarding folic acid 
supplement use and smoking cessation. Compliance to start or continue to take folic acid 
supplements was determined by measuring red blood cell folate levels before and after 
counseling (chapter 8). This study demonstrated that preconception counseling improves 
folate status among 80% of women planning pregnancy. Biochemical validation of smoking 
by cotinine assay is described in the first part of chapter 9. Serum and urine cotinine 
concentrations are both applicable for confirmation of smokers and non-smokers. However, 
because serum cotinine varies less over the course of the day than urine cotinine, serum is 
more practical for use in a clinical setting to confirm smoking status (chapter 9.1). The effect 
of smoking cessation advice is then evaluated in the second part of this chapter by measuring 
serum cotinine concentrations in couples before and after preconception counseling (chapter 
9.2).
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We confirmed previous reports that a significant number of women and men underreport their 
smoking habits (33% and 44%, respectively). Although three-fourths of smoking women had 
lower serum cotinine concentrations after counseling, none of them had given up smoking 
completely.
Part IV
P art IV of this thesis encompasses examples of current practice and future implications for 
preconception care. Experiences from an outpatient clinic for preconception care at a 
university hospital in the period 1996-2000 are described in chapter 10. The preconception 
outpatient clinic for high-risk women (i.e., women with previous obstetric complications, 
medication use or chronic illnesses) helped to minimize risk factors for adverse pregnancy 
outcome by early detection and treatment of diagnosed abnormalities and by providing 
extensive counseling. In chapter 11, a preliminary cost-effectiveness evaluation of 
preconception counseling for all women planning pregnancy is presented with regard to folic 
acid supplementation and smoking cessation. Assuming that 50% of women would seek 
preconception counseling, total costs would amount to 4.1 million Euro. When considering 
folic acid supplement use and smoking-related morbidity and mortality only, 22 cases of 
neural tube defects, 98 low birth weight babies, 10 very low birth weight babies and 7 
perinatal deaths could be prevented by a single counseling session. This results in net costs of 
3.0 million Euro, or 20,000 Euro per prevented adverse outcome.
Conclusions
Although there is still no consensus in the Netherlands on the provision of wide-scale 
implementation of preconception counseling, our studies now provide additional arguments in 
favor of preconception care. We have shown that preconception counseling does not induce 
anxiety, that compliance to recommended interventions is high as shown by women who start 
to take folic acid supplements, and that screening can be carried out efficiently and effectively 
using a questionnaire. In the Netherlands, general practitioners are probably the most suitable 
primary care workers to provide (initial) preconception counseling. Furthermore, in a recent 
study among 129 midwives in Rotterdam and surrounding districts, 80% of them reported to
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be willing to provide preconception counseling in the future (unpublished data). It is certainly 
possible that this group of health care workers may play an important role in the provision of 
preconception care in the primary care setting if it is to be implemented not only for a high 
risk population, but for the population at large.
There are several issues holding back the widespread implementation of preconception 
counseling. First, evidence of improved outcome in the population at large, directly attributed 
to preconception counseling, is still lacking. As a randomized clinical trial on preconception 
counseling in relation to the vast spectrum of pregnancy outcomes would be very difficult, we 
should concentrate on observational methods. In light of common sense, we cannot withhold 
an intervention from women who we feel could potentially benefit in order to prove its effect. 
Future research should therefore focus on standardized documentation and registration of 
preconceptional interventions, such as those described in our evaluation of an outpatient clinic 
for preconception counseling, and subsequent pregnancy outcome. Secondly, preconception 
care can never guarantee a successful pregnancy outcome. Birth defects, perinatal deaths, and 
maternal complications such as preeclampsia will continue to occur due to factors that are not 
yet understood or beyond our control.
We can, however, do the utmost to minimize factors that are within our capacity. One should 
keep in mind that despite all available facilities and our continuous efforts to optimize 
antenatal care, the incidence of a number of adverse pregnancy outcomes has not gone down 
or has even increased slightly in past years. The birth prevalence of neural tube defects, 
however, has gone down in the past decade in the Netherlands, which may at least in part be 
attributable to the periconceptional intake of folic acid supplements. This trend is likely to 
continue as more and more women become aware of folic acid and take supplements in the 
recommended period. Considering that 11% of all preterm births, 6% of very pre-term births 
and 6% of all infant mortality is attributable to maternal smoking, preconceptional smoking 
cessation counseling should ultimately lead to a lower incidence of these common neonatal 
adverse outcomes as well.
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Although preconception counseling will require an initial investment of 4-6 million Euro, the 
savings due to prevented morbidity and mortality for a wide spectrum of adverse outcomes 
are likely to result in a favorable cost-savings balance. Moreover, the immeasurable 
importance to couples of a healthy child cannot be expressed in economic terms. The true 
feasibility of nation-wide preconception counseling can probably only be evaluated if we 
make its provision widely available. This will require a great collaborative effort between 
gynecologists, clinical geneticists, family physicians, nurses, midwives, and other 
professionals involved in reproductive care, in which the past experiences and recent studies 
should be used as a framework to facilitate such efforts. Only then can we conclude from our 
efforts and practice whether preconception counseling should and can be effectively offered 
to all women planning pregnancy.
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Samenvatting
Deel I
Deel I van dit proefschrift bestaat uit een algemene inleiding over preconceptionele 
advisering, een reeds langer bestaand concept voor de primaire preventie van maternale en 
perinatale morbiditeit en mortaliteit door het vroegtijdig opsporen en reduceren van 
beïnvloedbare risicofactoren. In hoofdstuk 1 worden de achtergrond en doelstellingen van dit 
proefschrift beschreven. Hoofdstuk 2 geeft een literatuuroverzicht van de doelstellingen, de 
opzet en structuur van bestaande klinieken in diverse landen en de mogelijke nadelen en 
obstakels van implementatie van preconceptionele advisering in de eerste- en tweedelijns 
gezondheidszorg. Hoewel er wereldwijd reeds jarenlang veel voorstanders zijn van 
preconceptionele zorg, bestaat er nog steeds geen consensus over wie deze zorg zou moeten 
gaan geven, onder welke voorwaarden, en over de te bereiken doelgroep.
Deel II
Deel II van dit proefschrift betreft de preconceptionele screening. Hoofdstuk 3 beschrijft het 
gebruik van een vragenlijst voor het inventariseren van risicofactoren en hoe het gebruik 
ervan de preconceptionele screening zou kunnen vereenvoudigen. Uit deze studie kan worden 
geconcludeerd dat deze screening efficiënt en betrouwbaar kan worden uitgevoerd met behulp 
van een screeningsvragenlij st, en dat gebruik ervan veel tijd zou besparen door alleen de 
relevante problemen aan het licht te brengen die verdere aandacht behoeven. Hoofdstuk 4 
beschrijft de invloed van preconceptionele screening op angstgevoelens in een laagrisico 
populatie. De volledige (20-punts) versie van de Spielberger State Trait Anxiety Inventory 
(STAI) werd door echtparen ingevuld voor en na de preconceptionele advisering, waaruit 
bleek dat er geen significante verandering in angstgevoelens optreedt ten gevolge van de 
advisering. De meerderheid van echtparen zou deze vorm van zorg aanraden aan vrienden en 
kennissen met een zwangerschapswens. Hoofdstuk 5 beschrijft het gebruik van de verkorte 
versie van de STAI (6 vragen), waaruit blijkt dat de bestaande verkorte versie valide zijn om 
veranderingen in toestandsangst door screeningsprogramma’s te meten. Tevens bleek uit dit 
onderzoek dat angstgevoelens van hoogrisico vrouwen afnemen na advisering. Concluderend 
blijkt uit deze studies dat er geen nadelige psychologische effecten kunnen worden 
toegeschreven aan preconceptionele advisering.
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Deel III
Deel III beschrijft een aantal aspecten van periconceptionele gezondheid en de voorbereiding 
op een zwangerschap. Preliminaire data over de voedingsinname en andere leefstijlfactoren 
van vrouwen met zwangerschapswens worden in hoofdstuk 6 gepresenteerd. De 
voedingsinname blijkt suboptimaal door een overmatige inname van energie, verzadigde 
vetten en eiwitten, en een marginale of deficiënte inname van een aantal micronutriënten 
waaronder ijzer, vitaminen A en D, seleen en koper. Bijna alle vrouwen met 
zwangerschapswens (96%) gaven aan in enige mindere mate alcohol te drinken, en minder 
dan de helft slikte foliumzuursupplementen in de preconceptionele periode. In hoofdstuk 7 
worden een aantal aspecten van de voedingsstatus van aanstaande moeders nader beschreven. 
De relatie tussen maternale bloedparameters in de periconceptionele periode en spontane 
abortus en geboortegewicht werd onderzocht. Een verminderde daling van kreatinine, 
urinezuur en hematocriet werd geassocieerd met een verhoogd risico op spontane abortus. Een 
negatief verband werd aangetoond tussen maternaal roken en geboortegewicht, met een 
gemiddeld lager geboortegewicht van 183 g bij kinderen van rokende moeders. Tevens waren 
zowel het maternaal preconceptioneel gewicht als leeftijd sterk gerelateerd aan het 
geboortegewicht van het kind.
In het tweede gedeelte van deel III  is het effect van preconceptionele advisering bestudeerd. 
Daartoe werd gemeten in welke mate de gegeven adviezen tijdens een preconceptioneel 
consult betreffende het gebruik van foliumzuursupplementen en het stoppen met roken 
werden opgevolgd. Het opvolgen van het advies te beginnen met foliumzuursuppletie of 
daarmee door te gaan werd geëvalueerd door de foliumzuurconcentraties in bloed voor en na 
advisering te meten (hoofdstuk 8). Deze studie heeft aangetoond dat preconceptionele 
advisering leidt tot verbetering van de foliumzuurstatus bij 80% van de vrouwen met een 
zwangerschapswens. Biochemische bevestiging van rookgedrag door middel van 
cotininemetingen wordt beschreven in het eerste deel van hoofdstuk 9. Hoewel de 
cotinineconcentraties gemeten in zowel serum als urine beide als betrouwbaar kunnen worden 
beschouwd, is het meten van cotinineconcentraties in serum praktischer in een klinische 
setting omdat deze waarden minder variëren over de dag (hoofdstuk 9.1). In het tweede deel 
van dit hoofdstuk is het effect van preconceptionele advisering op rookgedrag bestudeerd 
door cotinine concentraties in bloed te meten voor en na advisering (hoofdstuk 9.2).
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Evenals in eerdere studies werd onderrapportage van rookgedrag door een aanzienlijk 
percentage vrouwen en mannen (respectievelijk 33 en 44%) aangetoond. Hoewel driekwart 
van rokende vrouwen lagere serum cotinine concentraties had na advisering, was er geen 
enkele vrouw volledig gestopt met roken.
Deel IV
Deel IV van dit proefschrift beschrijft een voorbeeld van eeen structuur van preconceptionele 
zorg evenals implicaties voor de toekomst. Ervaringen uit een polikliniek voor 
preconceptionele advisering in een academisch ziekenhuis in de periode 1996-2000 worden in 
hoofdstuk 10 beschreven. De polikliniek voor hoogrisico vrouwen (onder andere vrouwen 
met een belaste obstetrische voorgeschiedenis, medicatiegebruik of een chronische 
aandoening) droeg bij aan het minimaliseren van risicofactoren voor een ongunstige 
zwangerschapuitkomst door vroege opsporing en behandeling van vastgestelde afwijkingen 
en uitgebreide advisering. In Hoofdstuk 11 wordt een eerste kosten-effectiviteitsevaluatie van 
preconceptionele advisering voor alle vrouwen met zwangerschapswens gepresenteerd met 
betrekking tot foliumzuursuppletie en stoppen met roken. Als 50% van vrouwen gebruik zou 
maken van preconceptionele advisering, bedragen de totale kosten 4,1 miljoen Euro. Indien 
slechts het gebruik van foliumzuur en perinatale morbiditeit en mortaliteit door maternaal 
roken worden beschouwd, zouden er 22 gevallen van spina bifida, 98 dysmaturen, 10 extreme 
dysmaturen en 7 perinatale sterftes kunnen worden voorkomen door een eenmalig advies. Dit 
vertaalt zich in netto kosten van 3,0 miljoen Euro, of 20.000 Euro per voorkómen 
probleemgeval.
Conclusies
Hoewel er in Nederland nog geen consensus bestaat over preconceptionele advisering voor 
alle vrouwen in de vruchtbare levensfase, leveren de door ons verrichte studies nu extra 
argumenten op in het voordeel van preconceptionele zorg. Wij hebben aangetoond dat 
preconceptionele advisering niet leidt tot toegenomen angst onder echtparen, dat het gegeven 
advies daadwerkelijk grotendeels wordt opgevolgd zoals aangetoond door vrouwen die
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foliumzuur gaan slikken, en dat screening betrouwbaar en efficiënt kan worden uitgevoerd 
door middel van een vragenlijst. In Nederland zijn huisartsen waarschijnlijk de meest 
geschikte beroepsgroep voor het geven van een (eerste) preconceptioneel advies. Tevens 
blijkt uit een recente studie onder 129 verloskundigen in Rotterdam dat 80% van hen bereid 
zou zijn om in de toekomst preconceptionele advisering te geven (niet gepubliceerde data). 
Het is goed denkbaar dat deze beroepsgroep een belangrijke rol zou kunnen gaan spelen 
indien preconceptionele zorg geïmplementeerd zou worden voor de algemene populatie, en 
niet slechts voor hoogrisico echtparen.
Er bestaan echter een aantal factoren die de grootschalige implementatie van preconceptionele 
advisering tegen houden. Het wetenschappelijk bewijs ontbreekt nog steeds dat 
preconceptionele advisering leidt tot een verbeterde zwangerschapsuitkomst in de algemene 
populatie. Omdat de uitvoering van een gerandomiseerde klinische trial in relatie tot de vele 
zwangerschapsuitkomsten zeer moeilijk zou zijn, verdient het de aanbeveling om ons vooral 
te richten op observationele studies. Het valt echter niet te verdedigen om interventies 
waarvan het effect aannemelijk is achterwege te laten in het kader van onderzoek. Toekomstig 
onderzoek zou zich daarom moeten richten op protocollering en vastlegging van 
preconceptionele interventies in relatie tot de zwangerschapsuitkomst. Ten tweede zal 
preconceptionele advisering nooit een goede zwangerschapsuitkomst kunnen garanderen. 
Aangeboren afwijkingen, perinatale sterfte en maternale complicaties zoals preëclampsie 
zullen blijven voorkomen door oorzaken die niet beïnvloedbaar zijn of waarvan de 
pathofysiologie vooralsnog onopgehelderd is.
Uiteraard kunnen we ons wel volledig inzetten om de beïnvloedbare risicofactoren zo veel 
mogelijk te reduceren. Men dient zich te realiseren dat ondanks de beschikbare mogelijkheden 
en alle inspanningen om de huidige antenatale zorg te optimaliseren, de incidentie van een 
aantal ongunstige zwangerschapsuitkomsten niet is afgenomen of zelfs gestegen is in de 
afgelopen jaren. De geboorteprevalentie van kinderen met neuraalbuisdefecten is de laatste 10 
jaar wel gedaald in Nederland, mogelijk toe te schrijven aan de periconceptionele inname van 
foliumzuur. Deze trend zal zich waarschijnlijk voortzetten als de kennis omtrent foliumzuur 
toeneemt en vrouwen steeds vaker foliumzuur gaan slikken in de periconceptionele periode. 
Aangezien 11% van alle vroeggeboorten, 6% van extreme vroeggeboorten en 6% van alle 
perinatale sterfte direct toe te schrijven is aan maternaal roken, zal preconceptionele
183
advisering dien aangaande leiden tot een afname van deze ongunstige zwangerschaps- 
uitkomsten.
Hoewel preconceptionele advisering een initiële investering van 4 tot 6 miljoen Euro zou 
vergen, zal dit waarschijnlijk ruim worden bespaard door voorkómen kosten door de preventie 
van perinatale en maternale morbiditeit en mortaliteit. Los van deze kosten-batenoverweging, 
valt het belang van een gezond kind niet uit te drukken in economische termen. Het bieden 
van preconceptionele advisering aan alle vrouwen met zwangerschapswens is waarschijnlijk 
dé manier om de daadwerkelijke haalbaarheid en uitvoerbaarheid ervan te evalueren. Dit zal 
een grote inspanning en samenwerking vergen van gynaecologen, klinisch genetici, 
huisartsen, verpleegkundigen, verloskundigen en alle andere beroepsmatig betrokkenen, 
waarbij de opgedane ervaringen en recente onderzoeksgegevens zouden moeten dienen als 
leidraad. Pas dan zal uit de praktijk moeten blijken of het daadwerkelijk zinvol is om 
preconceptionele advisering te bieden aan alle vrouwen met zwangerschapswens.
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